Kit or device for detecting early stage pancreatic cancer or pancreatic cancer precursor lesions and detection method

Abstract

To provide a method for detecting early stage pancreatic cancer or pancreatic cancer precursor lesions.SOLUTION: A kit or device for detecting early stage pancreatic cancer or pancreatic cancer precursor lesions, comprising a nucleic acid capable of specifically binding to miRNA in a specimen from a test subject, and a method for detecting early stage pancreatic cancer or pancreatic cancer precursor lesions, comprising in vitro measurement of the expression level of the miRNA.SELECTED DRAWING: Figure 4

Description

[Technical Field]

[0001] The present invention provides a method for testing whether a subject has early pancreatic cancer or a precursor lesion of pancreatic cancer. a nucleic acid capable of specifically binding to a specific miRNA, A kit or device for detecting precursor lesions and a method for measuring the expression level of the miRNA using the nucleic acid The present invention relates to a method for detecting early stage pancreatic cancer or a precursor lesion of pancreatic cancer, comprising measuring [Background technology]

[0002] The pancreas is an exocrine gland that secretes pancreatic juice, a digestive fluid, and sends it to the digestive tract through the pancreatic duct. It also functions as an endocrine gland that secretes hormones such as insulin and glucagon into the blood. It also has

[0003] The pancreas is surrounded by many organs, including the stomach, duodenum, small intestine, liver, and gallbladder, so early detection of cancer is possible. Not only is it difficult to detect, it is asymptomatic, progresses very quickly, and metastasizes to other organs. It has properties such as stinging and has an extremely poor prognosis compared to other cancers. 2011, published by the National Cancer Center, Cancer Control and Information Center (Tokyo, Japan) According to statistics on cancer mortality rates by site in Japan in 2015, the number of deaths from pancreatic cancer was 28,822. The 5-year relative survival rate by site from 2003 to 2005 was lowest for pancreatic cancer, and men 7.1% in men and 6.9% in women.

[0004] As described in Non-Patent Document 1, the basic treatment for pancreatic cancer is surgery, systemic chemotherapy, or chemotherapy depending on the stage of progression. Chemotherapy, radiation therapy, or a combination of these is used. 15-20% of pancreatic cancer patients Although surgery is performed because it is curable, the majority of patients who do not undergo surgery have locally advanced disease. It is thought that the disease is progressing or has metastasized.

[0005] UICC(Unio Internationalis Contra Cancru) m) the progression of pancreatic cancer is stage 0, IA, IB, IIA, IIB, III, I Stages I-III account for more than half of the five-year survival cases. At the time of diagnosis, more than 70% of cases were in Stage IVa or Stage IVb. As described in Non-Patent Document 1, the 5-year survival rate for pancreatic cancer is 4. 5.8%, stage IB 36.3%, stage IIA 29.4%, stag e IIB: 10.6%, stage III: 5.9%, stage IV: 4.0% The prognosis for stage III and stage IV is extremely poor, so early diagnosis is recommended. It is necessary to detect pancreatic cancer at an early stage and treat it.

[0006] As described in Non-Patent Document 2, abdominal ultrasound is a simple and convenient method for diagnosing pancreatic cancer. This minimally invasive test is extremely useful in outpatient care and screening. Pancreatic cancer and lesions in the tail of the pancreas are often difficult to visualize. The rate of findings in pancreatic images obtained through examinations is approximately 1%, and the rate of pancreatic cancer detection is low at approximately 0.06% or less. Tumor markers for detecting pancreatic cancer include, for example, CA19-9 as a carbohydrate antigen, Spa Glycolysis, such as n-1, CA50, CA242, Dupan-2, TAG-72, and urinary fucose Other known antigens besides the chain include CEA, POA, and TPS. The way it is used is that if the blood concentration is higher or lower than a predetermined standard value, it indicates cancer. For example, as described in Non-Patent Document 3, the standard value of CEA is 5 ng / m The standard value for CA19-9 is set at 37U / mL, and if the value is higher than that, However, tumor marker evaluation is often limited to advanced pancreatic cancer. In most cases, early-stage pancreatic cancer does not show abnormal values. Even with abdominal ultrasound and car scans, the detection rate of pancreatic cancer is low, and these screening tests for pancreatic cancer detection The implementation of this method is problematic in terms of cost-effectiveness.

[0007] On the other hand, it is known that cystic diseases occurring in the pancreas can become malignant and progress to invasive cancer. It can be considered a precursor to cancer. As described in Non-Patent Document 4, cystic disease The malignancy of the cyst is determined by the cyst diameter, wall thickening, diameter of the main pancreatic duct, mural nodules, main pancreatic duct stenosis, lymph node enlargement, and cyst size. In the case of intraductal papillary mucinous neoplasm, which is a type of cystic disease, , 40.4% are malignant and 30.8% are invasive cancer, so the prognosis is poor. However, observation and resection are recommended.

[0008] Although it is still in the research stage, as shown in Patent Documents 1 to 5 and Non-Patent Document 5, The expression level of microRNA (miRNA) in a biological sample, or the expression of miRNA Combining the amount of IL-14 and the expression levels of other protein markers to identify pancreatic cancer There are reports that:

[0009] Patent Document 1 describes the use of hsa-miR-125a-3p and hsa-miR-204 in blood. -3p, hsa-miR-3648 in combination with several other miRNAs to detect pancreatic cancer It shows how to do this.

[0010] Patent Document 2 describes the use of hsa-miR-1908-5p and hsa-miR-672 in blood. Combining miRNAs such as 9-5p and hsa-miR-5195-3p to detect pancreatic cancer It shows how to get it out.

[0011] Patent Document 3 describes a method for combining miR-23a-3p in blood with several dozen other miRNAs. A method for detecting pancreatic cancer using this method has been shown.

[0012] Patent Document 4 describes miRNAs whose expression levels are higher in the blood of pancreatic cancer patients than in healthy individuals. hsa-miR-1268a, hsa-miR-939-5p, and hsa-miR- 642b-3p is listed and is used in combination with dozens of other miRNAs to detect pancreatic cancer. It also shows how to assess the risk of developing pancreatic cancer.

[0013] Patent Document 5 describes how hsa-miR-296-5p in blood is separated from several dozen other miRNAs. Combined methods for detecting pancreatic cancer and precursor lesions, and assessing the risk of developing pancreatic cancer It shows how to do this.

[0014] Non-patent document 5 describes miRNAs whose expression levels are increased in the blood of pancreatic cancer patients compared to healthy subjects. hsa-miR-638, hsa-miR-3196, hsa-miR-1225-3 p, etc., and methods for detecting pancreatic cancer by combining several of these miRNAs are being proposed. The law is set out. [Prior art documents] [Patent documents]

[0015] [Patent Document 1] Japanese Patent Application Laid-Open No. 2015-107091 [Patent Document 2] International Publication No. 2015 / 182781 [Patent Document 3] US Patent Application Publication No. 2015 / 0011414 [Patent Document 4] Special Publication No. 2015-502176 [Patent Document 5] International Publication No. 2015 / 153679 [Non-patent literature]

[0016] [Non-Patent Document 1] Tetsuya Mine, "Pancreas", Japan Pancreas Society, 2007, Vol. 22, pp. 10-13 [Non-patent document 2] Japan Pancreas Society "Evidence-Based Guidelines for the Management of Pancreatic Cancer 2009 Edition" CQ1 Diagnostic Method http: / / www.suizou.org / PCMG2009 / cq1 / cq1-3.html [Non-patent document 3] Kiyoshi Kurokawa et al., Clinical Laboratory Data Book, 2013, pp. 633, 636 (Igaku Shoin, Tokyo, Japan) [Non-patent document 4] International Pancreas Society Working Group, International Guidelines for the Management of IPMN / MCN (2012 Edition), pp. 4-6, 8-9 [Non-patent document 5] Miyamae M et al., 2015, British Journal of Cancer, Vol. 113, (10) p1467-1476 Summary of the Invention [Problem to be solved by the invention]

[0017] The object of the present invention is to find a novel tumor marker for early stage pancreatic cancer or pancreatic cancer precursor lesion, and to Effective detection of early stage pancreatic cancer or precursor lesions of pancreatic cancer using nucleic acids that can specifically bind to markers As described in Non-Patent Document 2, a method for detecting pancreatic cancer is provided. Tumor markers include, for example, carbohydrate antigens such as CA19-9, Span-1, and CA50. CA242, Dupan-2, TAG-72, urinary fucose, or antibodies other than glycans CEA, POA, and TPS are known to be the tumor markers for pancreatic cancer screening. The sensitivity is 70-80% for CA19-9, 70-80% for Span-1, and 70-80% for Dupan-2. The specificity is 50-60%, CEA 30-60%, and CA50 60%. The false positive rate is also high at 20-30%, so other cancers and / or pancreatic cancers and / or pancreatic cancers are not considered. There is also a possibility of false positives of benign tumors and / or benign diseases in surrounding organs. The sensitivity of detecting early-stage pancreatic cancer is generally low, and the positive rate of CA19-9 is low for pancreatic cancers smaller than 2 cm. Only 52% of cases were positive, so it is not useful for detecting early-stage pancreatic cancer. The tumor markers produced by Lewis blood type negative patients do not produce antigens, so they show false negative results. In addition, the test is not suitable for some subjects. In contrast, the detection rates by MRI and CT are insufficient, at 19.9% ​​and 1.2-2.6%, respectively. Therefore, the use of tumor markers for the detection of precursor lesions of pancreatic cancer is not recommended.

[0018] Although still in the research stage, microRNAs (miR) in biological samples such as blood There are reports on the use of the expression level of NA to distinguish pancreatic cancer, as shown below. It has not yet been put into practical use as a method for detecting early-stage pancreatic cancer or precursor lesions of pancreatic cancer.

[0019] In Patent Document 1, miR-125a-3p, miR-204-3p, and miR- A method for detecting pancreatic cancer using 3648 in combination with several other miRNAs has been demonstrated. Only healthy subjects were used as a negative control group for pancreatic cancer, and no studies were performed on cancers or benign diseases of organs other than the pancreas. There is no description of a method for detecting specific precursor lesions of pancreatic cancer using blood. Not yet.

[0020] In Patent Document 2, hsa-miR-1908-5p and hsa-miR-672 in blood Combining miRNAs such as 9-5p and hsa-miR-5195-3p to detect pancreatic cancer However, only a few samples from patients with early-stage pancreatic cancer were included, and There is no description of the specific accuracy, sensitivity, specificity, and other detection performance for blood. Furthermore, no specific method for detecting precursor lesions of pancreatic cancer has been described.

[0021] In Patent Document 3, hsa-miR-23a-3p in blood is compared with several dozen other miRNAs. Although a method for detecting pancreatic cancer by combining these methods has been shown, there are no specific methods for detecting early-stage pancreatic cancer. There is no description of the detection performance such as the degree, sensitivity, and specificity. There is no mention of cancers other than those in the upper gastrointestinal tract, and no description of methods for detecting precursor lesions to pancreatic cancer. It has not been done.

[0022] Patent Document 4 describes hsa-miR-1268a, hsa-miR-939-5p, and , hsa-miR-642b-3p in combination with dozens of other miRNAs to treat pancreatic cancer and pancreatic Although methods for detecting cancer precursor lesions have been proposed, their specific accuracy, sensitivity, and specificity for pancreatic cancer are unknown. There is no description of the detection performance of the abnormality, etc., and organs other than the pancreas are used as a negative control for pancreatic cancer. There is no mention of cancer.

[0023] In Patent Document 5, hsa-miR-296-5p in blood is compared with several dozen other miRNAs. A method for detecting pancreatic cancer and precursor lesions of pancreatic cancer by combining these two methods has been shown, but There is no description of the specific accuracy, sensitivity, specificity, and other detection performance of the method, and there is no description of the specific accuracy, sensitivity, specificity, and detection performance of the method for pancreatic cancer precursor lesions. As a negative control group, cancers and benign diseases of organs other than the pancreas were not measured, and specific specificity was not There is also no mention of.

[0024] In Non-Patent Document 5, miRNAs whose expression levels are increased in the blood of pancreatic cancer patients compared to healthy subjects are hsa-miR-638, hsa-miR-3196, hsa-miR-1225-3 p, etc., and methods for detecting pancreatic cancer by combining several of these miRNAs are being proposed. However, there is no description of cancer of organs other than the pancreas as a negative control group for pancreatic cancer. do not have.

[0025] Thus, existing tumor markers are not sufficient for detecting early stage pancreatic cancer or precursor lesions of pancreatic cancer. The performance of markers is low, and the performance and detection methods of markers still in the research stage are not specified. Therefore, when using these methods, it is difficult to differentiate healthy subjects into patients with early-stage pancreatic cancer or pancreatic cancer precursor lesions. This may lead to unnecessary additional testing due to false positives, or may lead to the diagnosis of early-stage pancreatic cancer or pancreatic cancer precursor lesions. If they are overlooked, treatment opportunities may be missed. Measuring miRNAs increases the cost of testing, making it difficult to measure them in large-scale screening such as health checkups. It is difficult to use for cleaning. Also, it is difficult to collect pancreatic tissue for measuring tumor markers. Since this is highly invasive to patients and undesirable, we are developing a method for detecting blood samples that can be collected minimally invasively. It is possible to identify patients with early stage pancreatic cancer or precursors of pancreatic cancer, and patients with early stage pancreatic cancer or precursors of pancreatic cancer are classified as patients with early stage pancreatic cancer or precursors of pancreatic cancer. A highly accurate marker for early pancreatic cancer or pancreatic cancer precursor lesions that can correctly distinguish healthy subjects from healthy subjects. In particular, since early detection and resection of pancreatic cancer is the only curative treatment, There is a strong need for a highly effective marker for early stage pancreatic cancer or precursor lesions of pancreatic cancer. [Means for solving the problem]

[0026] As a result of intensive research to solve the above problems, the present inventors have discovered a method for detecting leukemia in an early stage from blood that can be collected minimally invasively. We have identified several genes that can be used as markers for detecting pancreatic cancer or pancreatic cancer precursor lesions, and Significant detection of early stage pancreatic cancer or precursor lesions of pancreatic cancer by using heterologously binding nucleic acids This has led to the completion of the present invention.

[0027] <Summary of the Invention> That is, the present invention has the following features. (1) miR-6784-5p, a marker for early pancreatic cancer or precursor lesions of pancreatic cancer, -1181, miR-671-5p, miR-6857-5p, miR-4276, mi R-1914-3p, miR-149-3p, miR-937-5p, miR-4675 , miR-6795-5p, miR-4731-5p, miR-5090, miR-36 20-5p, miR-1343-5p, miR-6717-5p, miR-6825-5 p, miR-6738-5p, miR-6769a-5p, miR-4728-5p, m iR-652-5p, miR-4257, miR-6785-5p, miR-7110- 5p, miR-6887-5p, miR-887-3p, miR-1228-5p, mi R-5572, miR-6782-5p, miR-4298, miR-6786-5p, miR-5010-5p, miR-6087, miR-6765-5p, miR-673 2-5p, miR-6787-5p, miR-6737-5p, miR-128-2-5 p, miR-4270, miR-6861-5p, miR-6756-5p, miR-1 229-5p, miR-6891-5p, miR-6848-5p, miR-1237- 5p, miR-30c-1-3p, miR-1233-5p, miR-211-3p, m iR-4758-5p, miR-614, miR-6746-5p, miR-1915- 5p, miR-4688, miR-3917, miR-5787, miR-4632-5 p, miR-6126, miR-135a-3p, miR-8063, miR-5698 , miR-6089, miR-498, miR-296-3p, miR-4419b, m iR-6802-5p, miR-6829-5p, miR-6803-5p, miR-1 199-5p, miR-6840-3p, miR-6752-5p, miR-6798- 5p, miR-6131, miR-4667-5p, miR-6510-5p, miR- 4690-5p, miR-920, miR-23b-3p, miR-4448, miR- 2110, miR-4706, miR-7845-5p, miR-6808-5p, mi R-4447, miR-6869-5p, miR-6794-5p, miR-6511a -5p, miR-6824-5p, miR-6766-3p, miR-6511a-5p and miR-6749-5p. A kit for detecting early stage pancreatic cancer or a precursor lesion of pancreatic cancer, comprising a nucleic acid capable of specifically binding to a nucleotide .

[0028] (2) miR-6784-5p is hsa-miR-6784-5p and miR-11 81 is hsa-miR-1181, and miR-671-5p is hsa-miR-67 1-5p, miR-6857-5p is hsa-miR-6857-5p, and m iR-4276 is hsa-miR-4276, and miR-1914-3p is hsa- miR-1914-3p and miR-149-3p are hsa-miR-149-3p , miR-937-5p is hsa-miR-937-5p, and miR-467 5 is hsa-miR-4675, and miR-6795-5p is hsa-miR-67 95-5p, and miR-4731-5p is hsa-miR-4731-5p; miR-5090 is hsa-miR-5090, and miR-3620-5p is hsa -miR-3620-5p, and miR-1343-5p is hsa-miR-1343 -5p, miR-6717-5p is hsa-miR-6717-5p, and mi R-6825-5p is hsa-miR-6825-5p, and miR-6738-5p is hsa-miR-6738-5p, and miR-6769a-5p is hsa-miR -6769a-5p, and miR-4728-5p is hsa-miR-4728-5p , miR-652-5p is hsa-miR-652-5p, and miR-425 7 is hsa-miR-4257, and miR-6785-5p is hsa-miR-67 85-5p, and miR-7110-5p is hsa-miR-7110-5p; miR-6887-5p is hsa-miR-6887-5p, and miR-887-3 p is hsa-miR-887-3p, and miR-1228-5p is hsa-miR- 1228-5p, miR-5572 is hsa-miR-5572, and miR- 6782-5p is hsa-miR-6782-5p, and miR-4298 is hsa- miR-4298 and miR-6786-5p are hsa-miR-6786-5p. miR-5010-5p is hsa-miR-5010-5p, and miR-60 87 is hsa-miR-6087, and miR-6765-5p is hsa-miR-6 765-5p, miR-6732-5p is hsa-miR-6732-5p , miR-6787-5p is hsa-miR-6787-5p, and miR-6737 -5p is hsa-miR-6737-5p, and miR-128-2-5p is hsa- miR-128-2-5p and miR-4270 are hsa-miR-4270 , miR-6861-5p is hsa-miR-6861-5p, and miR-6756 -5p is hsa-miR-6756-5p, and miR-1229-5p is hsa-m iR-1229-5p and miR-6891-5p are hsa-miR-6891-5 p, miR-6848-5p is hsa-miR-6848-5p, and miR- 1237-5p is hsa-miR-1237-5p, and miR-30c-1-3p is hsa-miR-30c-1-3p, and miR-1233-5p is hsa-miR- 1233-5p, miR-211-3p is hsa-miR-211-3p, miR-4758-5p is hsa-miR-4758-5p, and miR-614 is h sa-miR-614 and miR-6746-5p is hsa-miR-6746-5 p, miR-1915-5p is hsa-miR-1915-5p, and miR- 4688 is hsa-miR-4688 and miR-3917 is hsa-miR-39 17, miR-5787 is hsa-miR-5787, and miR-4632- 5p is hsa-miR-4632-5p, and miR-6126 is hsa-miR-6 126, miR-135a-3p is hsa-miR-135a-3p, and mi R-8063 is hsa-miR-8063, and miR-5698 is hsa-miR- 5698, miR-6089 is hsa-miR-6089, and miR-498 is hsa-miR-498, and miR-296-3p is hsa-miR-296-3 p, miR-4419b is hsa-miR-4419b, and miR-6802 -5p is hsa-miR-6802-5p, and miR-6829-5p is hsa-m iR-6829-5p and miR-6803-5p are hsa-miR-6803-5 p, miR-1199-5p is hsa-miR-1199-5p, and miR- 6840-3p is hsa-miR-6840-3p, and miR-6752-5p is h sa-miR-6752-5p and miR-6798-5p are hsa-miR-67 98-5p, miR-6131 is hsa-miR-6131, and miR-46 67-5p is hsa-miR-4667-5p, and miR-6510-5p is hsa -miR-6510-5p and miR-4690-5p is hsa-miR-4690 -5p, miR-920 is hsa-miR-920, and miR-23b-3p is hsa-miR-23b-3p and miR-4448 is hsa-miR-4448 , miR-2110 is hsa-miR-2110, and miR-4706 is hs a-miR-4706 and miR-7845-5p is hsa-miR-7845-5 p, miR-6808-5p is hsa-miR-6808-5p, and miR- 4447 is hsa-miR-4447 and miR-6869-5p is hsa-miR -6869-5p, and miR-6794-5p is hsa-miR-6794-5p miR-6511a-5p is hsa-miR-6511a-5p, and miR- 6824-5p is hsa-miR-6824-5p, and miR-6766-3p is h sa-miR-6766-3p and miR-6511a-5p are hsa-miR-6 511a-5p, and miR-6749-5p is hsa-miR-6749-5p. The kit according to (1).

[0029] (3) The nucleic acid is a polynucleotide represented by any one of the following (a) to (e): (a) SEQ ID NO: 1 to 83, 227 to 229, 246, 248, and 250 or a polynucleotide consisting of a base sequence in which u is t a nucleotide, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases; (b) SEQ ID NO: 1 to 83, 227 to 229, 246, 248, and 250 a polynucleotide comprising a base sequence to be (c) SEQ ID NO: 1 to 83, 227 to 229, 246, 248, and 250 A base sequence complementary to the base sequence in which u is t or the base sequence in which u is t a polynucleotide consisting of, or a variant or derivative thereof, or a polynucleotide containing 15 or more consecutive bases Fragments of Muso, (d) SEQ ID NO: 1 to 83, 227 to 229, 246, 248, and 250 A base sequence complementary to the base sequence in which u is t or the base sequence in which u is t a polynucleotide comprising (e) A polynucleotide that binds to any one of the polynucleotides (a) to (d) under stringent conditions. hybridizing polynucleotides, The kit according to (1) or (2), wherein the polynucleotide is selected from the group consisting of:

[0030] (4) The above kit detects miR-19, another marker for early pancreatic cancer or pancreatic cancer precursor lesions. 08-5p, miR-6729-5p, miR-5195-3p, miR-638, mi R-6125, miR-3178, miR-3196, miR-8069, miR-47 23-5p, miR-4746-3p, miR-4689, miR-6816-5p, m iR-6757-5p, miR-7109-5p, miR-6724-5p, miR-1 225-3p, miR-6875-5p, miR-7108-5p, miR-4508, miR-6085, miR-6779-5p, miR-642a-3p, miR-469 5-5p, miR-7847-3p, miR-3197, miR-6769b-5p, m iR-7641, miR-187-5p, miR-3185, miR-2861, miR -3940-5p, miR-1203, miR-615-5p, miR-4787-5p , miR-1343-3p, miR-6813-5p, miR-1225-5p, miR -602, miR-4488, miR-125a-3p, miR-5100, miR-4 294, miR-1231, miR-6765-3p, miR-4442, miR-71 8, miR-6780b-5p, miR-6090, miR-6845-5p, miR- 4741、miR-4467、miR-4707-5p、miR-4271、miR-4 673、miR-3184-5p、miR-1469、miR-4640-5p、miR -663a、miR-6791-5p、miR-6826-5p、miR-4433b- 3p、miR-1915-3p、miR-4417、miR-4449、miR-470 7-3p、miR-3180-3p、miR-5585-3p、miR-1268a、m iR-8072、miR-296-5p、miR-204-3p、miR-4454、m iR-6722-3p、miR-1290、miR-3622a-5p、miR-939 -5p、miR-675-5p、miR-3131、miR-4648、miR-126 8b、miR-6741-5p、miR-6893-5p、miR-3162-5p、m iR-642b-3p、miR-4734、miR-150-3p、miR-8089、 miR-6805-3p、miR-7113-3p、miR-6850-5p、miR- 6799-5p、miR-6768-5p、miR-92b-5p、miR-3679- 5p、miR-4792、miR-3656、miR-92a-2-5p、miR-44 66、miR-4513、miR-6781-5p、miR-4649-5p、miR- 6775-5p、miR-4651、miR-3195、miR-6726-5p、mi R-6872-3p、miR-371a-5p、miR-6777-5p、miR-67 89-5p、miR-7975、miR-6821-5p、miR-4534、miR- 619-5p、miR-7107-5p、miR-1228-3p、miR-6774- 5p、miR-6805-5p、miR-23a-3p、miR-4665-5p、mi R-4505, miR-4638-5p, miR-24-3p, miR-3135b, m iR-4745-5p, miR-128-1-5p, miR-4476, miR-468 7-3p, miR-3665, miR-6806-5p, miR-3937, miR-7 11, miR-3141, miR-3188, miR-4281, miR-5196-5 p, miR-6880-5p, miR-3960, miR-3648, miR-6721 -5p, miR-4492, miR-744-5p, miR-7704, miR-474 9-5p, miR-762, miR-6836-3p, miR-6727-5p, miR -4739, miR-7977, miR-4484, miR-6515-3p, miR- 373-5p, miR-4258, miR-4674, miR-3180, miR-60 76, miR-1238-5p, miR-4463, miR-4486, miR-473 At least one selected from the group consisting of miR-4286, miR-4739, and miR-4286. Any one of (1) to (3) further comprising a nucleic acid capable of specifically binding to one polynucleotide. The kit according to any one of the preceding claims.

[0031] (5) miR-1908-5p is hsa-miR-1908-5p and miR-67 29-5p is hsa-miR-6729-5p, and miR-5195-3p is hsa -miR-5195-3p, miR-638 is hsa-miR-638, and m iR-6125 is hsa-miR-6125 and miR-3178 is hsa-miR -3178, miR-3196 is hsa-miR-3196, and miR-80 69 is hsa-miR-8069, and miR-4723-5p is hsa-miR-4 723-5p, and miR-4746-3p is hsa-miR-4746-3p , miR-4689 is hsa-miR-4689, and miR-6816-5p is hs a-miR-6816-5p and miR-6757-5p are hsa-miR-675 7-5p, miR-7109-5p is hsa-miR-7109-5p, and m iR-6724-5p is hsa-miR-6724-5p, and miR-1225-3 p is hsa-miR-1225-3p and miR-6875-5p is hsa-miR -6875-5p, and miR-7108-5p is hsa-miR-7108-5p miR-4508 is hsa-miR-4508 and miR-6085 is hsa -miR-6085 and miR-6779-5p is hsa-miR-6779-5p , miR-642a-3p is hsa-miR-642a-3p, and miR-4 695-5p is hsa-miR-4695-5p, and miR-7847-3p is hs a-miR-7847-3p, and miR-3197 is hsa-miR-3197. miR-6769b-5p is hsa-miR-6769b-5p, and miR-7 641 is hsa-miR-7641, and miR-187-5p is hsa-miR-1 87-5p, miR-3185 is hsa-miR-3185, and miR-28 61 is hsa-miR-2861, and miR-3940-5p is hsa-miR-3 940-5p, miR-1203 is hsa-miR-1203, and miR-6 15-5p is hsa-miR-615-5p, and miR-4787-5p is hsa- miR-4787-5p and miR-1343-3p are hsa-miR-1343- 3p, miR-6813-5p is hsa-miR-6813-5p, and miR -1225-5p is hsa-miR-1225-5p, and miR-602 is hsa- miR-602, miR-4488 is hsa-miR-4488, and miR- 125a-3p is hsa-miR-125a-3p, and miR-5100 is hsa- miR-5100, miR-4294 is hsa-miR-4294, and miR -1231 is hsa-miR-1231, and miR-6765-3p is hsa-mi miR-6765-3p, miR-4442 is hsa-miR-4442, and mi R-718 is hsa-miR-718, and miR-6780b-5p is hsa-mi R-6780b-5p, miR-6090 is hsa-miR-6090, and m iR-6845-5p is hsa-miR-6845-5p, and miR-4741 is h sa-miR-4741, and miR-4467 is hsa-miR-4467; miR-4707-5p is hsa-miR-4707-5p, and miR-4271 is hsa-miR-4271 and miR-4673 are hsa-miR-4673 , miR-3184-5p is hsa-miR-3184-5p, and miR-1469 is hsa-miR-1469 and miR-4640-5p is hsa-miR-464 0-5p, miR-663a is hsa-miR-663a, and miR-679 1-5p is hsa-miR-6791-5p, and miR-6826-5p is hsa- miR-6826-5p and miR-4433b-3p are hsa-miR-4433 b-3p, miR-1915-3p is hsa-miR-1915-3p, and m iR-4417 is hsa-miR-4417 and miR-4449 is hsa-miR -4449, and miR-4707-3p is hsa-miR-4707-3p; miR-3180-3p is hsa-miR-3180-3p, and miR-5585- 3p is hsa-miR-5585-3p, and miR-1268a is hsa-miR- 1268a, miR-8072 is hsa-miR-8072, and miR-29 6-5p is hsa-miR-296-5p, and miR-204-3p is hsa-mi miR-204-3p, miR-4454 is hsa-miR-4454, and miR -6722-3p is hsa-miR-6722-3p, and miR-1290 is hsa -miR-1290, and miR-3622a-5p is hsa-miR-3622a- 5p, miR-939-5p is hsa-miR-939-5p, and miR-6 75-5p is hsa-miR-675-5p, and miR-3131 is hsa-miR -3131, miR-4648 is hsa-miR-4648, and miR-12 68b is hsa-miR-1268b, and miR-6741-5p is hsa-miR -6741-5p, and miR-6893-5p is hsa-miR-6893-5p miR-3162-5p is hsa-miR-3162-5p, and miR-64 2b-3p is hsa-miR-642b-3p, and miR-4734 is hsa-mi R-4734, miR-150-3p is hsa-miR-150-3p, and m iR-8089 is hsa-miR-8089, and miR-6805-3p is hsa- miR-6805-3p and miR-7113-3p are hsa-miR-7113- 3p, miR-6850-5p is hsa-miR-6850-5p, and miR -6799-5p is hsa-miR-6799-5p, and miR-6768-5p is hsa-miR-6768-5p and miR-92b-5p are hsa-miR-92 b-5p, miR-3679-5p is hsa-miR-3679-5p, and m iR-4792 is hsa-miR-4792 and miR-3656 is hsa-miR -3656, and miR-92a-2-5p is hsa-miR-92a-2-5p. miR-4466 is hsa-miR-4466, and miR-4513 is hsa- miR-4513 and miR-6781-5p are hsa-miR-6781-5p. miR-4649-5p is hsa-miR-4649-5p, and miR-67 75-5p is hsa-miR-6775-5p, and miR-4651 is hsa-mi R-4651, miR-3195 is hsa-miR-3195, and miR-6 726-5p is hsa-miR-6726-5p, and miR-6872-3p is hs a-miR-6872-3p and miR-371a-5p are hsa-miR-371 a-5p, miR-6777-5p is hsa-miR-6777-5p, and m iR-6789-5p is hsa-miR-6789-5p, and miR-7975 is h sa-miR-7975 and miR-6821-5p is hsa-miR-6821- 5p, miR-4534 is hsa-miR-4534, and miR-619-5 p is hsa-miR-619-5p, and miR-7107-5p is hsa-miR- 7107-5p, and miR-1228-3p is hsa-miR-1228-3p. miR-6774-5p is hsa-miR-6774-5p, and miR-680 5-5p is hsa-miR-6805-5p, and miR-23a-3p is hsa-m iR-23a-3p and miR-4665-5p are hsa-miR-4665-5p , miR-4505 is hsa-miR-4505, and miR-4638-5p is hsa-miR-4638-5p, and miR-24-3p is hsa-miR-24 -3p, miR-3135b is hsa-miR-3135b, and miR-47 45-5p is hsa-miR-4745-5p, and miR-128-1-5p is hs a-miR-128-1-5p and miR-4476 is hsa-miR-4476 miR-4687-3p is hsa-miR-4687-3p, and miR-36 65 is hsa-miR-3665, and miR-6806-5p is hsa-miR-6 806-5p, miR-3937 is hsa-miR-3937, and miR-7 11 is hsa-miR-711 and miR-3141 is hsa-miR-3141 miR-3188 is hsa-miR-3188, and miR-4281 is hsa -miR-4281 and miR-5196-5p is hsa-miR-5196-5p , miR-6880-5p is hsa-miR-6880-5p, and miR-3 960 is hsa-miR-3960 and miR-3648 is hsa-miR-364 8, miR-6721-5p is hsa-miR-6721-5p, and miR- 4492 is hsa-miR-4492, and miR-744-5p is hsa-miR- 744-5p, miR-7704 is hsa-miR-7704, and miR-4 749-5p is hsa-miR-4749-5p, and miR-762 is hsa-mi R-762, and miR-6836-3p is hsa-miR-6836-3p; miR-6727-5p is hsa-miR-6727-5p, and miR-4739 is hsa-miR-4739 and miR-7977 , miR-4484 is hsa-miR-4484, and miR-6515-3p is hs a-miR-6515-3p and miR-373-5p are hsa-miR-373- 5p, miR-4258 is hsa-miR-4258, and miR-4674 is hsa-miR-4674 and miR-3180 are hsa-miR-3180 , miR-6076 is hsa-miR-6076, and miR-1238-5p is hs a-miR-1238-5p and miR-4463 is hsa-miR-4463 miR-4486 is hsa-miR-4486, and miR-4730 is hsa- miR-4730, miR-4286 is hsa-miR-4286, and miR The kit according to (4), wherein -4739 is hsa-miR-4739.

[0032] (6) The nucleic acid is a polynucleotide represented by any one of the following (f) to (j): (f) a sequence represented by any one of SEQ ID NOs: 84 to 226, 230 to 245, 247, and 249; or a polynucleotide consisting of a base sequence in which u is t a fragment thereof containing 15 or more consecutive bases, (g) a sequence represented by any one of SEQ ID NOs: 84 to 226, 230 to 245, 247, and 249 a polynucleotide comprising a base sequence (h) a sequence number represented by any one of SEQ ID NOs: 84 to 226, 230 to 245, 247, and 249; or a base sequence complementary to the base sequence in which u is t a polynucleotide comprising 15 or more consecutive bases, a variant thereof, a derivative thereof, or a polynucleotide comprising 15 or more consecutive bases Fragments of, (i) Represented by any of SEQ ID NOs: 84 to 226, 230 to 245, 247, and 249 or a base sequence complementary to the base sequence in which u is t in the base sequence. a polynucleotide comprising the (j) A method for detecting a polynucleotide that is hybridized with any one of the polynucleotides (f) to (i) under stringent conditions. hybridizing polynucleotides, The kit according to (4) or (5), wherein the polynucleotide is selected from the group consisting of:

[0033] (7) miR-6784-5p, a marker for early pancreatic cancer or precursor lesions of pancreatic cancer, -1181, miR-671-5p, miR-6857-5p, miR-4276, mi R-1914-3p, miR-149-3p, miR-937-5p, miR-4675 , miR-6795-5p, miR-4731-5p, miR-5090, miR-36 20-5p, miR-1343-5p, miR-6717-5p, miR-6825-5 p, miR-6738-5p, miR-6769a-5p, miR-4728-5p, m iR-652-5p、miR-4257、miR-6785-5p、miR-7110- 5p、miR-6887-5p、miR-887-3p、miR-1228-5p、mi R-5572、miR-6782-5p、miR-4298、miR-6786-5p、 miR-5010-5p、miR-6087、miR-6765-5p、miR-673 2-5p、miR-6787-5p、miR-6737-5p、miR-128-2-5 p、miR-4270、miR-6861-5p、miR-6756-5p、miR-1 229-5p、miR-6891-5p、miR-6848-5p、miR-1237- 5p、miR-30c-1-3p、miR-1233-5p、miR-211-3p、m iR-4758-5p、miR-614、miR-6746-5p、miR-1915- 5p、miR-4688、miR-3917、miR-5787、miR-4632-5 p, miR-6126, miR-135a-3p, miR-8063, miR-5698 miR-6089, miR-498, miR-296-3p, miR-4419b, m iR-6802-5p、miR-6829-5p、miR-6803-5p、miR-1 199-5p、miR-6840-3p、miR-6752-5p、miR-6798- 5p、miR-6131、miR-4667-5p、miR-6510-5p、miR- 4690-5p、miR-920、miR-23b-3p、miR-4448、miR- 2110、miR-4706、miR-7845-5p、miR-6808-5p、mi R-4447、miR-6869-5p、miR-6794-5p、miR-6511a -5p、miR-6824-5p、miR-6766-3p、miR-6511a-5p and miR-6749-5p. A device for detecting early stage pancreatic cancer or a precursor lesion of pancreatic cancer, comprising a heterologously binding nucleic acid.

[0034] (8) miR-6784-5p is hsa-miR-6784-5p, and miR-11 81 is hsa-miR-1181, and miR-671-5p is hsa-miR-67 1-5p, miR-6857-5p is hsa-miR-6857-5p, and m iR-4276 is hsa-miR-4276, and miR-1914-3p is hsa- miR-1914-3p and miR-149-3p are hsa-miR-149-3p , miR-937-5p is hsa-miR-937-5p, and miR-467 5 is hsa-miR-4675, and miR-6795-5p is hsa-miR-67 95-5p, and miR-4731-5p is hsa-miR-4731-5p; miR-5090 is hsa-miR-5090, and miR-3620-5p is hsa -miR-3620-5p, and miR-1343-5p is hsa-miR-1343 -5p, miR-6717-5p is hsa-miR-6717-5p, and mi R-6825-5p is hsa-miR-6825-5p, and miR-6738-5p is hsa-miR-6738-5p, and miR-6769a-5p is hsa-miR -6769a-5p, and miR-4728-5p is hsa-miR-4728-5p , miR-652-5p is hsa-miR-652-5p, and miR-425 7 is hsa-miR-4257, and miR-6785-5p is hsa-miR-67 85-5p, and miR-7110-5p is hsa-miR-7110-5p; miR-6887-5p is hsa-miR-6887-5p, and miR-887-3 p is hsa-miR-887-3p, and miR-1228-5p is hsa-miR- 1228-5p, miR-5572 is hsa-miR-5572, and miR- 6782-5p is hsa-miR-6782-5p, and miR-4298 is hsa- miR-4298 and miR-6786-5p are hsa-miR-6786-5p. miR-5010-5p is hsa-miR-5010-5p, and miR-60 87 is hsa-miR-6087, and miR-6765-5p is hsa-miR-6 765-5p, miR-6732-5p is hsa-miR-6732-5p , miR-6787-5p is hsa-miR-6787-5p, and miR-6737 -5p is hsa-miR-6737-5p, and miR-128-2-5p is hsa- miR-128-2-5p and miR-4270 are hsa-miR-4270 , miR-6861-5p is hsa-miR-6861-5p, and miR-6756 -5p is hsa-miR-6756-5p, and miR-1229-5p is hsa-m iR-1229-5p and miR-6891-5p are hsa-miR-6891-5 p, miR-6848-5p is hsa-miR-6848-5p, and miR- 1237-5p is hsa-miR-1237-5p, and miR-30c-1-3p is hsa-miR-30c-1-3p, and miR-1233-5p is hsa-miR- 1233-5p, miR-211-3p is hsa-miR-211-3p, miR-4758-5p is hsa-miR-4758-5p, and miR-614 is h sa-miR-614 and miR-6746-5p is hsa-miR-6746-5 p, miR-1915-5p is hsa-miR-1915-5p, and miR- 4688 is hsa-miR-4688 and miR-3917 is hsa-miR-39 17, miR-5787 is hsa-miR-5787, and miR-4632- 5p is hsa-miR-4632-5p, and miR-6126 is hsa-miR-6 126, miR-135a-3p is hsa-miR-135a-3p, and mi R-8063 is hsa-miR-8063, and miR-5698 is hsa-miR- 5698, miR-6089 is hsa-miR-6089, and miR-498 is hsa-miR-498, and miR-296-3p is hsa-miR-296-3 p, miR-4419b is hsa-miR-4419b, and miR-6802 -5p is hsa-miR-6802-5p, and miR-6829-5p is hsa-m iR-6829-5p and miR-6803-5p are hsa-miR-6803-5 p, miR-1199-5p is hsa-miR-1199-5p, and miR- 6840-3p is hsa-miR-6840-3p, and miR-6752-5p is h sa-miR-6752-5p and miR-6798-5p are hsa-miR-67 98-5p, miR-6131 is hsa-miR-6131, and miR-46 67-5p is hsa-miR-4667-5p, and miR-6510-5p is hsa -miR-6510-5p and miR-4690-5p is hsa-miR-4690 -5p, miR-920 is hsa-miR-920, and miR-23b-3p is hsa-miR-23b-3p and miR-4448 is hsa-miR-4448 , miR-2110 is hsa-miR-2110, and miR-4706 is hs a-miR-4706 and miR-7845-5p is hsa-miR-7845-5 p, miR-6808-5p is hsa-miR-6808-5p, and miR- 4447 is hsa-miR-4447 and miR-6869-5p is hsa-miR -6869-5p, and miR-6794-5p is hsa-miR-6794-5p miR-6511a-5p is hsa-miR-6511a-5p, and miR- 6824-5p is hsa-miR-6824-5p, and miR-6766-3p is h sa-miR-6766-3p and miR-6511a-5p are hsa-miR-6 511a-5p, and miR-6749-5p is hsa-miR-6749-5p. The device according to (7).

[0035] (9) The nucleic acid is a polynucleotide represented by any one of the following (a) to (e): (a) SEQ ID NO: 1 to 83, 227 to 229, 246, 248, and 250 or a polynucleotide consisting of a base sequence in which u is t a nucleotide, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases; (b) SEQ ID NO: 1 to 83, 227 to 229, 246, 248, and 250 a polynucleotide comprising a base sequence to be (c) SEQ ID NO: 1 to 83, 227 to 229, 246, 248, and 250 A base sequence complementary to the base sequence in which u is t or the base sequence in which u is t a polynucleotide consisting of, or a variant or derivative thereof, or a polynucleotide containing 15 or more consecutive bases Fragments of Muso, (d) SEQ ID NO: 1 to 83, 227 to 229, 246, 248, and 250 A base sequence complementary to the base sequence in which u is t or the base sequence in which u is t a polynucleotide comprising (e) A polynucleotide that binds to any one of the polynucleotides (a) to (d) under stringent conditions. hybridizing polynucleotides, The device according to (7) or (8), wherein the polynucleotide is selected from the group consisting of .

[0036] (10) The device is characterized in that it is capable of detecting miR-, another marker for early stage pancreatic cancer or a precursor lesion of pancreatic cancer, 1908-5p, miR-6729-5p, miR-5195-3p, miR-638, miR-6125, miR-3178, miR-3196, miR-8069, miR- 4723-5p, miR-4746-3p, miR-4689, miR-6816-5p , miR-6757-5p, miR-7109-5p, miR-6724-5p, miR -1225-3p, miR-6875-5p, miR-7108-5p, miR-450 8, miR-6085, miR-6779-5p, miR-642a-3p, miR-4 695-5p, miR-7847-3p, miR-3197, miR-6769b-5p , miR-7641, miR-187-5p, miR-3185, miR-2861, m iR-3940-5p、miR-1203、miR-615-5p、miR-4787- 5p、miR-1343-3p、miR-6813-5p、miR-1225-5p、m iR-602、miR-4488、miR-125a-3p、miR-5100、miR -4294、miR-1231、miR-6765-3p、miR-4442、miR- 718、miR-6780b-5p、miR-6090、miR-6845-5p、mi R-4741、miR-4467、miR-4707-5p、miR-4271、miR -4673、miR-3184-5p、miR-1469、miR-4640-5p、m iR-663a、miR-6791-5p、miR-6826-5p、miR-4433 b-3p、miR-1915-3p、miR-4417、miR-4449、miR-4 707-3p、miR-3180-3p、miR-5585-3p、miR-1268a miR-8072, miR-296-5p, miR-204-3p, miR-4454 miR-6722-3p, miR-1290, miR-3622a-5p, miR-9 39-5p、miR-675-5p、miR-3131、miR-4648、miR-1 268b、miR-6741-5p、miR-6893-5p、miR-3162-5p miR-642b-3p, miR-4734, miR-150-3p, miR-808 9、miR-6805-3p、miR-7113-3p、miR-6850-5p、mi R-6799-5p、miR-6768-5p、miR-92b-5p、miR-367 9-5p、miR-4792、miR-3656、miR-92a-2-5p、miR- 4466、miR-4513、miR-6781-5p、miR-4649-5p、mi R-6775-5p, miR-4651, miR-3195, miR-6726-5p, miR-6872-3p, miR-371a-5p, miR-6777-5p, miR- 6789-5p, miR-7975, miR-6821-5p, miR-4534, mi R-619-5p, miR-7107-5p, miR-1228-3p, miR-677 4-5p, miR-6805-5p, miR-23a-3p, miR-4665-5p, miR-4505, miR-4638-5p, miR-24-3p, miR-3135b , miR-4745-5p, miR-128-1-5p, miR-4476, miR-4 687-3p, miR-3665, miR-6806-5p, miR-3937, miR -711, miR-3141, miR-3188, miR-4281, miR-5196 -5p, miR-6880-5p, miR-3960, miR-3648, miR-67 21-5p, miR-4492, miR-744-5p, miR-7704, miR-4 749-5p, miR-762, miR-6836-3p, miR-6727-5p, m iR-4739, miR-7977, miR-4484, miR-6515-3p, mi R-373-5p, miR-4258, miR-4674, miR-3180, miR- 6076, miR-1238-5p, miR-4463, miR-4486, miR-4 730, miR-4286, and miR-4739. Any of (7) to (9) further comprising a nucleic acid capable of specifically binding to another polynucleotide. Any device described in

[0037] (11) miR-1908-5p is hsa-miR-1908-5p, and miR-6 729-5p is hsa-miR-6729-5p, and miR-5195-3p is hs a-miR-5195-3p, and miR-638 is hsa-miR-638; miR-6125 is hsa-miR-6125 and miR-3178 is hsa-mi miR-3178, miR-3196 is hsa-miR-3196, and miR-8 069 is hsa-miR-8069, and miR-4723-5p is hsa-miR- 4723-5p, and miR-4746-3p is hsa-miR-4746-3p. miR-4689 is hsa-miR-4689, and miR-6816-5p is hsa-miR-4689. sa-miR-6816-5p and miR-6757-5p are hsa-miR-67 57-5p, and miR-7109-5p is hsa-miR-7109-5p; miR-6724-5p is hsa-miR-6724-5p, and miR-1225- 3p is hsa-miR-1225-3p, and miR-6875-5p is hsa-mi miR-6875-5p and miR-7108-5p is hsa-miR-7108-5p , miR-4508 is hsa-miR-4508, and miR-6085 is hs a-miR-6085 and miR-6779-5p is hsa-miR-6779-5 p, miR-642a-3p is hsa-miR-642a-3p, and miR- 4695-5p is hsa-miR-4695-5p, and miR-7847-3p is h sa-miR-7847-3p and miR-3197 is hsa-miR-3197 miR-6769b-5p is hsa-miR-6769b-5p, and miR- 7641 is hsa-miR-7641, and miR-187-5p is hsa-miR- 187-5p, miR-3185 is hsa-miR-3185, and miR-2 861 is hsa-miR-2861, and miR-3940-5p is hsa-miR- 3940-5p, miR-1203 is hsa-miR-1203, and miR- 615-5p is hsa-miR-615-5p, and miR-4787-5p is hsa -miR-4787-5p, and miR-1343-3p is hsa-miR-1343 -3p, miR-6813-5p is hsa-miR-6813-5p, and mi R-1225-5p is hsa-miR-1225-5p, and miR-602 is hsa -miR-602, miR-4488 is hsa-miR-4488, and miR -125a-3p is hsa-miR-125a-3p, and miR-5100 is hsa -miR-5100, miR-4294 is hsa-miR-4294, and mi R-1231 is hsa-miR-1231, and miR-6765-3p is hsa-m iR-6765-3p, miR-4442 is hsa-miR-4442, and m iR-718 is hsa-miR-718, and miR-6780b-5p is hsa-m iR-6780b-5p, miR-6090 is hsa-miR-6090, miR-6845-5p is hsa-miR-6845-5p, and miR-4741 is hsa-miR-4741 and miR-4467 , miR-4707-5p is hsa-miR-4707-5p, and miR-4271 is hsa-miR-4271 and miR-4673 is hsa-miR-4673 miR-3184-5p is hsa-miR-3184-5p, and miR-146 9 is hsa-miR-1469, and miR-4640-5p is hsa-miR-46 40-5p, miR-663a is hsa-miR-663a, and miR-67 91-5p is hsa-miR-6791-5p, and miR-6826-5p is hsa -miR-6826-5p, and miR-4433b-3p is hsa-miR-443 3b-3p, miR-1915-3p is hsa-miR-1915-3p, miR-4417 is hsa-miR-4417 and miR-4449 is hsa-mi R-4449, miR-4707-3p is hsa-miR-4707-3p , miR-3180-3p is hsa-miR-3180-3p, and miR-5585 -3p is hsa-miR-5585-3p, and miR-1268a is hsa-miR -1268a, miR-8072 is hsa-miR-8072, and miR-2 96-5p is hsa-miR-296-5p, and miR-204-3p is hsa-m iR-204-3p, miR-4454 is hsa-miR-4454, and mi R-6722-3p is hsa-miR-6722-3p, and miR-1290 is hs a-miR-1290 and miR-3622a-5p are hsa-miR-3622a -5p, miR-939-5p is hsa-miR-939-5p, and miR- 675-5p is hsa-miR-675-5p, and miR-3131 is hsa-mi R-3131, miR-4648 is hsa-miR-4648, and miR-1 268b is hsa-miR-1268b, and miR-6741-5p is hsa-mi miR-6741-5p and miR-6893-5p is hsa-miR-6893-5p , miR-3162-5p is hsa-miR-3162-5p, and miR-6 42b-3p is hsa-miR-642b-3p, and miR-4734 is hsa-m iR-4734, miR-150-3p is hsa-miR-150-3p, miR-8089 is hsa-miR-8089, and miR-6805-3p is hsa -miR-6805-3p, and miR-7113-3p is hsa-miR-7113 -3p, miR-6850-5p is hsa-miR-6850-5p, and mi R-6799-5p is hsa-miR-6799-5p, and miR-6768-5p is hsa-miR-6768-5p, and miR-92b-5p is hsa-miR-9 2b-5p, and miR-3679-5p is hsa-miR-3679-5p; miR-4792 is hsa-miR-4792 and miR-3656 is hsa-mi R-3656, and miR-92a-2-5p is hsa-miR-92a-2-5p. miR-4466 is hsa-miR-4466, and miR-4513 is hsa -miR-4513 and miR-6781-5p is hsa-miR-6781-5p , miR-4649-5p is hsa-miR-4649-5p, and miR-6 775-5p is hsa-miR-6775-5p, and miR-4651 is hsa-m iR-4651, miR-3195 is hsa-miR-3195, and miR- 6726-5p is hsa-miR-6726-5p, and miR-6872-3p is h sa-miR-6872-3p and miR-371a-5p are hsa-miR-37 1a-5p, miR-6777-5p is hsa-miR-6777-5p, miR-6789-5p is hsa-miR-6789-5p, and miR-7975 is hsa-miR-7975 and miR-6821-5p are hsa-miR-6821 -5p, miR-4534 is hsa-miR-4534, and miR-619- 5p is hsa-miR-619-5p and miR-7107-5p is hsa-miR -7107-5p, and miR-1228-3p is hsa-miR-1228-3p. miR-6774-5p is hsa-miR-6774-5p, and miR-68 05-5p is hsa-miR-6805-5p, and miR-23a-3p is hsa- miR-23a-3p and miR-4665-5p are hsa-miR-4665-5 p, miR-4505 is hsa-miR-4505, and miR-4638-5 p is hsa-miR-4638-5p, and miR-24-3p is hsa-miR-2 4-3p, miR-3135b is hsa-miR-3135b, and miR-4 745-5p is hsa-miR-4745-5p, and miR-128-1-5p is h sa-miR-128-1-5p and miR-4476 is hsa-miR-4476 , miR-4687-3p is hsa-miR-4687-3p, and miR-3 665 is hsa-miR-3665, and miR-6806-5p is hsa-miR- 6806-5p, miR-3937 is hsa-miR-3937, and miR- 711 is hsa-miR-711 and miR-3141 is hsa-miR-3141 , miR-3188 is hsa-miR-3188, and miR-4281 is hs a-miR-4281 and miR-5196-5p is hsa-miR-5196-5 p, miR-6880-5p is hsa-miR-6880-5p, and miR- 3960 is hsa-miR-3960 and miR-3648 is hsa-miR-36 48, miR-6721-5p is hsa-miR-6721-5p, and miR -4492 is hsa-miR-4492, and miR-744-5p is hsa-miR -744-5p, miR-7704 is hsa-miR-7704, and miR- 4749-5p is hsa-miR-4749-5p, and miR-762 is hsa-m iR-762, miR-6836-3p is hsa-miR-6836-3p , miR-6727-5p is hsa-miR-6727-5p, and miR-4739 is hsa-miR-4739 and miR-7977 is hsa-miR-7977 miR-4484 is hsa-miR-4484, and miR-6515-3p is hsa-miR-4484. sa-miR-6515-3p and miR-373-5p are hsa-miR-373 -5p, miR-4258 is hsa-miR-4258, and miR-4674 is hsa-miR-4674 and miR-3180 is hsa-miR-3180 miR-6076 is hsa-miR-6076, and miR-1238-5p is hsa-miR-6076. sa-miR-1238-5p and miR-4463 is hsa-miR-4463 miR-4486 is hsa-miR-4486, and miR-4730 is hsa -miR-4730, miR-4286 is hsa-miR-4286, mi The device according to (10), wherein R-4739 is hsa-miR-4739.

[0038] (12) The nucleic acid is a polynucleotide represented by any one of the following (f) to (j): (f) a sequence represented by any one of SEQ ID NOs: 84 to 226, 230 to 245, 247, and 249; or a polynucleotide consisting of a base sequence in which u is t a fragment thereof containing 15 or more consecutive bases, (g) a sequence represented by any one of SEQ ID NOs: 84 to 226, 230 to 245, 247, and 249 a polynucleotide comprising a base sequence (h) a sequence number represented by any one of SEQ ID NOs: 84 to 226, 230 to 245, 247, and 249; or a base sequence complementary to the base sequence in which u is t a polynucleotide comprising 15 or more consecutive bases, a variant thereof, a derivative thereof, or a polynucleotide comprising 15 or more consecutive bases Fragments of, (i) Represented by any of SEQ ID NOs: 84 to 226, 230 to 245, 247, and 249 or a base sequence complementary to the base sequence in which u is t in the base sequence. a polynucleotide comprising the (j) A polynucleotide that binds to any of the polynucleotides (f) to (i) above under stringent conditions. hybridizing polynucleotides, The device according to (10) or (11), which is a polynucleotide selected from the group consisting of Chair.

[0039] (13) The device is a device for measurement by hybridization technology. The device according to any one of (7) to (12).

[0040] (14) The method according to (13), wherein the hybridization technique is a nucleic acid array technique. device.

[0041] (15) The kit according to any one of (1) to (6) or (7) to (14). The device is used to measure the expression level of a target nucleic acid in a specimen of a subject, and the measured expression level is The expression level of the gene in the subject's pancreas and the expression level of the gene in the control healthy subjects measured in the same manner were used to determine whether the subject has early stage pancreatic cancer or pancreatic cancer. Precursor lesions of pancreatic cancer or no early stage pancreatic cancer or precursor lesions of pancreatic cancer and assessing in vitro the presence or absence of early stage pancreatic cancer or pancreatic cancer precursors in the subject. Detecting early stage pancreatic cancer or pancreatic cancer precursors in a subject, including detecting the presence or absence of a lesion. Lesion detection methods.

[0042] (16) The kit according to any one of (1) to (6) or (7) to (14). The device is used to measure the expression level of the target gene in the subject's sample, and the diagnosis of early-stage pancreatic cancer or The gene expression levels of samples from subjects known to have pancreatic cancer precursor lesions were compared with those of healthy subjects. The gene expression levels of previous specimens were used as training samples, and the data were used to analyze early stage pancreatic cancer or pre-pancreatic cancer. A discriminant function that can distinguish between a diseased and a healthy individual is generated based on the subject. The expression level of the target gene in the previous sample was then substituted, thereby determining whether early stage pancreatic cancer or pancreatic cancer precursor disease was present. and assessing the presence or absence of early stage pancreatic cancer or pancreatic cancer precursor disease in a subject. How to detect anomalies.

[0043] (17) The method according to (15) or (16), wherein the subject is a human.

[0044] (18) The sample according to any one of (15) to (17), wherein the sample is blood, serum, or plasma. How to do it.

[0045] <Terminology> Terms used herein have the following definitions.

[0046] As used herein, "pancreatic cancer" refers to invasive ductal carcinoma of the pancreas. Specifically, it refers to papillary adenocarcinoma (PAP) that forms in the pancreas. illary adenocarcinoma), tubular adenocarcinoma ocarcinoma), poorly differentiated adenocarcinoma adenocarcinoma), adenosquamous carcinoma cinoma), mucinous carcinoma, anaplastic carcinoma (anap) Pancreatic carcinoma) ("Pancreatic Cancer Guidelines," 6th edition, supplement) Revised edition, 2013, Japan Pancreas Society, Kanehara Publishing (Tokyo, Japan), pp. 27-28).

[0047] As used herein, the term "precursor lesion of pancreatic cancer" refers to an exocrine tumor (ExC) that forms in the pancreas. Serous cystic tumors are classified as cystic tumors. scysticneoplasms (SCNs), serous cystadenomas (SCNs) tadenoma (SCA), serous cystadenocarcinoma (SCA), serous cystadenocarcinoma (SCA) cinoma (SCC), mucinous cystic neoplasia sms:MCNs), mucinous cystadenomas (MCNs), Mucinous cystadenomas (MCNs) A) Mucinous cystadenocarcinoma (MC) C) Intraductal papillary mucinous neoplasm intraductal papillary mucinous adenomas (IPMNs), alpapillary-mucinous adenoma (IPMA), intraductal papillary mucinoma Liquid adenocarcinoma (intraductal papillary-mucinous carcinoma) oma:IPMC), etc. ("Pancreatic Cancer Guidelines," 6th revised edition, 2013 , Japan Pancreas Society, Kanehara Publishing (Tokyo, Japan), pp. 24-27).

[0048] In this specification, the "stage of progression of pancreatic cancer" refers to the local progression of the main tumor, lymph node metastasis, and distant metastasis. Depending on the stage, it can be divided into stages 0, IA, IB, IIA, IIB, III, IVa, and IVb. ("Pancreatic Cancer Treatment Guidelines," 6th revised edition, 2013, Japan Pancreas Society, Kanehara Publishing (Tokyo, Japan), pp. 55-57).

[0049] As used herein, "early pancreatic cancer" refers to stage 0, IA, IB, IIA, and IIB. This refers to pancreatic cancer.

[0050] As used herein, "advanced pancreatic cancer" refers to stage III, IVa, and IVb pancreatic cancer. say.

[0051] As used herein, the term "benign disease" refers to a non-malignant tumor disease involving an organ.

[0052] As used herein, the terms "nucleotide," "polynucleotide," "DNA," The use of abbreviations such as "RNA" is prohibited in the preparation of specifications containing nucleotide sequences or amino acid sequences. Guidelines for Patent Literature" (edited by the Japan Patent Office) and common practice in the art. do.

[0053] As used herein, the term "polynucleotide" refers to RNA, DNA, and RNA / DNA ( The term "DNA" refers to nucleic acids that include both cDNA and chimeric DNA. The above-mentioned RNA includes total DNA, genomic DNA, and synthetic DNA. l RNA, mRNA, rRNA, miRNA, siRNA, snoRNA, snRNA In this specification, the term "RNA" includes both non-coding RNA and synthetic RNA. "Synthetic DNA" and "synthetic RNA" are defined as those that contain a specific base sequence (either a natural sequence or a non-natural sequence). ) can be artificially produced using, for example, an automatic nucleic acid synthesizer. As used herein, the term "non-natural sequence" is used in a broad sense. and which differ from the native sequence by, for example, one or more nucleotide substitutions, deletions, Sequences containing insertions and / or additions (i.e., mutant sequences), including one or more modified nucleotides In addition, the term "polynucleotide" as used herein includes sequences containing the polynucleotides (i.e., modified sequences), etc. The term nucleic acid is used interchangeably with nucleic acid.

[0054] As used herein, the term "fragment" refers to a fragment having a continuous partial base sequence of a polynucleotide. It is a polynucleotide having 15 or more bases, preferably 17 or more bases, and more preferably 1 It is desirable that the length be 9 bases or more.

[0055] As used herein, the term "gene" refers not only to RNA and double-stranded DNA, but also to any of the components thereof. Each strand contains a single strand of DNA, such as the positive strand (or sense strand) or the complementary strand (or antisense strand). The term "subject matter" is intended to encompass all subjects, and is not particularly limited by its length.

[0056] Therefore, in this specification, unless otherwise specified, the term "gene" includes human genomic DNA. Double-stranded DNA, single-stranded DNA (positive strand), and single-stranded DNA with a sequence complementary to the positive strand (complementary strand) (e.g., cDNA), microRNA (miRNA), and fragments thereof, and The term "gene" includes any of a specific base sequence (or sequence number). Not only are genes represented by the numbers (genes) but also the RNAs and biological Functionally equivalent RNAs, such as homologs (i.e., homologs or orthologs), "Nucleic acids" encoding variants, such as genetic polymorphisms, and derivatives are included. The "nucleic acid" encoding the mutant or derivative specifically includes a nucleic acid encoding the stringent A nucleotide sequence represented by any one of SEQ ID NOs: 1 to 812, or a salt thereof, under mild conditions. The base sequence has a base sequence that hybridizes with the complementary sequence of the base sequence in which u is t. The term "gene" does not refer to any specific functional region. It may include, for example, an expression control region, a coding region, an exon, or an intron. Furthermore, a "gene" may be contained within a cell, or may be released outside the cell and exist independently. They may also be encapsulated in small vesicles called exosomes.

[0057] As used herein, "exosomes" (also known as "exosomes") are molecules secreted from cells. Exosomes are small vesicles enclosed in a lipid bilayer membrane. They originate from multivesicular endosomes and are extracellular. When released into the environment, they lose internal biological substances such as genes (e.g., RNA and DNA) and proteins. Exosomes are found in bodily fluids such as blood, serum, plasma, and lymph. is known.

[0058] As used herein, the term "transcription product" refers to a RNA synthesized using the DNA sequence of a gene as a template. A refers to the region called the promoter upstream of the gene where RNA polymerase is located. and binds to the 3' end of the DNA, and binds a ribonucleotide to the 3' end so that it is complementary to the base sequence of the DNA. This RNA contains not only the gene itself but also the the region from the transcription start site to the poly(A) sequence, including the coding region, exon or intron The entire sequence is included, all the way to the termini.

[0059] In addition, in this specification, unless otherwise specified, "microRNA (miRNA)" means It is transcribed as a hairpin-like RNA precursor and has RNase III cleavage activity. It is cleaved by sRNA cleavage enzymes and incorporated into a protein complex called RISC, Non-coding RNAs of 15 to 25 bases involved in RNA translational repression are used intentionally. Furthermore, as used herein, "miRNA" is represented by a specific base sequence (or SEQ ID NO:). In addition to the miRNAs themselves, we also study the precursors of these miRNAs (pre-miRNAs, p ri-miRNAs), and miRNAs with equivalent biological functions, e.g., homologs ( It also includes variants such as homologs or orthologs, genetic polymorphisms, and derivatives. Such precursors, homologues, variants or derivatives include, in particular, those listed in the miRBase Identified by release 20 (http: / / www.mirbase.org / ) Any of SEQ ID NOs: 1 to 812 can be isolated under the stringent conditions described below. A nucleic acid sequence that hybridizes with the complementary sequence of any of the specific nucleic acid sequences represented by Furthermore, the term "miRNA" as used herein can be used to refer to a specific miRNA. " may be a gene product of a miR gene, and such a gene product is a mature miR NA (for example, 15 to 25 bases involved in the translational repression of mRNA as described above, or 19 to 25 bases, non-coding RNA) or miRNA precursor (e.g., pr miRNAs (e-miRNA or pri-miRNA).

[0060] As used herein, the term "probe" refers to RNA generated by gene expression or a probe derived therefrom. Polynucleotides and / or includes polynucleotides complementary thereto.

[0061] As used herein, the term "primer" refers to an RNA generated by gene expression or a primer therefor. A polynucleotide that specifically recognizes and amplifies the polynucleotide from which it is derived and / or The present invention encompasses polynucleotides complementary to the sequences of the sequences of the present invention.

[0062] Here, the complementary polynucleotide (complementary strand, reverse strand) is any one of SEQ ID NOs: 1 to 812. a base sequence defined by the above formula, or a base sequence in which u is t; The full-length sequence of a polynucleotide consisting of the above, or a partial sequence thereof (for convenience, this is referred to as the correct sequence here) base-complementary to the nucleotide sequence (called the "strand") based on base pairing relationships such as A:T(U) and G:C It also refers to a polynucleotide represented by any of SEQ ID NOs: 1 to 812. "Complementary base sequence" to the base sequence in which u is t or the base sequence in which u is t The expression "a polynucleotide consisting of a sequence" is understood in essentially the same way.

[0063] As used herein, "stringent conditions" refers to conditions under which a nucleic acid probe is highly sensitive to other sequences. to a detectably greater extent (e.g., the average of background measurements plus background The number of hybridizations to the target sequence is determined by the number of hybridizations (measurements of at least 2 times the standard error of the round measurement). Stringent conditions are sequence-dependent and are conditions under which hybridization is The stringency of hybridization and / or washing conditions varies depending on the environment in which they are performed. By controlling the gene expression, a target sequence that is 100% complementary to the nucleic acid probe is obtained. Specific examples of "stringent conditions" are described below.

[0064] As used herein, the term "Tm value" refers to the time at which the double-stranded portion of a polynucleotide is denatured into a single strand. means the temperature at which double-stranded and single-stranded molecules exist in a 1:1 ratio.

[0065] As used herein, the term "variant" refers to a naturally occurring variant of a nucleic acid resulting from polymorphism, mutation, etc. or a variant thereof, or any of the base sequences of SEQ ID NOs: 1 to 812, or In the base sequence in which u is t, or in a partial sequence thereof, one or more (e.g., one to several) ) or a variant containing a deletion, substitution, addition or insertion of a base in said base sequence or Partial sequences of approximately 90% or more, approximately 95% or more, approximately 97% or more, approximately 98% or more, approximately 99% or more a variant showing 100% identity to the base sequence, or a polynucleotide containing the base sequence or a partial sequence thereof A nucleic acid that hybridizes with the above-defined oligonucleotide under stringent conditions. It means acid.

[0066] As used herein, "several" refers to an integer of about 10, 9, 8, 7, 6, 5, 4, 3, or 2. means.

[0067] As used herein, the term "mutant" refers to a mutation obtained by site-directed mutagenesis or PCR. They can be produced using well-known techniques such as heterotransferase.

[0068] As used herein, "% identity" refers to the percentage of identity between proteins or sequences as determined by BLAST or FASTA as described above. using a gene search system, with or without introducing gaps, can be determined (Zheng Zhang et al., 2000, J. Comput. Biol., Vol. 7, p. 203-214; Altschul, S.F. et al., 1990 , Journal of Molecular Biology, Vol. 215, p. 403 -410; Pearson, WR et al., 1988, Proc. Natl. Aca d. Sci. USA, Vol. 85, p2444-2448).

[0069] As used herein, the term "derivative" refers to a modified nucleic acid, for example, but not limited to, labeling with a fluorophore or the like. modified nucleotides (e.g., halogenated, alkyl, such as methyl, methoxy, etc.); Reconstruction of nucleotides and bases containing alkoxy, thio, carboxymethyl, etc. groups nucleotides that have undergone double bond saturation, deamination, and substitution of oxygen molecules with sulfur molecules derivatives including PNA (peptide nucleic acid; Niel Sen, PE et al., 1991, Science, Vol. 254, pp. 1497-500) , LNA (locked nucleic acid; Obika, S. et al., 1998 Tetrahedron Lett., Vol. 39, p. 5401-5404) It means to

[0070] In the present specification, the above-mentioned miRNAs that are markers for early stage pancreatic cancer or pancreatic cancer precursor lesions are used. The "nucleic acid" capable of specifically binding to a polynucleotide selected from the group consisting of a synthetic or prepared nucleic acid The nucleic acid is specifically a "nucleic acid probe" or "primer" that detects early stage pancreatic cancer in a subject. To detect the presence or absence of early stage pancreatic cancer or precursor lesions of pancreatic cancer, or Presence or absence of pancreatic cancer, degree of prevalence, and presence or absence and degree of improvement of early pancreatic cancer or pancreatic cancer precursor lesions , to diagnose the sensitivity of early stage pancreatic cancer or precursor lesions to treatment of pancreatic cancer, or Screening for candidate substances useful for the prevention, improvement, or treatment of pancreatic cancer or pancreatic cancer precursor lesions These include the development of early stage pancreatic cancer or precursors of pancreatic cancer. In relation to the above, in vivo, particularly in samples such as body fluids such as blood and urine, any of SEQ ID NOs: 1 to 812 A nucleic acid capable of specifically recognizing and binding to a transcription product or its cDNA synthesis nucleic acid represented by These nucleotides include nucleotides, oligonucleotides, and polynucleotides. Based on the above properties, the peptides, oligonucleotides and polynucleotides can be used in vivo, in tissues and They can be used as probes to detect the above genes expressed in cells, etc., and also as probes to detect genes expressed in vivo. Furthermore, it can be effectively used as a primer for amplifying the above gene.

[0071] As used herein, the term "detection" refers to inspection, measurement, determination, or determination assistance. In addition, the term "evaluation" as used herein refers to test results or measurement results. It is used to include assisting in diagnosis or evaluation based on the above.

[0072] As used herein, a "subject" refers to a human, a primate, including a chimpanzee, a dog, a cat, or the like. Any pet animals, livestock animals such as cows, horses, sheep, goats, rodents such as mice and rats The preferred subject is a human. A "healthy subject" is also a mammal that is not affected by the cancer to be detected. The preferred healthy subject is a human.

[0073] As used herein, "P" or "P value" refers to the probability that a statistical test will yield a positive result under the null hypothesis. indicates the probability that a statistic more extreme than the statistic calculated from the actual data will be observed. Therefore, the smaller the "P" or "P value," the more significant the difference between the compared subjects.

[0074] As used herein, "sensitivity" refers to the value of (the number of true positives) / (the number of true positives + the number of false negatives). High sensitivity means that early detection of pancreatic cancer or precursor lesions of pancreatic cancer is possible. This leads to complete removal of the cancer and a reduced recurrence rate.

[0075] As used herein, "specificity" means (number of true negatives) / (number of true negatives + number of false positives). High specificity would prevent misclassification of healthy individuals as patients with early-stage pancreatic cancer or pancreatic cancer precursor lesions. This will prevent unnecessary additional testing, reducing the burden on patients and cutting medical costs.

[0076] In this specification, "accuracy" means the value of (number of true positives + number of true negatives) / (total number of cases). Accuracy indicates the percentage of all samples for which the discrimination results were correct, and is used to evaluate detection performance. This will be the first indicator.

[0077] In this specification, the term "specimen" to be determined, detected or diagnosed refers to a specimen containing early stage pancreatic cancer or The development of precursor lesions of pancreatic cancer, the progression of early pancreatic cancer or precursor lesions of pancreatic cancer, or early pancreatic cancer or pancreatic cancer Tissues and living organisms in which the expression of the gene of the present invention changes as the therapeutic effect on precursor lesions is exerted. Specifically, this refers to pancreatic tissue and its surrounding blood vessels, lymph nodes, and organs, as well as tissue suspected of metastasis. The organs and skin that are used for the production of vitamin D, as well as bodily fluids such as blood, urine, saliva, sweat, and tissue exudates, are regulated by the blood. This refers to serum, plasma, and other samples such as feces and hair. Specifically, it refers to genes such as RNA and miRNA.

[0078] As used herein, "hsa-miR-6784-5p gene" or "hsa-mi The term "miR-6784-5p" refers to hsa-miR-6784-5p as set forth in SEQ ID NO: 1. p gene (miRBase Accession No. MIMAT0027468) Other species homologs or orthologs are also included. E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6784-5p" can be obtained by the method The precursor of "hsa-mir-6784" (miRBase A Accession No. MI0022629, SEQ ID NO: 251) is known.

[0079] As used herein, "hsa-miR-1181 gene" or "hsa-miR-1 The term "miR-1181" refers to the hsa-miR-1181 gene (miRB1) set forth in SEQ ID NO: 2. ase Accession No. MIMAT0005826) and other species homologues Genes include those listed in Subramanian S et al., 2004, By the method described in Oncogene, Vol. 27, pp. 2015-2026, 2008 Furthermore, "hsa-miR-1181" can be obtained by using a hairpin "hsa-mir-1181" (miRBase Accession No. o.MI0006274, SEQ ID NO: 252) is known.

[0080] As used herein, "hsa-miR-671-5p gene" or "hsa-miR The term "miR-671-5p" refers to the hsa-miR-671-5p gene set forth in SEQ ID NO: 3. miRBase Accession No. MIMAT0003880 and others This includes species homologs or orthologs. E et al., 2006, Genome Res, vol. 16, pp. 1289-1298 Furthermore, "hsa-miR-671-5p" can be obtained by the method The miRBase Accession No. 1 (hsa-mir-671) has a hairpin-like structure as a target. The sequence number of the gene encoding the nucleotide sequence of the present invention is 253 (sequence number MI0003760, sequence number 253).

[0081] As used herein, "hsa-miR-6857-5p gene" or "hsa-mi The term "miR-6857-5p" refers to hsa-miR-6857-5p as set forth in SEQ ID NO: 4. p gene (miRBase Accession No. MIMAT0027614) Other species homologs or orthologs are also included. E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6857-5p" can be obtained by the method The precursor of "hsa-mir-6857" (miRBase A Accession No. MI0022703, SEQ ID NO: 254) is known.

[0082] As used herein, "hsa-miR-4276 gene" or "hsa-miR-4 The term "miR-4276" refers to the hsa-miR-4276 gene (miRB) set forth in SEQ ID NO: 5. ase Accession No. MIMAT0016904) and other species homologues Genes include those derived from genes that are homologous to orthologues of the gene. It can be obtained by the method described in LoS One, Vol. 4, e7192. "hsa-miR-4276" is a precursor of "hsa-m" which has a hairpin-like structure. ir-4276” (miRBase Accession No. MI0015882, SEQ ID NO: 255) is known.

[0083] As used herein, "hsa-miR-1914-3p gene" or "hsa-mi The term "hsa-miR-1914-3p" refers to hsa-miR-1914-3p as set forth in SEQ ID NO: 6. p gene (miRBase Accession No. MIMAT0007890) Other species homologs or orthologs are also included. The method described in Stem Cells, Vol. 26, pp. 2496-2505, 2008 In addition, "hsa-miR-1914-3p" can be obtained by The miRBase Accession No. 140626666, which has a hairpin-like structure, is sion No. MI0008335, SEQ ID NO: 256) is known.

[0084] As used herein, "hsa-miR-149-3p gene" or "hsa-miR The term "miR-149-3p" refers to the hsa-miR-149-3p gene set forth in SEQ ID NO: 7. miRBase Accession No. MIMAT0004609 and others This includes species homologs or orthologs. Tana M et al., 2002, Curr Biol, Vol. 12, p735-739 Furthermore, "hsa-miR-149-3p" can be obtained by the method described above. The precursor, "hsa-mir-149" (miRBase Ac Accession No. MI0000478, SEQ ID NO: 257) is known.

[0085] As used herein, "hsa-miR-937-5p gene" or "hsa-miR The term "miR-937-5p" refers to the hsa-miR-937-5p gene set forth in SEQ ID NO: 8. miRBase Accession No. MIMAT0022938 and others The gene includes homologs or orthologues of biological species. 2007, Cancer Res, Vol. 67, p. 6031-6043 Furthermore, "hsa-miR-937-5p" can be obtained by The apin-like structure of "hsa-mir-937" (miRBase Accession No. No. MI0005759, SEQ ID NO: 258) is known.

[0086] As used herein, "hsa-miR-4675 gene" or "hsa-miR-4 The term "miR-4675" refers to the hsa-miR-4675 gene (miRB) set forth in SEQ ID NO: 9. ase Accession No. MIMAT0019757) and other species homologues Genes include those derived from Persson H et al., 2011. It can be obtained by the method described in Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4675" has a hairpin-like structure as its precursor. "hsa-mir-4675" (miRBase Accession No. MI00 17306, SEQ ID NO: 259) is known.

[0087] As used herein, "hsa-miR-6795-5p gene" or "hsa-mi The term "miR-6795-5p" refers to hsa-miR-6795- 5p gene (miRBase Accession No. MIMAT0027490) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 In addition, "hsa-miR-6795-5p" can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6795" (miRBase Accession No. MI0022640, SEQ ID NO: 260) is known.

[0088] As used herein, "hsa-miR-4731-5p gene" or "hsa-mi The term "miR-4731-5p" refers to hsa-miR-4731-5p as set forth in SEQ ID NO: 11. 5p gene (miRBase Accession No. MIMAT0019853) and other species homologs or orthologs. The method described in N H et al., 2011, Cancer Res, Vol. 71, pp. 78-86 Furthermore, "hsa-miR-4731-5p" can be obtained by The miRBase Accession No. 1 (hsa-mir-4731) has a hairpin-like structure. The sequence number of the gene encoding the nucleotide sequence of the present invention is 261 (sequence number MI0017368, sequence number 261).

[0089] As used herein, "hsa-miR-5090 gene" or "hsa-miR-5 The term "miR-5090" refers to the hsa-miR-5090 gene (miR Base Accession No. MIMAT0021082) and other species of Homo sapiens Genes include genes that are either homologs or orthologs. Obtained by the method described in Radiat Res, Vol. 52, p. 425-432 In addition, "hsa-miR-5090" has a hairpin-like structure as its precursor. Take "hsa-mir-5090" (miRBase Accession No. MI 0017979, SEQ ID NO: 262) is known.

[0090] As used herein, "hsa-miR-3620-5p gene" or "hsa-mi The term "miR-3620-5p" refers to hsa-miR-3620-5p as set forth in SEQ ID NO: 13. 5p gene (miRBase Accession No. MIMAT0022967) and other species homologs or orthologs. D et al., 2010, BMC Biol, Vol. 8, p. 58. In addition, "hsa-miR-3620-5p" has a hairpin "hsa-mir-3620" (miRBase Accession No. o.MI0016011, sequence number 263) is known.

[0091] As used herein, "hsa-miR-1343-5p gene" or "hsa-mi The term "hsa-miR-1343-5p" refers to hsa-miR-1343- 5p gene (miRBase Accession No. MIMAT0027038) and other species homologs or orthologs. The method described in N H et al., 2011, Cancer Res, Vol. 71, pp. 78-86 Furthermore, "hsa-miR-1343-5p" can be obtained by The miRBase Accession No. 1343 (hsa-mir-1343) has a hairpin-like structure. The sequence number of the gene encoding the nucleotide sequence of the present invention is 264 (sequence number MI0017320, sequence number 264).

[0092] As used herein, "hsa-miR-6717-5p gene" or "hsa-mi The term "hsa-miR-6717-5p" refers to hsa-miR-6717-5p as set forth in SEQ ID NO: 15. 5p gene (miRBase Accession No. MIMAT0025846) and other species homologs or orthologs. 2012, Gene, Vol. 497, pp. 330-335 In addition, "hsa-miR-6717-5p" has a hairpin-like structure as its precursor. The structure of "hsa-mir-6717" (miRBase Accession No. .MI0022551, sequence number 265) is known.

[0093] As used herein, "hsa-miR-6825-5p gene" or "hsa-mi The term "miR-6825-5p" refers to hsa-miR-6825-5p as set forth in SEQ ID NO: 16. 5p gene (miRBase Accession No. MIMAT0027550) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 In addition, "hsa-miR-6825-5p" can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6825" (miRBase Accession No. MI0022670, SEQ ID NO: 266) is known.

[0094] As used herein, "hsa-miR-6738-5p gene" or "hsa-mi The term "miR-6738-5p" refers to hsa-miR-6738-5p as set forth in SEQ ID NO: 17. 5p gene (miRBase Accession No. MIMAT0027377) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 In addition, "hsa-miR-6738-5p" can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6738" (miRBase Accession No. MI0022583, SEQ ID NO: 267) is known.

[0095] As used herein, "hsa-miR-6769a-5p gene" or "hsa-m The term "hsa-miR-6769a-5p" refers to hsa-miR-6769a-5p as set forth in SEQ ID NO: 18. 9a-5p gene (miRBase Accession No. MIMAT00274 38) and other species homologs or orthologs. ewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645 The "hsa-miR-6769a-5p" gene can be obtained by the method described in the literature. " has a hairpin-like structure as its precursor "hsa-mir-6769a" (miR Base Accession No. MI0022614, SEQ ID NO: 268) is known are.

[0096] As used herein, "hsa-miR-4728-5p gene" or "hsa-mi The term "miR-4728-5p" refers to hsa-miR-4728-5p as set forth in SEQ ID NO: 19. 5p gene (miRBase Accession No. MIMAT0019849) and other species homologs or orthologs. The method described in N H et al., 2011, Cancer Res, Vol. 71, pp. 78-86 Furthermore, "hsa-miR-4728-5p" can be obtained by The miRBase Accession No. 1000026666644444444 is a miR-based gene that has a hairpin-like structure. The sequence of the gene encoding the nucleotide sequence of the present invention is known to be nucleotide sequence no. MI0017365, sequence number 269.

[0097] As used herein, "hsa-miR-652-5p gene" or "hsa-miR The term "miR-652-5p" refers to the hsa-miR-652-5p gene set forth in SEQ ID NO: 20. gene (miRBase Accession No. MIMAT0022709) and its It also includes homologs or orthologues from other species. M et al., 2006, Proc Natl Acad Sci USA, vol. 103, p. 3687-3692. R-652-5p is a precursor of hsa-mir-65, which has a hairpin-like structure. 2" (miRBase Accession No. MI0003667, SEQ ID NO: 27 0) is known.

[0098] As used herein, "hsa-miR-4257 gene" or "hsa-miR-4 The term "miR-4257" refers to the hsa-miR-4257 gene (miR Base Accession No. MIMAT0016878) and other species of Homo sapiens Genes include genes that are homologs or orthologs. It can be obtained by the method described in PLoS One, Vol. 4, e7192. "hsa-miR-4257" has a hairpin-like structure as its precursor, "hsa- mir-4257” (miRBase Accession No. MI0015856 , SEQ ID NO: 271) is known.

[0099] As used herein, "hsa-miR-6785-5p gene" or "hsa-mi The term "miR-6785-5p" refers to hsa-miR-6785- 5p gene (miRBase Accession No. MIMAT0027470) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 hsa-miR-6785-5p can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6785" (miRBase Accession No. MI0022630, SEQ ID NO: 272) is known.

[0100] As used herein, "hsa-miR-7110-5p gene" or "hsa-mi The term "miR-7110-5p" refers to hsa-miR-7110-5p as set forth in SEQ ID NO: 23. 5p gene (miRBase Accession No. MIMAT0028117) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 hsa-miR-7110-5p can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-7110" (miRBase Accession No. MI0022961, SEQ ID NO: 273) is known.

[0101] As used herein, "hsa-miR-6887-5p gene" or "hsa-mi The term "miR-6887-5p" refers to hsa-miR-6887- 5p gene (miRBase Accession No. MIMAT0027674) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 In addition, "hsa-miR-6887-5p" can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6887" (miRBase Accession No. MI0022734, SEQ ID NO: 274) is known.

[0102] As used herein, "hsa-miR-887-3p gene" or "hsa-miR The term "miR-887-3p" refers to the hsa-miR-887-3p gene set forth in SEQ ID NO: 25. gene (miRBase Accession No. MIMAT0004951) and its It also includes homologs or orthologues from other species. E et al., 2006, Genome Res, Vol. 16, p1289-1298 hsa-miR-887-3p can be obtained by the method The miRBase Accelerator, "hsa-mir-887" (miRBase Accelerator), has a hairpin-like structure. Session No. MI0005562, SEQ ID NO: 275) is known.

[0103] As used herein, "hsa-miR-1228-5p gene" or "hsa-mi The term "miR-1228-5p" refers to hsa-miR-1228-5p as set forth in SEQ ID NO: 26. 5p gene (miRBase Accession No. MIMAT0005582) and other species homologs or orthologs. kov E et al., 2007, Mol Cell, vol. 28, pp. 328-336 hsa-miR-1228-5p can be obtained by the method The miRBase Ac receptor has a hairpin-like structure as a carrier. Accession No. MI0006318, SEQ ID NO: 276) is known.

[0104] As used herein, "hsa-miR-5572 gene" or "hsa-miR-5 The term "miR-5572" refers to the hsa-miR-5572 gene (miR Base Accession No. MIMAT0022260) and other species of Homo sapiens Genes include genes that are either homologs or orthologs. Oral Dis, Vol. 18, pp. 127-131. In addition, "hsa-miR-5572" has a hairpin-like structure as its precursor. "hsa-mir-5572" (miRBase Accession No. MI00 19117, sequence number 277) is known.

[0105] As used herein, "hsa-miR-6782-5p gene" or "hsa-mi The term "miR-6782-5p" refers to hsa-miR-6782-5p as set forth in SEQ ID NO: 28. 5p gene (miRBase Accession No. MIMAT0027464) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 In addition, "hsa-miR-6782-5p" can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6782" (miRBase Accession No. MI0022627, SEQ ID NO: 278) is known.

[0106] As used herein, "hsa-miR-4298 gene" or "hsa-miR-4 The term "miR-4298" refers to the hsa-miR-4298 gene (miR Base Accession No. MIMAT0016852) and other species of Homo sapiens Genes include genes that are homologs or orthologs. It can be obtained by the method described in PLoS One, Vol. 4, e7192. "hsa-miR-4298" has a hairpin-like structure as its precursor, "hsa- mir-4298” (miRBase Accession No. MI0015830 , SEQ ID NO: 279) is known.

[0107] As used herein, "hsa-miR-6786-5p gene" or "hsa-mi The term "miR-6786-5p" refers to hsa-miR-6786-5p as set forth in SEQ ID NO: 30. 5p gene (miRBase Accession No. MIMAT0027472) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 In addition, "hsa-miR-6786-5p" can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6786" (miRBase Accession No. MI0022631, SEQ ID NO: 280) is known.

[0108] As used herein, "hsa-miR-5010-5p gene" or "hsa-mi The term "hsa-miR-5010-5p" refers to hsa-miR-5010- 5p gene (miRBase Accession No. MIMAT0021043) and other species homologs or orthologues. The method described in TB et al., 2011, RNA Biol, Vol. 8, p. 378-383 Furthermore, "hsa-miR-5010-5p" can be obtained by The miRBase Accession No. 10002666644444 forms a hairpin-like structure. sion No. MI0017878, SEQ ID NO: 281) is known.

[0109] As used herein, "hsa-miR-6087 gene" or "hsa-miR-6 The term "miR-6087" refers to the hsa-miR-6087 gene (miR-6087) set forth in SEQ ID NO: 32. Base Accession No. MIMAT0023712) and other species of Homo sapiens Genes include genes with a homolog or ortholog. by the method described in tem Cells Dev, Vol. 21, pp. 2049-2057 Furthermore, "hsa-miR-6087" can be obtained by using a hairpin The miRBase Accession No. 100001266344444 has a similar structure to "hsa-mir-6087" (miRBase Accession No. 1000012663444444). o.MI0020364, SEQ ID NO: 282) is known.

[0110] As used herein, "hsa-miR-6765-5p gene" or "hsa-mi The term "miR-6765-5p" refers to hsa-miR-6765-5p as set forth in SEQ ID NO: 33. 5p gene (miRBase Accession No. MIMAT0027430) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 In addition, "hsa-miR-6765-5p" can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6765" (miRBase Accession No. MI0022610, SEQ ID NO: 283) is known.

[0111] As used herein, "hsa-miR-6732-5p gene" or "hsa-mi The term "miR-6732-5p" refers to hsa-miR-6732-5p as set forth in SEQ ID NO: 34. 5p gene (miRBase Accession No. MIMAT0027365) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 hsa-miR-6732-5p can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6732" (miRBase Accession No. MI0022577, SEQ ID NO: 284) is known.

[0112] As used herein, "hsa-miR-6787-5p gene" or "hsa-mi The term "miR-6787-5p" refers to hsa-miR-6787- 5p gene (miRBase Accession No. MIMAT0027474) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 In addition, "hsa-miR-6787-5p" can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6787" (miRBase Accession No. MI0022632, SEQ ID NO: 285) is known.

[0113] As used herein, "hsa-miR-6737-5p gene" or "hsa-mi The term "miR-6737-5p" refers to hsa-miR-6737-5p as set forth in SEQ ID NO: 36. 5p gene (miRBase Accession No. MIMAT0027375) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 In addition, "hsa-miR-6737-5p" can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6737" (miRBase Accession No. MI0022582, SEQ ID NO: 286) is known.

[0114] As used herein, "hsa-miR-128-2-5p gene" or "hsa-m The term "miR-128-2-5p" refers to hsa-miR-128 as set forth in SEQ ID NO: 37. -2-5p gene (miRBase Accession No. MIMAT00310 95) and other species homologs or orthologs. os-Quintana M et al., 2002, Curr Biol, vol. 12, p735- 739. 2-5p" has a hairpin-like structure as its precursor, "hsa-mir-128-2" (miRBase Accession No. MI0000727, SEQ ID NO: 287) is known.

[0115] As used herein, "hsa-miR-4270 gene" or "hsa-miR-4 The term "miR-4270" refers to the hsa-miR-4270 gene (miR Base Accession No. MIMAT0016900) and other species of Homo sapiens Genes include genes that are homologs or orthologs. It can be obtained by the method described in PLoS One, Vol. 4, e7192. The precursor of "hsa-miR-4270" has a hairpin-like structure. mir-4270” (miRBase Accession No. MI0015878 , SEQ ID NO: 288) is known.

[0116] As used herein, "hsa-miR-6861-5p gene" or "hsa-mi The term "hsa-miR-6861-5p" refers to hsa-miR-6861-5p as set forth in SEQ ID NO: 39. 5p gene (miRBase Accession No. MIMAT0027623) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 hsa-miR-6861-5p can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6861" (miRBase Accession No. MI0022708, SEQ ID NO: 289) is known.

[0117] As used herein, "hsa-miR-6756-5p gene" or "hsa-mi The term "miR-6756-5p" refers to hsa-miR-6756-5p as set forth in SEQ ID NO: 40. 5p gene (miRBase Accession No. MIMAT0027412) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 In addition, "hsa-miR-6756-5p" can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6756" (miRBase Accession No. MI0022601, SEQ ID NO: 290) is known.

[0118] As used herein, "hsa-miR-1229-5p gene" or "hsa-mi The term "miR-1229-5p" refers to hsa-miR-1229-5p as set forth in SEQ ID NO: 41. 5p gene (miRBase Accession No. MIMAT0022942) and other species homologs or orthologs. kov E et al., 2007, Mol Cell, vol. 28, pp. 328-336 hsa-miR-1229-5p can be obtained by the method The miRBase Ac receptor has a hairpin-like structure as a carrier. Accession No. MI0006319, SEQ ID NO: 291) is known.

[0119] As used herein, "hsa-miR-6891-5p gene" or "hsa-mi The term "miR-6891-5p" refers to hsa-miR-6891-5p as set forth in SEQ ID NO: 42. 5p gene (miRBase Accession No. MIMAT0027682) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 In addition, "hsa-miR-6891-5p" can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6891" (miRBase Accession No. MI0022738, SEQ ID NO: 292) is known.

[0120] As used herein, "hsa-miR-6848-5p gene" or "hsa-mi The term "miR-6848-5p" refers to hsa-miR-6848-5p as set forth in SEQ ID NO: 43. 5p gene (miRBase Accession No. MIMAT0027596) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 In addition, "hsa-miR-6848-5p" can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6848" (miRBase Accession No. MI0022694, SEQ ID NO: 293) is known.

[0121] As used herein, "hsa-miR-1237-5p gene" or "hsa-mi The term "hsa-miR-1237-5p" refers to hsa-miR-1237- 5p gene (miRBase Accession No. MIMAT0022946) and other species homologs or orthologs. kov E et al., 2007, Mol Cell, vol. 28, pp. 328-336 hsa-miR-1237-5p can be obtained by the method The miRBase Ac receptor has a hairpin-like structure as a precursor protein, hsa-mir-1237 (miRBase Ac Accession No. MI0006327, SEQ ID NO: 294) is known.

[0122] As used herein, "hsa-miR-30c-1-3p gene" or "hsa-m The term "hsa-miR-30c-1-3p" refers to hsa-miR-30c set forth in SEQ ID NO: 45. -1-3p gene (miRBase Accession No. MIMAT00046 74) and other species homologs or orthologs. os-Quintana M et al., 2002, Curr Biol, vol. 12, p735- 739. 1-3p" has a hairpin-like structure as its precursor, "hsa-mir-30c-1" (miRBase Accession No. MI0000736, SEQ ID NO: 295) is known.

[0123] As used herein, "hsa-miR-1233-5p gene" or "hsa-mi The term "hsa-miR-1233-5p" refers to hsa-miR-1233- 5p gene (miRBase Accession No. MIMAT0022943) and other species homologs or orthologs. kov E et al., 2007, Mol Cell, vol. 28, pp. 328-336 hsa-miR-1233-5p can be obtained by the method The hairpin-like structure of the precursor protein "hsa-mir-1233-1, hsa-mir-1" 233-2” (miRBase Accession No. MI0006323, MI 0015973, SEQ ID NOs: 296, 297) are known.

[0124] As used herein, "hsa-miR-211-3p gene" or "hsa-miR The term "miR-211-3p" refers to the hsa-miR-211-3p gene set forth in SEQ ID NO: 47. gene (miRBase Accession No. MIMAT0022694) and its It also includes homologs or orthologues from other species. It can be obtained by the method described in Science, Vol. 299, p. 1540, 2003. In addition, "hsa-miR-211-3p" has a hairpin-like structure as its precursor. The miRBase Accession No. 0000287, SEQ ID NO: 298) is known.

[0125] As used herein, "hsa-miR-4758-5p gene" or "hsa-mi The term "miR-4758-5p" refers to hsa-miR-4758-5p as set forth in SEQ ID NO: 48. 5p gene (miRBase Accession No. MIMAT0019903) and other species homologs or orthologs. The method described in N H et al., 2011, Cancer Res, Vol. 71, pp. 78-86 Furthermore, "hsa-miR-4758-5p" can be obtained by The miRBase Accession No. 100626666444 (hsa-mir-4758) has a hairpin-like structure as a The sequence number of the nucleotide sequence ...

[0126] As used herein, "hsa-miR-614 gene" or "hsa-miR-61 The term "miR-614" refers to the hsa-miR-614 gene (miRBas) set forth in SEQ ID NO: 49. e Accession No. MIMAT0003282) and homologs in other species orthologues thereof. Genes are as follows: Cummins JM et al., 2006, Proc Natl Acad Sci USA, vol. 103, p3687-3692 Furthermore, "hsa-miR-614" can be obtained by the method described in The precursor of the hairpin-like structure "hsa-mir-614" (miRBase A Accession No. MI0003627, SEQ ID NO: 300) is known.

[0127] As used herein, "hsa-miR-6746-5p gene" or "hsa-mi The term "miR-6746-5p" refers to hsa-miR-6746-5p as set forth in SEQ ID NO: 50. 5p gene (miRBase Accession No. MIMAT0027392) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 hsa-miR-6746-5p can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6746" (miRBase Accession No. MI0022591, SEQ ID NO: 301) is known.

[0128] As used herein, "hsa-miR-1915-5p gene" or "hsa-mi The term "miR-1915-5p" refers to hsa-miR-1915- 5p gene (miRBase Accession No. MIMAT0007891) and other species homologs or orthologs. , 2008, Stem Cells, Vol. 26, pp. 2496-2505 Furthermore, "hsa-miR-1915-5p" can be obtained by The miRBase Accession No. 1544444 (hsa-mir-1915) has a hairpin-like structure as a The sequence number of the nucleotide sequence ...

[0129] As used herein, "hsa-miR-4688 gene" or "hsa-miR-4 The term "miR-4688" refers to the hsa-miR-4688 gene (miR Base Accession No. MIMAT0019777) and other species of Homo sapiens Genes include genes that are either homologs or orthologs. It can be obtained by the method described in Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4688" has a hairpin-like structure as its precursor. The miRBase Accession No. MI0 017321, SEQ ID NO: 303) is known.

[0130] As used herein, "hsa-miR-3917 gene" or "hsa-miR-3 The term "miR-3917" refers to the hsa-miR-3917 gene (miR Base Accession No. MIMAT0018191) and other species of Homo sapiens Genes include genes that are either logs or orthologs. It can be obtained by the method described in PLoS One, Vol. 5, e9637, 2010. In addition, "hsa-miR-3917" has a hairpin-like structure as its precursor. "hsa-mir-3917" (miRBase Accession No. MI00 16423, SEQ ID NO: 304) is known.

[0131] As used herein, "hsa-miR-5787 gene" or "hsa-miR-5 The term "miR-5787" refers to the hsa-miR-5787 gene (miR Base Accession No. MIMAT0023252) and other species of Homo sapiens Genes include genes with a log or ortholog. In Chem Biophys Res Commun, Vol. 415, p. 567-572 hsa-miR-5787 can be obtained by the method described in the The precursor of "hsa-mir-5787" (miRBase A Accession No. MI0019797, SEQ ID NO: 305) is known.

[0132] As used herein, "hsa-miR-4632-5p gene" or "hsa-mi The term "miR-4632-5p" refers to hsa-miR-4632-5p as set forth in SEQ ID NO: 55. 5p gene (miRBase Accession No. MIMAT0022977) and other species homologs or orthologs. The method described in N H et al., 2011, Cancer Res, Vol. 71, pp. 78-86 Furthermore, "hsa-miR-4632-5p" can be obtained by The miRBase Accession No. 100116666444444444 is a miR-based gene that has a hairpin-like structure as a target protein. The sequence number of the gene encoding the nucleotide sequence of the present invention is 306 (sequence number MI0017259, sequence number 306).

[0133] As used herein, "hsa-miR-6126 gene" or "hsa-miR-6 The term "miR-6126" refers to the hsa-miR-6126 gene (miR-6126) set forth in SEQ ID NO: 56. Base Accession No. MIMAT0024599) and other species of Homo sapiens Genes include genes that are either homologs or orthologs. , J Virol, Vol. 86, pp. 5278-5287. In addition, "hsa-miR-6126" has a hairpin-like structure as its precursor. The miRBase Accession No. MI0 021260, SEQ ID NO: 307) is known.

[0134] As used herein, "hsa-miR-135a-3p gene" or "hsa-mi The term "hsa-miR-135a-3p" refers to hsa-miR-135a-3p as set forth in SEQ ID NO: 57. 3p gene (miRBase Accession No. MIMAT0004595) and other species homologs or orthologues. Quintana M et al., 2002, Curr Biol, vol. 12, pp. 735-739 The miR-135a-3p gene can be obtained by the method described in " is a precursor of "hsa-mir-135a-1" (mi RBase Accession No. MI0000452, sequence number 308) is known. It is being done.

[0135] As used herein, "hsa-miR-8063 gene" or "hsa-miR-8 The term "miR-8063" refers to the hsa-miR-8063 gene (miR-8063) set forth in SEQ ID NO: 58. Base Accession No. MIMAT0030990) and other species of Homo sapiens Genes include genes that are homologs or orthologs. It can be obtained by the method described in Shock, Vol. 39, pp. 480-487. In addition, "hsa-miR-8063" has a hairpin-like structure as its precursor, "hsa -mir-8063” (miRBase Accession No. MI002589 9, SEQ ID NO: 309) is known.

[0136] As used herein, "hsa-miR-5698 gene" or "hsa-miR-5 The term "miR-5698" refers to the hsa-miR-5698 gene (miR Base Accession No. MIMAT0022491) and other species of Homo sapiens The genes include genes that are homologous or orthologous. It can be obtained by the method described in PLoS One, Vol. 6, e24950. In addition, "hsa-miR-5698" has a hairpin-like structure as its precursor. hsa-mir-5698” (miRBase Accession No. MI001 9305, SEQ ID NO: 310) is known.

[0137] As used herein, "hsa-miR-6089 gene" or "hsa-miR-6 The term "miR-6089" refers to the hsa-miR-6089 gene (miR-6089) set forth in SEQ ID NO: 60. Base Accession No. MIMAT0023714) and other species of Homo sapiens Genes include genes with a homolog or ortholog. by the method described in tem Cells Dev, Vol. 21, pp. 2049-2057 Furthermore, "hsa-miR-6089" can be obtained by using a hairpin "hsa-mir-6089-1, hsa-mir-6089-2" (mi RBase Accession No. MI0020366, MI0023563, Column numbers 311 and 312) are known.

[0138] As used herein, "hsa-miR-498 gene" or "hsa-miR-49 The term "miR-498" refers to the hsa-miR-498 gene (miRBas) set forth in SEQ ID NO: 61. e Accession No. MIMAT0002824) and homologs in other species orthologues thereof. Genes are listed in Bentwich I et al., 2005, It can be obtained by the method described in Nat Genet, Vol. 37, pp. 766-770. In addition, "hsa-miR-498" has a hairpin-like structure as its precursor. hsa-mir-498” (miRBase Accession No. MI0003 142, SEQ ID NO: 313) is known.

[0139] As used herein, "hsa-miR-296-3p gene" or "hsa-miR The term "miR-296-3p" refers to the hsa-miR-296-3p gene set forth in SEQ ID NO: 62. gene (miRBase Accession No. MIMAT0004679) and its It also includes homologs or orthologues from other species. According to the method described in HB et al., 2003, Dev Cell, Vol. 5, p. 351-358 In addition, "hsa-miR-296-3p" can be obtained as its precursor. The hairpin-like structure of "hsa-mir-296" (miRBase Accession No. n No. MI0000747, sequence number 314) is known.

[0140] As used herein, "hsa-miR-4419b gene" or "hsa-miR- The term "miR-4419b" refers to the hsa-miR-4419b gene set forth in SEQ ID NO: 63 ( miRBase Accession No. MIMAT0019034) and other organisms Species homologs or orthologs are included. It can be obtained by the method described in Blood, Vol. 116, p. 118-p. 127, 2000. In addition, "hsa-miR-4419b" has a hairpin-like structure as its precursor. Take "hsa-mir-4419b" (miRBase Accession No. I0016861, SEQ ID NO: 315) is known.

[0141] As used herein, "hsa-miR-6802-5p gene" or "hsa-mi The term "hsa-miR-6802-5p" refers to hsa-miR-6802-5p as set forth in SEQ ID NO: 64. 5p gene (miRBase Accession No. MIMAT0027504) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 In addition, "hsa-miR-6802-5p" can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6802" (miRBase Accession No. MI0022647, SEQ ID NO: 316) is known.

[0142] As used herein, "hsa-miR-6829-5p gene" or "hsa-mi The term "miR-6829-5p" refers to hsa-miR-6829-5p as set forth in SEQ ID NO: 65. 5p gene (miRBase Accession No. MIMAT0027558) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 In addition, "hsa-miR-6829-5p" can be obtained by the method described above. The precursor of the miR gene, "hsa-mir-6829" (miRBase Accession No. MI0022674, SEQ ID NO: 317) is known.

[0143] As used herein, "hsa-miR-6803-5p gene" or "hsa-mi The term "hsa-miR-6803-5p" refers to hsa-miR-6803- 5p gene (miRBase Accession No. MIMAT0027506) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 In addition, "hsa-miR-6803-5p" can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6803" (miRBase Accession No. MI0022648, SEQ ID NO: 318) is known.

[0144] As used herein, "hsa-miR-1199-5p gene" or "hsa-mi The term "miR-1199-5p" refers to hsa-miR-1199-5p as set forth in SEQ ID NO: 67. 5p gene (miRBase Accession No. MIMAT0031119) and other species homologs or orthologs. A et al., 2013, Int J Oncol, Vol. 42, p. 391-402 hsa-miR-1199-5p can be obtained by the method described above. The miRBase Accelerator has a hairpin-like structure called "hsa-mir-1199" ( Session No. MI0020340, SEQ ID NO: 319) is known.

[0145] As used herein, "hsa-miR-6840-3p gene" or "hsa-mi The term "miR-6840-3p" refers to hsa-miR-6840-3p as set forth in SEQ ID NO: 68. 3p gene (miRBase Accession No. MIMAT0027583) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 In addition, "hsa-miR-6840-3p" can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6840" (miRBase Accession No. MI0022686, SEQ ID NO: 320) is known.

[0146] As used herein, "hsa-miR-6752-5p gene" or "hsa-mi The term "miR-6752-5p" refers to hsa-miR-6752-5p as set forth in SEQ ID NO: 69. 5p gene (miRBase Accession No. MIMAT0027404) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 In addition, "hsa-miR-6752-5p" can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6752" (miRBase Accession No. MI0022597, SEQ ID NO: 321) is known.

[0147] As used herein, "hsa-miR-6798-5p gene" or "hsa-mi The term "hsa-miR-6798-5p" refers to hsa-miR-6798- 5p gene (miRBase Accession No. MIMAT0027496) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 hsa-miR-6798-5p can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6798" (miRBase Accession No. MI0022643, SEQ ID NO: 322) is known.

[0148] As used herein, "hsa-miR-6131 gene" or "hsa-miR-6 The term "miR-6131" refers to the hsa-miR-6131 gene (miR-6131) set forth in SEQ ID NO: 71. Base Accession No. MIMAT0024615) and other species of Homo sapiens Genes include genes that are homologous or orthologous. The method described in Genome Biol Evol, Vol. 4, p. 552-564, 2012 In addition, "hsa-miR-6131" can be obtained as its precursor. The hairpin-like structure of "hsa-mir-6131" (miRBase Accession No. on No. MI0021276, SEQ ID NO: 323) is known.

[0149] As used herein, "hsa-miR-4667-5p gene" or "hsa-mi The term "miR-4667-5p" refers to hsa-miR-4667-5p as set forth in SEQ ID NO: 72. 5p gene (miRBase Accession No. MIMAT0019743) and other species homologs or orthologs. The method described in N H et al., 2011, Cancer Res, Vol. 71, pp. 78-86 Furthermore, "hsa-miR-4667-5p" can be obtained by The miRBase Accession No. 1000012624444444 is a miR-based gene that has a hairpin-like structure. The sequence of the gene encoding the nucleotide sequence of the present invention is known to be nucleotide sequence no. MI0017297, sequence number 324.

[0150] As used herein, "hsa-miR-6510-5p gene" or "hsa-mi The term "miR-6510-5p" refers to hsa-miR-6510-5p as set forth in SEQ ID NO: 73. 5p gene (miRBase Accession No. MIMAT0025476) and other species homologs or orthologs. CE et al., 2011, Hum Mol Genet, vol. 20, pp. 4025-4040 hsa-miR-6510-5p can be obtained by the method described in the literature. , and its precursor, "hsa-mir-6510" (miRBas e Accession No. MI0022222, SEQ ID NO: 325) is known .

[0151] As used herein, "hsa-miR-4690-5p gene" or "hsa-mi The term "miR-4690-5p" refers to hsa-miR-4690-5p as set forth in SEQ ID NO: 74. 5p gene (miRBase Accession No. MIMAT0019779) and other species homologs or orthologs. The method described in N H et al., 2011, Cancer Res, Vol. 71, pp. 78-86 Furthermore, "hsa-miR-4690-5p" can be obtained by The miRBase Accession No. 100026 ...444444 is a miR-based gene that has a hairpin-like structure as a target protein. The sequence of the gene encoding the nucleotide sequence of the present invention is known to be nucleotide sequence no. MI0017323, sequence number 326.

[0152] As used herein, "hsa-miR-920 gene" or "hsa-miR-92 The term "miR-920" refers to the hsa-miR-920 gene (miRBas) set forth in SEQ ID NO: 75. e Accession No. MIMAT0004970) and homologs in other species orthologues, etc. Genes are listed in Novotny GW et al., 2007, It can be obtained by the method described in Int J Androl, Vol. 30, pp. 316-326. In addition, "hsa-miR-920" has a hairpin-like structure as its precursor. Take "hsa-mir-920" (miRBase Accession No. MI0 005712, SEQ ID NO: 327) is known.

[0153] As used herein, "hsa-miR-23b-3p gene" or "hsa-miR The term "miR-23b-3p" refers to the hsa-miR-23b-3p gene set forth in SEQ ID NO: 76. gene (miRBase Accession No. MIMAT0000418) and its This includes homologs or orthologues from other species. ntana M et al., 2002, Curr Biol, vol. 12, pp. 735-739 Furthermore, "hsa-miR-23b-3p" can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-23b" (miRBase A Accession No. MI0000439, SEQ ID NO: 328) is known.

[0154] As used herein, "hsa-miR-4448 gene" or "hsa-miR-4 The term "miR-4448" refers to the hsa-miR-4448 gene (miR Base Accession No. MIMAT0018967) and other species of Homo sapiens Genes include genes that are either logs or orthologs. It can be obtained by the method described in Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4448" has a precursor "hsa-miR-4448" that has a hairpin-like structure. sa-mir-4448” (miRBase Accession No. MI0016 791, SEQ ID NO: 329) is known.

[0155] As used herein, "hsa-miR-2110 gene" or "hsa-miR-2 The term "miR-2110" refers to the hsa-miR-2110 gene (miR Base Accession No. MIMAT0010133) and other species of Homo sapiens Genes include genes that are homologous or orthologous to the target gene. It can be obtained by the method described in Virol, Vol. 83, pp. 3333-3341. In addition, "hsa-miR-2110" has a hairpin-like structure as its precursor. hsa-mir-2110” (miRBase Accession No. MI001 0629, SEQ ID NO: 330) is known.

[0156] As used herein, "hsa-miR-4706 gene" or "hsa-miR-4 The term "miR-4706" refers to the hsa-miR-4706 gene (miR Base Accession No. MIMAT0019806) and other species of Homo sapiens Genes include genes that are either homologs or orthologs. It can be obtained by the method described in Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4706" has a hairpin-like structure as its precursor. The miRBase Accession No. "hsa-mir-4706" (MIRBase Accession No. MI0 017339, SEQ ID NO: 331) is known.

[0157] As used herein, "hsa-miR-7845-5p gene" or "hsa-mi The term "miR-7845-5p" refers to hsa-miR-7845-5p as set forth in SEQ ID NO: 80. 5p gene (miRBase Accession No. MIMAT0030420) and other species homologs or orthologues. , 2012, PLoS One, Vol. 7, e50746 In addition, "hsa-miR-7845-5p" has a hairpin The miRBase Accession No. 10000126637 has a similar structure to "hsa-mir-7845" (miRBase Accession No. 10000126637). o.MI0025515, sequence number 332) is known.

[0158] As used herein, "hsa-miR-6808-5p gene" or "hsa-mi The term "hsa-miR-6808-5p" refers to hsa-miR-6808- 5p gene (miRBase Accession No. MIMAT0027516) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 In addition, "hsa-miR-6808-5p" can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6808" (miRBase Accession No. MI0022653, SEQ ID NO: 333) is known.

[0159] As used herein, "hsa-miR-4447 gene" or "hsa-miR-4 The term "miR-4447" refers to the hsa-miR-4447 gene (miR Base Accession No. MIMAT0018966) and other species Homo sapiens Genes include genes that are either logs or orthologs. It can be obtained by the method described in Blood, Vol. 116, e118-e127. In addition, "hsa-miR-4447" has a hairpin-like structure as its precursor, "hsa-miR-4447". sa-mir-4447” (miRBase Accession No. MI0016 790, SEQ ID NO: 334) is known.

[0160] As used herein, "hsa-miR-6869-5p gene" or "hsa-mi The term "miR-6869-5p" refers to hsa-miR-6869-5p as set forth in SEQ ID NO: 83. 5p gene (miRBase Accession No. MIMAT0027638) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 In addition, "hsa-miR-6869-5p" can be obtained by the method described above. The precursor of the miR gene, "hsa-mir-6869" (miRBase Accession No. MI0022716, SEQ ID NO: 335) is known.

[0161] As used herein, "hsa-miR-1908-5p gene" or "hsa-mi The term "hsa-miR-1908-5p" refers to hsa-miR-1908- 5p gene (miRBase Accession No. MIMAT0007881) and other species homologs or orthologs. , 2008, Stem Cells, Vol. 26, pp. 2496-2505 Furthermore, "hsa-miR-1908-5p" can be obtained by The miRBase Accession No. 1006266666, which has a hairpin-like structure, is a nucleotide sequence of the miR-1908 gene. The sequence of the gene encoding the nucleotide sequence of the present invention is known to be nucleotide sequence no. MI0008329, sequence number 336.

[0162] As used herein, "hsa-miR-6729-5p gene" or "hsa-mi The term "miR-6729-5p" refers to hsa-miR-6729-5p as set forth in SEQ ID NO: 85. 5p gene (miRBase Accession No. MIMAT0027359) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 In addition, "hsa-miR-6729-5p" can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6729" (miRBase Accession No. MI0022574, SEQ ID NO: 337) is known.

[0163] As used herein, "hsa-miR-5195-3p gene" or "hsa-mi The term "miR-5195-3p" refers to hsa-miR-5195-3p as set forth in SEQ ID NO: 86. 3p gene (miRBase Accession No. MIMAT0021127) and other species homologs or orthologs. e D et al., 2011, Leukemia, Vol. 25, p. 1389-1399 hsa-miR-5195-3p can be obtained by the method The miRBase Ac receptor has a hairpin-like structure as a precursor protein, hsa-mir-5195 (miRBase Ac Accession No. MI0018174, SEQ ID NO: 338) is known.

[0164] As used herein, "hsa-miR-638 gene" or "hsa-miR-63 The term "miR-638" refers to the hsa-miR-638 gene (miRBas) set forth in SEQ ID NO: 87. e Accession No. MIMAT0003308) and homologs in other species orthologues thereof. Genes are as follows: Cummins JM et al., 2006, Proc Natl Acad Sci USA, vol. 103, p3687-3692 Furthermore, "hsa-miR-638" can be obtained by the method described in The precursor of the hairpin-like structure "hsa-mir-638" (miRBase A Accession No. MI0003653, SEQ ID NO: 339) is known.

[0165] As used herein, "hsa-miR-6125 gene" or "hsa-miR-6 The term "miR-6125" refers to the hsa-miR-6125 gene (miR-6125) set forth in SEQ ID NO: 88. Base Accession No. MIMAT0024598) and other species of Homo sapiens Genes include genes that are either homologs or orthologs. , J Virol, Vol. 86, pp. 5278-5287. In addition, "hsa-miR-6125" has a hairpin-like structure as its precursor. The miRBase Accession No. MI0 021259, SEQ ID NO: 340) is known.

[0166] As used herein, "hsa-miR-3178 gene" or "hsa-miR-3 The term "miR-3178" refers to the hsa-miR-3178 gene (miR-3178) set forth in SEQ ID NO: 89. Base Accession No. MIMAT0015055) and other species of Homo sapiens Genes include genes that are either homologs or orthologs. It can be obtained by the method described in PLoS One, Vol. 5, e9685. In addition, "hsa-miR-3178" has a hairpin-like structure as its precursor, "hsa -mir-3178” (miRBase Accession No. MI001421 2, SEQ ID NO: 341) is known.

[0167] As used herein, "hsa-miR-3196 gene" or "hsa-miR-3 The term "miR-3196" refers to the hsa-miR-3196 gene (miR Base Accession No. MIMAT0015080) and other species of Homo sapiens Genes include genes that are either homologs or orthologs. It can be obtained by the method described in PLoS One, Vol. 5, e9685. In addition, "hsa-miR-3196" has a hairpin-like structure as its precursor, "hsa -mir-3196” (miRBase Accession No. MI001424 1, SEQ ID NO: 342) is known.

[0168] As used herein, "hsa-miR-8069 gene" or "hsa-miR-8 The term "miR-8069" refers to the hsa-miR-8069 gene (miR-8069) set forth in SEQ ID NO: 91. Base Accession No. MIMAT0030996) and other species of Homo sapiens Genes include genes that are homologs or orthologs. It can be obtained by the method described in Shock, Vol. 39, pp. 480-487. In addition, "hsa-miR-8069" has a hairpin-like structure as its precursor, "hsa -mir-8069-1,hsa-mir-8069-2” (miRBase Acce Sequence No. MI0025905, MI0031519, SEQ ID NO: 343, 344 ) is known.

[0169] As used herein, "hsa-miR-4723-5p gene" or "hsa-mi The term "miR-4723-5p" refers to hsa-miR-4723-5p as set forth in SEQ ID NO: 92. 5p gene (miRBase Accession No. MIMAT0019838) and other species homologs or orthologs. The method described in N H et al., 2011, Cancer Res, Vol. 71, pp. 78-86 Furthermore, "hsa-miR-4723-5p" can be obtained by The miRBase Accession No. 1000026666444444444 is a miR-based gene that has a hairpin-like structure as a target protein. The sequence of the gene encoding the nucleotide sequence of the present invention is known to be nucleotide sequence no. MI0017359, sequence number 345.

[0170] As used herein, "hsa-miR-4746-3p gene" or "hsa-mi The term "miR-4746-3p" refers to hsa-miR-4746-3p as set forth in SEQ ID NO: 93. 3p gene (miRBase Accession No. MIMAT0019881) and other species homologs or orthologs. The method described in N H et al., 2011, Cancer Res, Vol. 71, pp. 78-86 Furthermore, "hsa-miR-4746-3p" can be obtained by The miRBase Accession No. 10000260 ... The sequence of the gene encoding the nucleotide sequence of the present invention is known to be nucleotide sequence no. MI0017385, sequence number 346.

[0171] As used herein, "hsa-miR-4689 gene" or "hsa-miR-4 The term "miR-4689" refers to the hsa-miR-4689 gene (miR Base Accession No. MIMAT0019778) and other species of Homo sapiens Genes include genes that are either homologs or orthologs. It can be obtained by the method described in Cancer Res, Vol. 71, pp. 78-86. In addition, "hsa-miR-4689" has a hairpin-like structure as its precursor. The miRBase Accession No. MI0 017322, SEQ ID NO: 347) is known.

[0172] As used herein, "hsa-miR-6816-5p gene" or "hsa-mi The term "miR-6816-5p" refers to hsa-miR-6816-5p as set forth in SEQ ID NO: 95. 5p gene (miRBase Accession No. MIMAT0027532) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 In addition, "hsa-miR-6816-5p" can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6816" (miRBase Accession No. MI0022661, SEQ ID NO: 348) is known.

[0173] As used herein, "hsa-miR-6757-5p gene" or "hsa-mi The term "hsa-miR-6757-5p" refers to hsa-miR-6757- 5p gene (miRBase Accession No. MIMAT0027414) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 In addition, "hsa-miR-6757-5p" can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-6757" (miRBase Accession No. MI0022602, SEQ ID NO: 349) is known.

[0174] As used herein, "hsa-miR-7109-5p gene" or "hsa-mi The term "hsa-miR-7109-5p" refers to hsa-miR-7109- 5p gene (miRBase Accession No. MIMAT0028115) and other species homologs or orthologs. G E et al., 2012, Genome Res, Vol. 22, p1634-1645 hsa-miR-7109-5p can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-7109" (miRBase Accession No. MI0022960, SEQ ID NO: 350) is known.

[0175] As used herein, "hsa-miR-6724-5p gene" or "hsa-mi The term "miR-6724-5p" refers to hsa-miR-6724-5p as set forth in SEQ ID NO: 98. 5p gene (miRBase Accession No. MIMAT0025856) and other species homologs or orthologs. 2012, Gene, Vol. 497, pp. 330-335 In addition, "hsa-miR-6724-5p" has a hairpin-like structure as its precursor. The structure is "hsa-mir-6724-1, hsa-mir-6724-2, hsa- mir-6724-3,hsa-mir-6724-4” (miRBase Access sion No. MI0022559, MI0031516, MI0031517, MI 0031518, SEQ ID NOs: 351, 352, 353, 354) are known.

[0176] As used herein, "hsa-miR-1225-3p gene" or "hsa-mi The term "miR-1225-3p" refers to hsa-miR-1225-3p as set forth in SEQ ID NO: 99. 3p gene (miRBase Accession No. MIMAT0005573) and other species homologs or orthologs. kov E et al., 2007, Mol Cell, vol. 28, pp. 328-336 hsa-miR-1225-3p can be obtained by the method The miRBase Ac receptor has a hairpin-like structure as a carrier. Accession No. MI0006311, SEQ ID NO: 355) is known.

[0177] As used herein, "hsa-miR-6875-5p gene" or "hsa-mi The term "miR-6875-5p" refers to hsa-miR-6875 as set forth in SEQ ID NO: 100. -5p gene (miRBase Accession No. MIMAT0027650 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6875-5p" can be obtained by the method described below. Its precursor, "hsa-mir-6875" (miRBase Accession No. MI0022722, SEQ ID NO: 356) is known.

[0178] As used herein, "hsa-miR-7108-5p gene" or "hsa-mi The term "miR-7108-5p" refers to hsa-miR-7108 as set forth in SEQ ID NO: 101. -5p gene (miRBase Accession No. MIMAT0028113 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-7108-5p" can be obtained by the method described above. Its precursor, "hsa-mir-7108" (miRBase Accession No. MI0022959, SEQ ID NO: 357) is known.

[0179] As used herein, "hsa-miR-4508 gene" or "hsa-miR-4 The term "miR-4508" refers to the hsa-miR-4508 gene (miR-4508) set forth in SEQ ID NO: 102. RBase Accession No. MIMAT0019045) and other species These include homologs or orthologs. Genes are listed in Jima DD et al., 2010 It can be obtained by the method described in Blood, Vol. 116, p. e118-e127. In addition, "hsa-miR-4508" has a hairpin-like structure as its precursor. hsa-mir-4508” (miRBase Accession No. MI001 6872, SEQ ID NO: 358) is known.

[0180] As used herein, "hsa-miR-6085 gene" or "hsa-miR-6 The term "miR-6085" refers to the hsa-miR-6085 gene (miR-6085) set forth in SEQ ID NO: 103. RBase Accession No. MIMAT0023710) and other species The gene includes homologs or orthologs. It can be obtained by the method described in 2012, RNA, Vol. 18, p. 472-484. In addition, "hsa-miR-6085" has a hairpin-like structure as its precursor. "hsa-mir-6085" (miRBase Accession No. MI00 20362, SEQ ID NO: 359) is known.

[0181] As used herein, "hsa-miR-6779-5p gene" or "hsa-mi The term "miR-6779-5p" refers to hsa-miR-6779 as set forth in SEQ ID NO: 104. -5p gene (miRBase Accession No. MIMAT0027458 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6779-5p" can be obtained by the method described above. Its precursor, "hsa-mir-6779" (miRBase Accession No. MI0022624, SEQ ID NO: 360) is known.

[0182] As used herein, "hsa-miR-642a-3p gene" or "hsa-mi The term "miR-642a-3p" refers to hsa-miR-642a set forth in SEQ ID NO: 105. -3p gene (miRBase Accession No. MIMAT0020924 ) and other species homologs or orthologues. ns JM et al., 2006, Proc Natl Acad Sci USA, 10 It can be obtained by the method described in Vol. 3, pp. 3687-3692. a-miR-642a-3p has a hairpin-like structure as its precursor, hsa-m ir-642a” (miRBase Accession No. MI0003657, SEQ ID NO: 361) is known.

[0183] As used herein, "hsa-miR-4695-5p gene" or "hsa-mi The term "miR-4695-5p" refers to hsa-miR-4695 as set forth in SEQ ID NO: 106. -5p gene (miRBase Accession No. MIMAT0019788 ) and other species homologs or orthologs. On H et al., 2011, Cancer Res, Vol. 71, p. 78-86 hsa-miR-4695-5p can be obtained by the method described above. The miRBase Accelerator has a hairpin-like structure called "hsa-mir-4695" ( Session No. MI0017328, SEQ ID NO: 362) is known.

[0184] As used herein, "hsa-miR-7847-3p gene" or "hsa-mi The term "miR-7847-3p" refers to hsa-miR-7847 as set forth in SEQ ID NO: 107. -3p gene (miRBase Accession No. MIMAT0030422 ) and other species homologs or orthologs. et al., 2012, PLoS One, Vol. 7, e50746 In addition, "hsa-miR-7847-3p" is a precursor of hairpin The miRBase Accession No. 100001266344 (hsa-mir-7847) has a phosphodiesterase-like structure. No. MI0025517, SEQ ID NO: 363) is known.

[0185] As used herein, "hsa-miR-3197 gene" or "hsa-miR-3 The term "miR-3197" refers to the hsa-miR-3197 gene (miR-3197) set forth in SEQ ID NO: 108. RBase Accession No. MIMAT0015082) and other species These genes include homologs or orthologs. It can be obtained by the method described in PLoS One, Vol. 5, e9685. In addition, "hsa-miR-3197" has a hairpin-like structure as its precursor, "hs a-mir-3197” (miRBase Accession No. MI00142 45, SEQ ID NO: 364) is known.

[0186] As used herein, "hsa-miR-6769b-5p gene" or "hsa-m The term "miR-6769b-5p" refers to hsa-miR-6769b-5p as set forth in SEQ ID NO: 109. 69b-5p gene (miRBase Accession No. MIMAT0027 620) and other species homologs or orthologs. Dewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645 The miR-6769b gene can be obtained by the method described in the above. p" has a hairpin-like structure as its precursor, "hsa-mir-6769b" (mi RBase Accession No. MI0022706, sequence number 365) It is being done.

[0187] As used herein, "hsa-miR-7641 gene" or "hsa-miR-7 The term "miR-7641" refers to the hsa-miR-7641 gene (miR-7641) set forth in SEQ ID NO: 110. RBase Accession No. MIMAT0029782) and other species These include homologs or orthologs. Genes are listed in Yoo JK et al., 2013, obtained by the method described in Arch Pharm Res, Vol. 36, pp. 353-358 In addition, "hsa-miR-7641" has a hairpin-like structure as its precursor. The structure of "hsa-mir-7641-1, hsa-mir-7641-2" (miR Base Accession No. MI0024975, MI0024976, sequence Numbers 366 and 367) are known.

[0188] As used herein, "hsa-miR-187-5p gene" or "hsa-miR The term "miR-187-5p" refers to hsa-miR-187-5p as set forth in SEQ ID NO: 111. Gene (miRBase Accession No. MIMAT0004561) and The gene includes homologs or orthologs of other organisms. Obtained by the method described in Science, Vol. 299, p. 1540, 2003 In addition, "hsa-miR-187-5p" has a hairpin-like structure as its precursor. The structure of "hsa-mir-187" (miRBase Accession No. I0000274, SEQ ID NO: 368) is known.

[0189] As used herein, "hsa-miR-3185 gene" or "hsa-miR-3 The term "miR-3185" refers to the hsa-miR-3185 gene (miR-3185) set forth in SEQ ID NO: 112. RBase Accession No. MIMAT0015065) and other species These genes include homologs or orthologs. It can be obtained by the method described in PLoS One, Vol. 5, e9685. In addition, "hsa-miR-3185" has a precursor "hs" which has a hairpin-like structure. a-mir-3185” (miRBase Accession No. MI00142 27, SEQ ID NO: 369) is known.

[0190] As used herein, "hsa-miR-2861 gene" or "hsa-miR-2 The term "miR-2861" refers to the hsa-miR-2861 gene (miR-2861) set forth in SEQ ID NO: 113. RBase Accession No. MIMAT0013802) and other species These genes include homologs or orthologs. Clin Invest, Vol. 119, pp. 3666-3677 In addition, "hsa-miR-2861" has a hairpin-like structure as its precursor. The structure of "hsa-mir-2861" (miRBase Accession No. .MI0013006, sequence number 370) is known.

[0191] As used herein, "hsa-miR-3940-5p gene" or "hsa-mi The term "miR-3940-5p" refers to hsa-miR-3940 as set forth in SEQ ID NO: 114. -5p gene (miRBase Accession No. MIMAT0019229 ) and other species homologs or orthologs. By the method described in JY et al., 2010, PLoS One, Vol. 5, e10563 Furthermore, "hsa-miR-3940-5p" can be obtained as a precursor of hsa-miR-3940-5p. The miRBase Accession No. 100001266666 (hsa-mir-3944) has an apin-like structure. n No. MI0016597, sequence number 371) is known.

[0192] As used herein, "hsa-miR-1203 gene" or "hsa-miR-1 The term "miR-1203" refers to the hsa-miR-1203 gene (miR-1203) set forth in SEQ ID NO: 115. RBase Accession No. MIMAT0005866) and other species These genes include homologs or orthologs. The method described in Leukemia, Vol. 22, pp. 330-338, In addition, "hsa-miR-1203" has a hairpin-like structure as its precursor. The miRBase Accession No. MI0 006335, SEQ ID NO: 372) is known.

[0193] As used herein, "hsa-miR-615-5p gene" or "hsa-miR The term "miR-615-5p" refers to hsa-miR-615-5p as set forth in SEQ ID NO: 116. Gene (miRBase Accession No. MIMAT0004804) and The gene includes homologs or orthologues of other organisms. JM et al., 2006, Proc Natl Acad Sci USA, vol. 103, It can be obtained by the method described in pp. 3687-3692. iR-615-5p is a precursor of hsa-mir-6, which has a hairpin-like structure. 15" (miRBase Accession No. MI0003628, SEQ ID NO: 3 73) is known.

[0194] As used herein, "hsa-miR-4787-5p gene" or "hsa-mi The term "miR-4787-5p" refers to hsa-miR-4787 set forth in SEQ ID NO: 117. -5p gene (miRBase Accession No. MIMAT0019956 ) and other species homologs or orthologs. On H et al., 2011, Cancer Res, Vol. 71, p. 78-86 hsa-miR-4787-5p can be obtained by the method described above. The miRBase Accelerator has a hairpin-like structure called "hsa-mir-4787" ( Session No. MI0017434, SEQ ID NO: 374) is known.

[0195] As used herein, "hsa-miR-1343-3p gene" or "hsa-mi The term "miR-1343-3p" refers to hsa-miR-1343 as set forth in SEQ ID NO: 118. -3p gene (miRBase Accession No. MIMAT0019776 ) and other species homologs or orthologs. On H et al., 2011, Cancer Res, Vol. 71, p. 78-86 hsa-miR-1343-3p can be obtained by the method described above. The miRBase Accelerator has a hairpin-like structure called "hsa-mir-1343" ( Session No. MI0017320, SEQ ID NO: 375) is known.

[0196] As used herein, "hsa-miR-6813-5p gene" or "hsa-mi The term "miR-6813-5p" refers to hsa-miR-6813 as set forth in SEQ ID NO: 119. -5p gene (miRBase Accession No. MIMAT0027526 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6813-5p" can be obtained by the method described below. Its precursor, "hsa-mir-6813" (miRBase Accession No. MI0022658, SEQ ID NO: 376) is known.

[0197] As used herein, "hsa-miR-1225-5p gene" or "hsa-mi The term "miR-1225-5p" refers to hsa-miR-1225 as set forth in SEQ ID NO: 120. -5p gene (miRBase Accession No. MIMAT0005572 ) and other species homologs or orthologs. Ikov E et al., 2007, Mol Cell, vol. 28, p328-336 Furthermore, "hsa-miR-1225-5p" can be obtained by the method The precursor of "hsa-mir-1225" (miRBase A Accession No. MI0006311, SEQ ID NO: 377) is known.

[0198] As used herein, "hsa-miR-602 gene" or "hsa-miR-60 The term "miR-602" refers to the hsa-miR-602 gene (miRBa se Accession No. MIMAT0003270) and other species homologs orthologues, etc. Genes are listed in Cummins JM et al., 2006 , Proc Natl Acad Sci USA, vol. 103, p3687-369 2. Furthermore, "hsa-miR-602" can be obtained by the method described in Its precursor, "hsa-mir-602" (miRBase Accession No. MI0003615, SEQ ID NO: 378) is known.

[0199] As used herein, "hsa-miR-4488 gene" or "hsa-miR-4 The term "miR-4488" refers to the hsa-miR-4488 gene (miR-4488) set forth in SEQ ID NO: 122. RBase Accession No. MIMAT0019022) and other species These include homologs or orthologs. Genes are listed in Jima DD et al., 2010 It can be obtained by the method described in Blood, Vol. 116, p. e118-e127. In addition, "hsa-miR-4488" has a hairpin-like structure as its precursor. hsa-mir-4488” (miRBase Accession No. MI001 6849, SEQ ID NO: 379) is known.

[0200] As used herein, "hsa-miR-125a-3p gene" or "hsa-mi The term "miR-125a-3p" refers to hsa-miR-125a as set forth in SEQ ID NO: 123. -3p gene (miRBase Accession No. MIMAT0004602 ) and other species homologs or orthologues. - Quintana M et al., 2002, Curr Biol, vol. 12, pp. 735-73 9. Also, "hsa-miR-125a-3 p” has a hairpin-like structure as its precursor “hsa-mir-125a” (miR Base Accession No. MI0000469, SEQ ID NO: 380) is known are.

[0201] As used herein, "hsa-miR-5100 gene" or "hsa-miR-5 The term "miR-5100" refers to the hsa-miR-5100 gene (miR-5100) set forth in SEQ ID NO: 124. RBase Accession No. MIMAT0022259) and other species These include homologs or orthologs. Genes are listed in Tandon M et al., 2012 Oral Dis, Vol. 18, pp. 127-131. In addition, "hsa-miR-5100" has a hairpin-like structure as its precursor. The miRBase Accession No. MI0 019116, SEQ ID NO: 381) is known.

[0202] As used herein, "hsa-miR-4294 gene" or "hsa-miR-4 The term "miR-4294" refers to the hsa-miR-4294 gene (mi RBase Accession No. MIMAT0016849) and other species These include homologs or orthologs. Genes are listed in Goff LA et al., 2009 It can be obtained by the method described in PLoS One, Vol. 4, e7192. In addition, "hsa-miR-4294" has a hairpin-like structure as its precursor, "hsa -mir-4294” (miRBase Accession No. MI001582 7, SEQ ID NO: 382) is known.

[0203] As used herein, "hsa-miR-1231 gene" or "hsa-miR-1 The term "miR-1231" refers to the hsa-miR-1231 gene (miR-1231) set forth in SEQ ID NO: 126. RBase Accession No. MIMAT0005586) and other species The gene includes homologs or orthologs. obtained by the method described in Mol Cell, Vol. 28, pp. 328-336, 2007. In addition, "hsa-miR-1231" has a hairpin-like structure as its precursor. The miRBase Accession No. MI0006321, SEQ ID NO: 383) is known.

[0204] As used herein, "hsa-miR-6765-3p gene" or "hsa-mi The term "miR-6765-3p" refers to hsa-miR-6765 as set forth in SEQ ID NO: 127. -3p gene (miRBase Accession No. MIMAT0027431 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6765-3p" can be obtained by the method described below. Its precursor, "hsa-mir-6765" (miRBase Accession No. MI0022610, SEQ ID NO: 384) is known.

[0205] As used herein, "hsa-miR-4442 gene" or "hsa-miR-4 The term "miR-4442" refers to the hsa-miR-4442 gene (miR-4442) set forth in SEQ ID NO: 128. RBase Accession No. MIMAT0018960) and other species These include homologs or orthologs. Genes are listed in Jima DD et al., 2010 It can be obtained by the method described in Blood, Vol. 116, p. e118-e127. In addition, "hsa-miR-4442" has a hairpin-like structure as its precursor. hsa-mir-4442” (miRBase Accession No. MI001 6785, SEQ ID NO: 385) is known.

[0206] As used herein, "hsa-miR-718 gene" or "hsa-miR-71 The term "miR-718" refers to the hsa-miR-718 gene (miRBa se Accession No. MIMAT0012735) and other species homologs orthologues, etc. Genes are described in Artzi S et al., 2008, BM C Bioinformatics, Vol. 9, p. 39 In addition, "hsa-miR-718" has a hairpin-like structure as its precursor. "hsa-mir-718" (miRBase Accession No. MI001 2489, SEQ ID NO: 386) is known.

[0207] As used herein, "hsa-miR-6780b-5p gene" or "hsa-m The term "miR-6780b-5p" refers to hsa-miR-6780b-5p as set forth in SEQ ID NO: 130. 80b-5p gene (miRBase Accession No. MIMAT0027 572) and other species homologs or orthologs. Dewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645 The miR-6780b gene can be obtained by the method described in the above. p" has a hairpin-like structure as its precursor, "hsa-mir-6780b" (mi RBase Accession No. MI0022681, sequence number 387) It is being done.

[0208] As used herein, "hsa-miR-6090 gene" or "hsa-miR-6 The term "miR-6090" refers to the hsa-miR-6090 gene (miR-6090) set forth in SEQ ID NO: 131. RBase Accession No. MIMAT0023715) and other species These genes include homologs or orthologs. Stem Cells Dev, Vol. 21, p. 2049-2057 In addition, "hsa-miR-6090" can be obtained by using hairpin as its precursor. The miRBase Accession No. 100001266664 (hsa-mir-6090) has a miR-like structure. No. MI0020367, SEQ ID NO: 388) are known.

[0209] As used herein, "hsa-miR-6845-5p gene" or "hsa-mi The term "miR-6845-5p" refers to hsa-miR-6845 as set forth in SEQ ID NO: 132. -5p gene (miRBase Accession No. MIMAT0027590 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6845-5p" can be obtained by the method described below. Its precursor, "hsa-mir-6845" (miRBase Accession No. MI0022691, SEQ ID NO: 389) is known.

[0210] As used herein, "hsa-miR-4741 gene" or "hsa-miR-4 The term "miR-4741" refers to the hsa-miR-4741 gene (miR-4741) set forth in SEQ ID NO: 133. RBase Accession No. MIMAT0019871) and other species The gene includes homologs or orthologs. 1, Cancer Res, Vol. 71, p. 78-86 In addition, "hsa-miR-4741" has a hairpin-like structure as its precursor. Take "hsa-mir-4741" (miRBase Accession No. MI 0017379, SEQ ID NO: 390) is known.

[0211] As used herein, "hsa-miR-4467 gene" or "hsa-miR-4 The term "miR-4467" refers to the hsa-miR-4467 gene (miR-4467) set forth in SEQ ID NO: 134. RBase Accession No. MIMAT0018994) and other species These include homologs or orthologs. Genes are listed in Jima DD et al., 2010 It can be obtained by the method described in Blood, Vol. 116, p. e118-e127. In addition, "hsa-miR-4467" has a hairpin-like structure as its precursor. hsa-mir-4467” (miRBase Accession No. MI001 6818, SEQ ID NO: 391) is known.

[0212] As used herein, "hsa-miR-4707-5p gene" or "hsa-mi The term "miR-4707-5p" refers to hsa-miR-4707 as set forth in SEQ ID NO: 135. -5p gene (miRBase Accession No. MIMAT0019807 ) and other species homologs or orthologs. On H et al., 2011, Cancer Res, Vol. 71, p. 78-86 hsa-miR-4707-5p can be obtained by the method described above. The miRBase Accelerator has a hairpin-like structure. Session No. MI0017340, SEQ ID NO: 392) is known.

[0213] As used herein, "hsa-miR-4271 gene" or "hsa-miR-4 The term "miR-4271" refers to the hsa-miR-4271 gene (miR-4271) set forth in SEQ ID NO: 136. RBase Accession No. MIMAT0016901) and other species These include homologs or orthologs. Genes are listed in Goff LA et al., 2009 It can be obtained by the method described in PLoS One, Vol. 4, e7192. In addition, "hsa-miR-4271" has a hairpin-like structure as its precursor, "hsa -mir-4271” (miRBase Accession No. MI001587 9, SEQ ID NO: 393) is known.

[0214] As used herein, "hsa-miR-4673 gene" or "hsa-miR-4 The term "miR-4673" refers to the hsa-miR-4673 gene (miR-4673) set forth in SEQ ID NO: 137. RBase Accession No. MIMAT0019755) and other species The gene includes homologs or orthologs. 1, Cancer Res, Vol. 71, p. 78-86 In addition, "hsa-miR-4673" has a hairpin-like structure as its precursor. Take "hsa-mir-4673" (miRBase Accession No. MI 0017304, SEQ ID NO: 394) is known.

[0215] As used herein, "hsa-miR-3184-5p gene" or "hsa-mi The term "miR-3184-5p" refers to hsa-miR-3184 set forth in SEQ ID NO: 138. -5p gene (miRBase Accession No. MIMAT0015064 ) and other species homologs or orthologs. By the method described in MS et al., 2010, PLoS One, Vol. 5, e9685 Furthermore, "hsa-miR-3184-5p" can be obtained as a precursor of hsa-miR-3184-5p. The apin-like structure of "hsa-mir-3184" (miRBase Accession No. n No. MI0014226, sequence number 395) is known.

[0216] As used herein, "hsa-miR-1469 gene" or "hsa-miR-1 The term "miR-1469" refers to the hsa-miR-1469 gene (miR-1469) set forth in SEQ ID NO: 139. RBase Accession No. MIMAT0007347) and other species These genes include homologs or orthologs. It can be obtained by the method described in BMC Genomics, Vol. 9, p. 157. In addition, "hsa-miR-1469" has a hairpin-like structure as its precursor. "hsa-mir-1469" (miRBase Accession No. MI00 07074, SEQ ID NO: 396) is known.

[0217] As used herein, "hsa-miR-4640-5p gene" or "hsa-mi The term "miR-4640-5p" refers to hsa-miR-4640 set forth in SEQ ID NO: 140. -5p gene (miRBase Accession No. MIMAT0019699 ) and other species homologs or orthologs. On H et al., 2011, Cancer Res, Vol. 71, p. 78-86 hsa-miR-4640-5p can be obtained by the method described above. The miRBase Accelerator has a hairpin-like structure called "hsa-mir-4640" ( Session No. MI0017267, SEQ ID NO: 397) is known.

[0218] As used herein, "hsa-miR-663a gene" or "hsa-miR-6 The term "miR-663a" refers to the hsa-miR-663a gene (mi RBase Accession No. MIMAT0003326) and other species The gene includes homologs or orthologs. 2006, Proc Natl Acad Sci USA, Vol. 103, p3687- 3692. miR a has a hairpin-like structure as its precursor, hsa-mir-663a (miR Base Accession No. MI0003672, SEQ ID NO: 398) is known are.

[0219] As used herein, "hsa-miR-6791-5p gene" or "hsa-mi The term "miR-6791-5p" refers to hsa-miR-6791 set forth in SEQ ID NO: 142. -5p gene (miRBase Accession No. MIMAT0027482 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6791-5p" can be obtained by the method described above. Its precursor, "hsa-mir-6791" (miRBase Accession No. MI0022636, SEQ ID NO: 399) is known.

[0220] As used herein, "hsa-miR-6826-5p gene" or "hsa-mi The term "miR-6826-5p" refers to hsa-miR-6826 set forth in SEQ ID NO: 143. -5p gene (miRBase Accession No. MIMAT0027552 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6826-5p" can be obtained by the method described below. Its precursor, "hsa-mir-6826" (miRBase Accession No. MI0022671, SEQ ID NO: 400) is known.

[0221] As used herein, "hsa-miR-4433b-3p gene" or "hsa-m The term "miR-4433b-3p" refers to hsa-miR-4433b-3p as set forth in SEQ ID NO: 144. 33b-3p gene (miRBase Accession No. MIMAT0030 414) and other species homologs or orthologs. By the method described in e H et al., 2012, PLoS One, Vol. 7, e50746 Furthermore, "hsa-miR-4433b-3p" can be obtained as its precursor. The miRBase Accession No. 100001266664 (hsa-mir-4433b) has a hairpin-like structure. sion No. MI0025511, SEQ ID NO: 401) is known.

[0222] As used herein, "hsa-miR-1915-3p gene" or "hsa-mi The term "miR-1915-3p" refers to hsa-miR-1915 as set forth in SEQ ID NO: 145. -3p gene (miRBase Accession No. MIMAT0007892 ) and other species homologs or orthologues. et al., 2008, Stem Cells, Vol. 26, p. 2496-2505 hsa-miR-1915-3p can be obtained by the method described above. The miRBase Accelerator has a hairpin-like structure called "hsa-mir-1915" ( Session No. MI0008336, SEQ ID NO: 402) is known.

[0223] As used herein, "hsa-miR-4417 gene" or "hsa-miR-4 The term "miR-4417" refers to the hsa-miR-4417 gene (miR-4417) set forth in SEQ ID NO: 146. RBase Accession No. MIMAT0018929) and other species These include homologs or orthologs. Genes are listed in Jima DD et al., 2010 It can be obtained by the method described in Blood, Vol. 116, p. e118-e127. In addition, "hsa-miR-4417" has a hairpin-like structure as its precursor. hsa-mir-4417” (miRBase Accession No. MI001 6753, SEQ ID NO: 403) is known.

[0224] As used herein, "hsa-miR-4449 gene" or "hsa-miR-4 The term "miR-4449" refers to the hsa-miR-4449 gene (miR-4449) set forth in SEQ ID NO: 147. RBase Accession No. MIMAT0018968) and other species These include homologs or orthologs. Genes are listed in Jima DD et al., 2010 It can be obtained by the method described in Blood, Vol. 116, p. e118-e127. In addition, "hsa-miR-4449" has a hairpin-like structure as its precursor. hsa-mir-4449” (miRBase Accession No. MI001 6792, SEQ ID NO: 404) is known.

[0225] As used herein, "hsa-miR-4707-3p gene" or "hsa-mi The term "miR-4707-3p" refers to hsa-miR-4707 as set forth in SEQ ID NO: 148. -3p gene (miRBase Accession No. MIMAT0019808 ) and other species homologs or orthologs. On H et al., 2011, Cancer Res, Vol. 71, p. 78-86 hsa-miR-4707-3p can be obtained by the method described above. The miRBase Accelerator has a hairpin-like structure. Session No. MI0017340, SEQ ID NO: 405) is known.

[0226] As used herein, "hsa-miR-3180-3p gene" or "hsa-mi The term "miR-3180-3p" refers to hsa-miR-3180 set forth in SEQ ID NO: 149. -3p gene (miRBase Accession No. MIMAT0015058 ) and other species homologs or orthologues. The method described in Hton CJ et al., 2010, PLoS One, Vol. 5, e9637 Furthermore, "hsa-miR-3180-3p" can be obtained by The hairpin-like structure of "hsa-mir-3180-1, hsa-mir-318 0-2,hsa-mir-3180-3” (miRBase Accession No. .MI0014214, MI0014215, MI0014217, SEQ ID NO: 406,4 07,408) are known.

[0227] As used herein, "hsa-miR-5585-3p gene" or "hsa-mi The term "miR-5585-3p" refers to hsa-miR-5585 as set forth in SEQ ID NO: 150. -3p gene (miRBase Accession No. MIMAT0022286 ) and other species homologs or orthologs. Lander MR et al., 2012, Nucleic Acids Res, vol. 40, p. 37-52. "85-3p" has a hairpin-like structure as its precursor "hsa-mir-5585" (miRBase Accession No. MI0019142, SEQ ID NO: 409) is known.

[0228] As used herein, "hsa-miR-1268a gene" or "hsa-miR- The term "miR-1268a" refers to the hsa-miR-1268a gene set forth in SEQ ID NO: 151. (miRBase Accession No. MIMAT0005922) and other Species homologs or orthologs are included. By the method described in Genome Res, Vol. 18, pp. 610-621, 2008. Furthermore, "hsa-miR-1268a" can be obtained by using hairpin as its precursor. The miRBase Accession No. 1268a (hsa-mir-1268a) has a miR-like structure. No. MI0006405, SEQ ID NO: 410) is known.

[0229] As used herein, "hsa-miR-8072 gene" or "hsa-miR-8 The term "miR-8072" refers to the hsa-miR-8072 gene (miR-8072) set forth in SEQ ID NO: 152. RBase Accession No. MIMAT0030999) and other species These include homologs or orthologs. Genes are listed in Wang HJ et al., 2013 , Shock, Vol. 39, pp. 480-487. In addition, "hsa-miR-8072" has a hairpin-like structure as its precursor, "hs a-mir-8072” (miRBase Accession No. MI00259 08, SEQ ID NO: 411) is known.

[0230] As used herein, "hsa-miR-296-5p gene" or "hsa-miR The term "miR-296-5p" refers to hsa-miR-296-5p as set forth in SEQ ID NO: 153. Gene (miRBase Accession No. MIMAT0000690) and The gene includes homologs or orthologues of other species. According to the method described in HB et al., 2003, Dev Cell, Vol. 5, pp. 351-358 Furthermore, "hsa-miR-296-5p" can be obtained as its precursor. The hairpin-like structure of "hsa-mir-296" (miRBase Accession No. on No. MI0000747, SEQ ID NO: 412) is known.

[0231] As used herein, "hsa-miR-204-3p gene" or "hsa-miR The term "miR-204-3p" refers to hsa-miR-204-3p as set forth in SEQ ID NO: 154. Gene (miRBase Accession No. MIMAT0022693) and The gene includes homologs or orthologs of other organisms. Obtained by the method described in Science, Vol. 299, p. 1540, 2003 In addition, "hsa-miR-204-3p" has a hairpin-like structure as its precursor. The miRBase Accession No. I0000284, SEQ ID NO: 413) is known.

[0232] As used herein, "hsa-miR-4454 gene" or "hsa-miR-4 The term "miR-4454" refers to the hsa-miR-4454 gene (miR-4454) set forth in SEQ ID NO: 155. RBase Accession No. MIMAT0018976) and other species These include homologs or orthologs. Genes are listed in Jima DD et al., 2010 It can be obtained by the method described in Blood, Vol. 116, p. e118-e127. In addition, "hsa-miR-4454" has a hairpin-like structure as its precursor. hsa-mir-4454” (miRBase Accession No. MI001 6800, SEQ ID NO: 414) is known.

[0233] As used herein, "hsa-miR-6722-3p gene" or "hsa-mi The term "miR-6722-3p" refers to hsa-miR-6722 as set forth in SEQ ID NO: 156. -3p gene (miRBase Accession No. MIMAT0025854 ) and other species homologs or orthologs. , 2012, Gene, Vol. 497, pp. 330-335 In addition, "hsa-miR-6722-3p" has a hairpin "hsa-mir-6722" (miRBase Accession No. o.MI0022557, SEQ ID NO: 415) is known.

[0234] As used herein, "hsa-miR-1290 gene" or "hsa-miR-1 The term "miR-1290" refers to the hsa-miR-1290 gene (miR-1290) set forth in SEQ ID NO: 157. RBase Accession No. MIMAT0005880) and other species These genes include homologs or orthologs. The method described in Genome Res, Vol. 18, pp. 610-621 In addition, "hsa-miR-1290" has a hairpin-like structure as its precursor. The miRBase Accession No. I0006352, SEQ ID NO: 416) is known.

[0235] As used herein, "hsa-miR-3622a-5p gene" or "hsa-m The term "hsa-miR-3622a-5p" refers to hsa-miR-3622a-5p as set forth in SEQ ID NO: 158. 22a-5p gene (miRBase Accession No. MIMAT0018 003) and other species homologs or orthologs. By the method described in Tten D et al., 2010, BMC Biol, Vol. 8, p. 58 Furthermore, "hsa-miR-3622a-5p" can be obtained as its precursor. The miRBase Accession No. 1000126666444444 forms a hairpin-like structure. sion No. MI0016013, SEQ ID NO: 417) is known.

[0236] As used herein, "hsa-miR-939-5p gene" or "hsa-miR The term "miR-939-5p" refers to hsa-miR-939-5p set forth in SEQ ID NO: 159. Gene (miRBase Accession No. MIMAT0004982) and The genes include homologs or orthologs of other species. The method described in Cancer Res, 2007, Vol. 67, p. 6031-6043 Furthermore, "hsa-miR-939-5p" can be obtained as its precursor. The miRBase Accession No. 1006266666, which has a hairpin-like structure, is a missense mutation in the miR-1 gene. on No. MI0005761, SEQ ID NO: 418) is known.

[0237] As used herein, "hsa-miR-675-5p gene" or "hsa-miR The term "miR-675-5p" refers to hsa-miR-675-5p as set forth in SEQ ID NO: 160. Gene (miRBase Accession No. MIMAT0004284) and The genes include homologs or orthologs of other species. It can be obtained by the method described in the RNA Journal, Vol. 13, pp. 313-316, 2007. In addition, "hsa-miR-675-5p" has a hairpin-like structure as its precursor. The miRBase Accession No. MI00 05416, SEQ ID NO: 419) is known.

[0238] As used herein, "hsa-miR-3131 gene" or "hsa-miR-3 The term "miR-3131" refers to the hsa-miR-3131 gene (miR-3131) set forth in SEQ ID NO: 161. RBase Accession No. MIMAT0014996) and other species These genes include homologs or orthologs. It can be obtained by the method described in PLoS One, Vol. 5, e9685. In addition, "hsa-miR-3131" has a hairpin-like structure as its precursor, "hs a-mir-3131” (miRBase Accession No. MI00141 51, SEQ ID NO: 420) is known.

[0239] As used herein, "hsa-miR-4648 gene" or "hsa-miR-4 The term "miR-4648" refers to the hsa-miR-4648 gene (miR-4648) set forth in SEQ ID NO: 162. RBase Accession No. MIMAT0019710) and other species The gene includes homologs or orthologs. 1, Cancer Res, Vol. 71, p. 78-86 In addition, "hsa-miR-4648" has a hairpin-like structure as its precursor. Take "hsa-mir-4648" (miRBase Accession No. MI 0017275, SEQ ID NO: 421) is known.

[0240] As used herein, "hsa-miR-1268b gene" or "hsa-miR- The term "miR-1268b" refers to the hsa-miR-1268b gene set forth in SEQ ID NO: 163. (miRBase Accession No. MIMAT0018925) and other Species homologs or orthologs are included. Obtained by the method described in Blood, Vol. 116, p. 118-127, 10 years ago. In addition, "hsa-miR-1268b" has a hairpin-like structure as its precursor. The miRBase Accession No. MI0016748, SEQ ID NO: 422) is known.

[0241] As used herein, "hsa-miR-6741-5p gene" or "hsa-mi The term "miR-6741-5p" refers to hsa-miR-6741 set forth in SEQ ID NO: 164. -5p gene (miRBase Accession No. MIMAT0027383 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6741-5p" can be obtained by the method described below. Its precursor, "hsa-mir-6741" (miRBase Accession No. MI0022586, SEQ ID NO: 423) is known.

[0242] As used herein, "hsa-miR-6893-5p gene" or "hsa-mi The term "miR-6893-5p" refers to hsa-miR-6893 as set forth in SEQ ID NO: 165. -5p gene (miRBase Accession No. MIMAT0027686 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6893-5p" can be obtained by the method described above. Its precursor, "hsa-mir-6893" (miRBase Accession No. MI0022740, SEQ ID NO: 424) is known.

[0243] As used herein, "hsa-miR-3162-5p gene" or "hsa-mi The term "miR-3162-5p" refers to hsa-miR-3162 set forth in SEQ ID NO: 166. -5p gene (miRBase Accession No. MIMAT0015036 ) and other species homologs or orthologs. By the method described in MS et al., 2010, PLoS One, Vol. 5, e9685 Furthermore, "hsa-miR-3162-5p" can be obtained as a precursor of hsa-miR-3162-5p. The miRBase Accession No. 1 (hsa-mir-3162) has an apin-like structure. n No. MI0014192, sequence number 425) is known.

[0244] As used herein, "hsa-miR-642b-3p gene" or "hsa-mi The term "miR-642b-3p" refers to hsa-miR-642b as set forth in SEQ ID NO: 167. -3p gene (miRBase Accession No. MIMAT0018444 ) and other species homologs or orthologues. obtained by the method described in n D et al., 2010, BMC Biol, Vol. 8, p. 58 In addition, "hsa-miR-642b-3p" is a precursor of hairpin The miRBase Accession No. 1000012666642b (hsa-mir-642b) has a miR-like structure. No. MI0016685, SEQ ID NO: 426) is known.

[0245] As used herein, "hsa-miR-4734 gene" or "hsa-miR-4 The term "miR-4734" refers to the hsa-miR-4734 gene (miR-4734) set forth in SEQ ID NO: 168. RBase Accession No. MIMAT0019859) and other species The gene includes homologs or orthologs. 1, Cancer Res, Vol. 71, p. 78-86 In addition, "hsa-miR-4734" has a hairpin-like structure as its precursor. Take "hsa-mir-4734" (miRBase Accession No. MI 0017371, SEQ ID NO: 427) is known.

[0246] As used herein, "hsa-miR-150-3p gene" or "hsa-miR The term "miR-150-3p" refers to hsa-miR-150-3p set forth in SEQ ID NO: 169. Gene (miRBase Accession No. MIMAT0004610) and The gene includes homologs or orthologues of other species. Intana M et al., 2002, Curr Biol, vol. 12, pp. 735-739 Furthermore, "hsa-miR-150-3p" can be obtained by the method described in Its precursor, "hsa-mir-150" (miRBase Accession No. MI0000479, SEQ ID NO: 428) is known.

[0247] As used herein, "hsa-miR-8089 gene" or "hsa-miR-8 The term "miR-8089" refers to the hsa-miR-8089 gene (miR-8089) set forth in SEQ ID NO: 170. RBase Accession No. MIMAT0031016) and other species These include homologs or orthologs. Genes are listed in Wang HJ et al., 2013 , Shock, Vol. 39, pp. 480-487. In addition, "hsa-miR-8089" has a hairpin-like structure as its precursor, "hs a-mir-8089” (miRBase Accession No. MI00259 25, SEQ ID NO: 429) is known.

[0248] As used herein, "hsa-miR-6805-3p gene" or "hsa-mi The term "miR-6805-3p" refers to hsa-miR-6805 as set forth in SEQ ID NO: 171. -3p gene (miRBase Accession No. MIMAT0027511 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6805-3p" can be obtained by the method described below. Its precursor, "hsa-mir-6805" (miRBase Accession No. MI0022650, SEQ ID NO: 430) is known.

[0249] As used herein, "hsa-miR-7113-3p gene" or "hsa-mi The term "miR-7113-3p" refers to hsa-miR-7113 as set forth in SEQ ID NO: 172. -3p gene (miRBase Accession No. MIMAT0028124 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-7113-3p" can be obtained by the method described below. Its precursor, "hsa-mir-7113" (miRBase Accession No. MI0022964, SEQ ID NO: 431) is known.

[0250] As used herein, "hsa-miR-6850-5p gene" or "hsa-mi The term "miR-6850-5p" refers to hsa-miR-6850 set forth in SEQ ID NO: 173. -5p gene (miRBase Accession No. MIMAT0027600 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6850-5p" can be obtained by the method described below. Its precursor, "hsa-mir-6850" (miRBase Accession No. MI0022696, SEQ ID NO: 432) is known.

[0251] As used herein, "hsa-miR-6799-5p gene" or "hsa-mi The term "miR-6799-5p" refers to hsa-miR-6799 as set forth in SEQ ID NO: 174. -5p gene (miRBase Accession No. MIMAT0027498 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6799-5p" can be obtained by the method described above. Its precursor, "hsa-mir-6799" (miRBase Accession No. MI0022644, SEQ ID NO: 433) is known.

[0252] As used herein, "hsa-miR-6768-5p gene" or "hsa-mi The term "miR-6768-5p" refers to hsa-miR-6768 as set forth in SEQ ID NO: 175. -5p gene (miRBase Accession No. MIMAT0027436 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6768-5p" can be obtained by the method described below. Its precursor, "hsa-mir-6768" (miRBase Accession No. MI0022613, SEQ ID NO: 434) is known.

[0253] As used herein, "hsa-miR-92b-5p gene" or "hsa-miR The term "miR-92b-5p" refers to hsa-miR-92b-5p as set forth in SEQ ID NO: 176. Gene (miRBase Accession No. MIMAT0004792) and The gene includes homologs or orthologues of other organisms. JM et al., 2006, Proc Natl Acad Sci USA, vol. 103, It can be obtained by the method described in pp. 3687-3692. iR-92b-5p is a precursor of hsa-mir-9, which has a hairpin-like structure. 2b" (miRBase Accession No. MI0003560, SEQ ID NO: 4 35) is known.

[0254] As used herein, "hsa-miR-3679-5p gene" or "hsa-mi The term "miR-3679-5p" refers to hsa-miR-3679 set forth in SEQ ID NO: 177. -5p gene (miRBase Accession No. MIMAT0018104 ) and other species homologs or orthologues. The method described in Hton CJ et al., 2010, PLoS One, Vol. 5, e9637 Furthermore, "hsa-miR-3679-5p" can be obtained by The miRBase Accession No. 100002666666444444444 has a hairpin-like structure as a target protein. The sequence of the gene encoding the nucleotide sequence of the present invention is known to be nucleotide sequence no. MI0016080, sequence number 436.

[0255] As used herein, "hsa-miR-4792 gene" or "hsa-miR-4 The term "miR-4792" refers to the hsa-miR-4792 gene (miR-4792) set forth in SEQ ID NO: 178. RBase Accession No. MIMAT0019964) and other species The gene includes homologs or orthologs. 1, Cancer Res, Vol. 71, p. 78-86 In addition, "hsa-miR-4792" has a hairpin-like structure as its precursor. Take "hsa-mir-4792" (miRBase Accession No. MI 0017439, SEQ ID NO: 437) is known.

[0256] As used herein, "hsa-miR-3656 gene" or "hsa-miR-3 The term "miR-3656" refers to the hsa-miR-3656 gene (miR-3656) set forth in SEQ ID NO: 179. RBase Accession No. MIMAT0018076) and other species These include homologs or orthologs. Genes are listed in Meiri E et al., 2010 , Nucleic Acids Res, Vol. 38, p. 6234-6246 hsa-miR-3656 can be obtained by the method described above. The miRBase Accession No. 10000266686 (hsa-mir-3656) has a hairpin-like structure. ion No. MI0016056, SEQ ID NO: 438) is known.

[0257] As used herein, "hsa-miR-92a-2-5p gene" or "hsa-m The term "miR-92a-2-5p" refers to hsa-miR-92a-2-5p as set forth in SEQ ID NO: 180. a-2-5p gene (miRBase Accession No. MIMAT0004 508) and other species homologs or orthologues. Urelatos Z et al., 2002, Genes Dev, Vol. 16, p720-728 The miR-92a-2-5 gene can be obtained by the method described in p" has a hairpin-like structure as its precursor, "hsa-mir-92a-2" (mi RBase Accession No. MI0000094, sequence number 439) It is being done.

[0258] As used herein, "hsa-miR-4466 gene" or "hsa-miR-4 The term "miR-4466" refers to the hsa-miR-4466 gene (miR-4466) set forth in SEQ ID NO: 181. RBase Accession No. MIMAT0018993) and other species These include homologs or orthologs. Genes are listed in Jima DD et al., 2010 It can be obtained by the method described in Blood, Vol. 116, p. e118-e127. In addition, "hsa-miR-4466" has a hairpin-like structure as its precursor. hsa-mir-4466” (miRBase Accession No. MI001 6817, SEQ ID NO: 440) is known.

[0259] As used herein, "hsa-miR-4513 gene" or "hsa-miR-4 The term "miR-4513" refers to the hsa-miR-4513 gene (miR-4513) set forth in SEQ ID NO: 182. RBase Accession No. MIMAT0019050) and other species These include homologs or orthologs. Genes are listed in Jima DD et al., 2010 It can be obtained by the method described in Blood, Vol. 116, p. e118-e127. In addition, "hsa-miR-4513" has a hairpin-like structure as its precursor. hsa-mir-4513” (miRBase Accession No. MI001 6879, SEQ ID NO: 441) is known.

[0260] As used herein, "hsa-miR-6781-5p gene" or "hsa-mi The term "miR-6781-5p" refers to hsa-miR-6781 set forth in SEQ ID NO: 183. -5p gene (miRBase Accession No. MIMAT0027462 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6781-5p" can be obtained by the method described below. Its precursor, "hsa-mir-6781" (miRBase Accession No. MI0022626, SEQ ID NO: 442) is known.

[0261] As used herein, "hsa-miR-4649-5p gene" or "hsa-mi The term "miR-4649-5p" refers to hsa-miR-4649 set forth in SEQ ID NO: 184. -5p gene (miRBase Accession No. MIMAT0019711 ) and other species homologs or orthologs. On H et al., 2011, Cancer Res, Vol. 71, p. 78-86 hsa-miR-4649-5p can be obtained by the method described above. The miRBase Accelerator has a hairpin-like structure called "hsa-mir-4649" ( Session No. MI0017276, SEQ ID NO: 443) is known.

[0262] As used herein, "hsa-miR-6775-5p gene" or "hsa-mi The term "miR-6775-5p" refers to hsa-miR-6775 set forth in SEQ ID NO: 185. -5p gene (miRBase Accession No. MIMAT0027450 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6775-5p" can be obtained by the method described below. Its precursor, "hsa-mir-6775" (miRBase Accession No. MI0022620, SEQ ID NO: 444) is known.

[0263] As used herein, "hsa-miR-4651 gene" or "hsa-miR-4 The term "miR-4651" refers to the hsa-miR-4651 gene (miR-4651) set forth in SEQ ID NO: 186. RBase Accession No. MIMAT0019715) and other species The gene includes homologs or orthologs. 1, Cancer Res, Vol. 71, p. 78-86 In addition, "hsa-miR-4651" has a hairpin-like structure as its precursor. Take "hsa-mir-4651" (miRBase Accession No. MI 0017279, SEQ ID NO: 445) is known.

[0264] As used herein, "hsa-miR-3195 gene" or "hsa-miR-3 The term "miR-3195" refers to the hsa-miR-3195 gene (miR-3195) set forth in SEQ ID NO: 187. RBase Accession No. MIMAT0015079) and other species These genes include homologs or orthologs. It can be obtained by the method described in PLoS One, Vol. 5, e9685. In addition, "hsa-miR-3195" has a hairpin-like structure as its precursor, "hs a-mir-3195” (miRBase Accession No. MI00142 40, SEQ ID NO: 446) is known.

[0265] As used herein, "hsa-miR-6726-5p gene" or "hsa-mi The term "miR-6726-5p" refers to hsa-miR-6726 set forth in SEQ ID NO: 188. -5p gene (miRBase Accession No. MIMAT0027353 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6726-5p" can be obtained by the method described above. Its precursor, "hsa-mir-6726" (miRBase Accession No. MI0022571, SEQ ID NO: 447) is known.

[0266] As used herein, "hsa-miR-6872-3p gene" or "hsa-mi The term "miR-6872-3p" refers to hsa-miR-6872 as set forth in SEQ ID NO: 189. -3p gene (miRBase Accession No. MIMAT0027645 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6872-3p" can be obtained by the method described below. Its precursor, "hsa-mir-6872" (miRBase Accession No. MI0022719, SEQ ID NO: 448) is known.

[0267] As used herein, "hsa-miR-371a-5p gene" or "hsa-mi The term "miR-371a-5p" refers to hsa-miR-371a set forth in SEQ ID NO: 190. -5p gene (miRBase Accession No. MIMAT0004687 ) and other species homologs or orthologues. R et al., 2004, Dev Biol, vol. 270, pp. 488-498 Furthermore, "hsa-miR-371a-5p" can be obtained by The miRBase Accession No. 100012666644 (hsa-mir-371a) forms a hairpin-like structure. The sequence number of the gene encoding the nucleotide sequence of the present invention is 449 (SEQ ID NO: MI0000779).

[0268] As used herein, "hsa-miR-6777-5p gene" or "hsa-mi The term "miR-6777-5p" refers to hsa-miR-6777 set forth in SEQ ID NO: 191. -5p gene (miRBase Accession No. MIMAT0027454 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6777-5p" can be obtained by the method described below. Its precursor, "hsa-mir-6777" (miRBase Accession No. MI0022622, SEQ ID NO: 450) is known.

[0269] As used herein, "hsa-miR-6789-5p gene" or "hsa-mi The term "miR-6789-5p" refers to hsa-miR-6789 set forth in SEQ ID NO: 192. -5p gene (miRBase Accession No. MIMAT0027478 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6789-5p" can be obtained by the method described below. Its precursor, "hsa-mir-6789" (miRBase Accession No. MI0022634, SEQ ID NO: 451) is known.

[0270] As used herein, "hsa-miR-7975 gene" or "hsa-miR-7 The term "miR-7975" refers to the hsa-miR-7975 gene (miR-7975) set forth in SEQ ID NO: 193. RBase Accession No. MIMAT0031178) and other species Genes include homologs or orthologs. A et al., 2013, Mol Endocrinol, Vol. 27, pp. 1128-1141 hsa-miR-7975 can be obtained by the method described in The precursor of the hairpin-like structure "hsa-mir-7975" (miRBase Accession No. MI0025751, SEQ ID NO: 452) is known.

[0271] As used herein, "hsa-miR-6821-5p gene" or "hsa-mi The term "miR-6821-5p" refers to hsa-miR-6821 set forth in SEQ ID NO: 194. -5p gene (miRBase Accession No. MIMAT0027542 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6821-5p" can be obtained by the method described below. Its precursor, "hsa-mir-6821" (miRBase Accession No. MI0022666, SEQ ID NO: 453) is known.

[0272] As used herein, "hsa-miR-4534 gene" or "hsa-miR-4 The term "miR-4534" refers to the hsa-miR-4534 gene (miR-4534) set forth in SEQ ID NO: 195. RBase Accession No. MIMAT0019073) and other species These include homologs or orthologs. Genes are listed in Jima DD et al., 2010 It can be obtained by the method described in Blood, Vol. 116, p. e118-e127. In addition, "hsa-miR-4534" has a hairpin-like structure as its precursor. hsa-mir-4534” (miRBase Accession No. MI001 6901, SEQ ID NO: 454) is known.

[0273] As used herein, "hsa-miR-619-5p gene" or "hsa-miR The term "miR-619-5p" refers to hsa-miR-619-5p set forth in SEQ ID NO: 196. Gene (miRBase Accession No. MIMAT0026622) and The gene includes homologs or orthologues of other organisms. JM et al., 2006, Proc Natl Acad Sci USA, vol. 103, It can be obtained by the method described in pp. 3687-3692. iR-619-5p is a precursor of hsa-mir-6, which has a hairpin-like structure. 19" (miRBase Accession No. MI0003633, SEQ ID NO: 4 55) is known.

[0274] As used herein, "hsa-miR-7107-5p gene" or "hsa-mi The term "miR-7107-5p" refers to hsa-miR-7107 as set forth in SEQ ID NO: 197. -5p gene (miRBase Accession No. MIMAT0028111 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-7107-5p" can be obtained by the method described above. Its precursor, "hsa-mir-7107" (miRBase Accession No. MI0022958, SEQ ID NO: 456) is known.

[0275] As used herein, "hsa-miR-1228-3p gene" or "hsa-mi The term "miR-1228-3p" refers to hsa-miR-1228 as set forth in SEQ ID NO: 198. -3p gene (miRBase Accession No. MIMAT0005583 ) and other species homologs or orthologs. Ikov E et al., 2007, Mol Cell, vol. 28, p328-336 Furthermore, "hsa-miR-1228-3p" can be obtained by the method described above. The precursor of "hsa-mir-1228" (miRBase A Accession No. MI0006318, SEQ ID NO: 457) is known.

[0276] As used herein, "hsa-miR-6774-5p gene" or "hsa-mi The term "miR-6774-5p" refers to hsa-miR-6774 set forth in SEQ ID NO: 199. -5p gene (miRBase Accession No. MIMAT0027448 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6774-5p" can be obtained by the method described above. Its precursor, "hsa-mir-6774" (miRBase Accession No. MI0022619, SEQ ID NO: 458) is known.

[0277] As used herein, "hsa-miR-6805-5p gene" or "hsa-mi The term "miR-6805-5p" refers to hsa-miR-6805 set forth in SEQ ID NO: 200. -5p gene (miRBase Accession No. MIMAT0027510 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6805-5p" can be obtained by the method described above. Its precursor, "hsa-mir-6805" (miRBase Accession No. MI0022650, SEQ ID NO: 459) is known.

[0278] As used herein, "hsa-miR-23a-3p gene" or "hsa-miR The term "miR-23a-3p" refers to hsa-miR-23a-3p as set forth in SEQ ID NO: 201. Gene (miRBase Accession No. MIMAT0000078) and The gene includes homologs or orthologues of other species. Intana M et al., 2001, Science, Vol. 294, p. 853-858 Furthermore, "hsa-miR-23a-3p" can be obtained by the method described above. The precursor of the hairpin-like structure "hsa-mir-23a" (miRBase A Accession No. MI0000079, SEQ ID NO: 460) is known.

[0279] As used herein, "hsa-miR-4665-5p gene" or "hsa-mi The term "miR-4665-5p" refers to hsa-miR-4665 as set forth in SEQ ID NO: 202. -5p gene (miRBase Accession No. MIMAT0019739 ) and other species homologs or orthologs. On H et al., 2011, Cancer Res, Vol. 71, p. 78-86 hsa-miR-4665-5p can be obtained by the method described above. The miRBase Accelerator has a hairpin-like structure called "hsa-mir-4665" ( Session No. MI0017295, SEQ ID NO: 461) is known.

[0280] As used herein, "hsa-miR-4505 gene" or "hsa-miR-4 The term "miR-4505" refers to the hsa-miR-4505 gene (miR-4505) set forth in SEQ ID NO: 203. RBase Accession No. MIMAT0019041) and other species These include homologs or orthologs. Genes are listed in Jima DD et al., 2010 It can be obtained by the method described in Blood, Vol. 116, p. e118-e127. In addition, "hsa-miR-4505" has a hairpin-like structure as its precursor. hsa-mir-4505” (miRBase Accession No. MI001 6868, SEQ ID NO: 462) is known.

[0281] As used herein, "hsa-miR-4638-5p gene" or "hsa-mi The term "miR-4638-5p" refers to hsa-miR-4638 as set forth in SEQ ID NO: 204. -5p gene (miRBase Accession No. MIMAT0019695 ) and other species homologs or orthologs. On H et al., 2011, Cancer Res, Vol. 71, p. 78-86 hsa-miR-4638-5p can be obtained by the method described above. The miRBase Accelerator has a hairpin-like structure called "hsa-mir-4638" ( Session No. MI0017265, SEQ ID NO: 463) is known.

[0282] As used herein, "hsa-miR-24-3p gene" or "hsa-miR- The term "miR-24-3p" refers to the hsa-miR-24-3p gene set forth in SEQ ID NO: 205. (miRBase Accession No. MIMAT0000080) and other The gene may be a homolog or ortholog of a species. Ana M et al., 2001, Science, Vol. 294, p. 853-858 Furthermore, "hsa-miR-24-3p" can be obtained by the method "hsa-mir-24-1, hsa-mir-24-2" which form a hairpin-like structure as (miRBase Accession No. MI0000080, MI000008 1, SEQ ID NOs: 464, 465) are known.

[0283] As used herein, "hsa-miR-3135b gene" or "hsa-miR- The term "miR-3135b" refers to the hsa-miR-3135b gene set forth in SEQ ID NO: 206. (miRBase Accession No. MIMAT0018985) and other Species homologs or orthologs are included. Obtained by the method described in Blood, Vol. 116, p. 118-127, 10 years ago. In addition, "hsa-miR-3135b" has a hairpin-like structure as its precursor. The miRBase Accession No. MI0016809, SEQ ID NO: 466) is known.

[0284] As used herein, "hsa-miR-4745-5p gene" or "hsa-mi The term "miR-4745-5p" refers to hsa-miR-4745 as set forth in SEQ ID NO: 207. -5p gene (miRBase Accession No. MIMAT0019878 ) and other species homologs or orthologs. On H et al., 2011, Cancer Res, Vol. 71, p. 78-86 hsa-miR-4745-5p can be obtained by the method described above. The miRBase Accelerator has a hairpin-like structure called "hsa-mir-4745" ( Session No. MI0017384, SEQ ID NO: 467) is known.

[0285] As used herein, "hsa-miR-128-1-5p gene" or "hsa-m The term "miR-128-1-5p" refers to hsa-miR-128-1-5p as set forth in SEQ ID NO: 208. 8-1-5p gene (miRBase Accession No. MIMAT0026 477) and other species homologs or orthologs. gos-Quintana M et al., 2002, Curr Biol, vol. 12, p. 735 The miR-128 can be obtained by the method described in Ref. 1-739. -1-5p is a precursor of hsa-mir-128-1, which has a hairpin-like structure. ” (miRBase Accession No. MI0000447, SEQ ID NO: 468 ) is known.

[0286] As used herein, "hsa-miR-4476 gene" or "hsa-miR-4 The term "miR-4476" refers to the hsa-miR-4476 gene (miR-4476) set forth in SEQ ID NO: 209. RBase Accession No. MIMAT0019003) and other species These include homologs or orthologs. Genes are listed in Jima DD et al., 2010 It can be obtained by the method described in Blood, Vol. 116, p. e118-e127. In addition, "hsa-miR-4476" has a hairpin-like structure as its precursor. hsa-mir-4476” (miRBase Accession No. MI001 6828, SEQ ID NO: 469) is known.

[0287] As used herein, "hsa-miR-4687-3p gene" or "hsa-mi The term "miR-4687-3p" refers to hsa-miR-4687 set forth in SEQ ID NO: 210. -3p gene (miRBase Accession No. MIMAT0019775 ) and other species homologs or orthologs. On H et al., 2011, Cancer Res, Vol. 71, p. 78-86 hsa-miR-4687-3p can be obtained by the method described above. The miRBase Accelerator has a hairpin-like structure called "hsa-mir-4687" ( Session No. MI0017319, SEQ ID NO: 470) is known.

[0288] As used herein, "hsa-miR-3665 gene" or "hsa-miR-3 The term "miR-3665" refers to the hsa-miR-3665 gene (miR-3665) set forth in SEQ ID NO: 211. RBase Accession No. MIMAT0018087) and other species Genes include homologs or orthologs. It can be obtained by the method described in Journal of Aquaculture, Vol. 434, pp. 338-345. In addition, "hsa-miR-3665" has a precursor "hs" which has a hairpin-like structure. a-mir-3665” (miRBase Accession No. MI00160 66, SEQ ID NO: 471) is known.

[0289] As used herein, "hsa-miR-6806-5p gene" or "hsa-mi The term "miR-6806-5p" refers to hsa-miR-6806 set forth in SEQ ID NO: 212. -5p gene (miRBase Accession No. MIMAT0027512 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6806-5p" can be obtained by the method described below. Its precursor, "hsa-mir-6806" (miRBase Accession No. MI0022651, SEQ ID NO: 472) is known.

[0290] As used herein, "hsa-miR-3937 gene" or "hsa-miR-3 The term "miR-3937" refers to the hsa-miR-3937 gene (miR-3937) set forth in SEQ ID NO: 213. RBase Accession No. MIMAT0018352) and other species These genes include homologs or orthologs. , PLoS One, Vol. 5, e10563. In addition, "hsa-miR-3937" has a hairpin-like structure as its precursor, "hs a-mir-3937” (miRBase Accession No. MI00165 93, SEQ ID NO: 473) is known.

[0291] As used herein, "hsa-miR-711 gene" or "hsa-miR-71 The term "miR-711" refers to the hsa-miR-711 gene (miRBa se Accession No. MIMAT0012734) and other species homologs orthologues, etc. Genes are described in Artzi S et al., 2008, BM C Bioinformatics, Vol. 9, p. 39 In addition, "hsa-miR-711" has a hairpin-like structure as its precursor. "hsa-mir-711" (miRBase Accession No. MI001 2488, SEQ ID NO: 474) is known.

[0292] As used herein, "hsa-miR-3141 gene" or "hsa-miR-3 The term "miR-3141" refers to the hsa-miR-3141 gene (miR-3141) set forth in SEQ ID NO: 215. RBase Accession No. MIMAT0015010) and other species These genes include homologs or orthologs. It can be obtained by the method described in PLoS One, Vol. 5, e9685. In addition, "hsa-miR-3141" has a hairpin-like structure as its precursor, "hs a-mir-3141” (miRBase Accession No. MI00141 65, SEQ ID NO: 475) is known.

[0293] As used herein, "hsa-miR-3188 gene" or "hsa-miR-3 The term "miR-3188" refers to the hsa-miR-3188 gene (miR-3188) set forth in SEQ ID NO: 216. RBase Accession No. MIMAT0015070) and other species These genes include homologs or orthologs. It can be obtained by the method described in PLoS One, Vol. 5, e9685. In addition, "hsa-miR-3188" has a hairpin-like structure as its precursor, "hs a-mir-3188” (miRBase Accession No. MI00142 32, SEQ ID NO: 476) is known.

[0294] As used herein, "hsa-miR-4281 gene" or "hsa-miR-4 The term "miR-4281" refers to the hsa-miR-4281 gene (miR-4281) set forth in SEQ ID NO: 217. RBase Accession No. MIMAT0016907) and other species These include homologs or orthologs. Genes are listed in Goff LA et al., 2009 It can be obtained by the method described in PLoS One, Vol. 4, e7192. In addition, "hsa-miR-4281" has a hairpin-like structure as its precursor, "hsa -mir-4281” (miRBase Accession No. MI001588 5, SEQ ID NO: 477) is known.

[0295] As used herein, "hsa-miR-5196-5p gene" or "hsa-mi The term "miR-5196-5p" refers to hsa-miR-5196 as set forth in SEQ ID NO: 218. -5p gene (miRBase Accession No. MIMAT0021128 ) and other species homologs or orthologues. te D et al., 2011, Leukemia, Vol. 25, p1389-1399 Furthermore, "hsa-miR-5196-5p" can be obtained by the method described above. The precursor of "hsa-mir-5196" (miRBase A Accession No. MI0018175, SEQ ID NO: 478) is known.

[0296] As used herein, "hsa-miR-6880-5p gene" or "hsa-mi The term "miR-6880-5p" refers to hsa-miR-6880 set forth in SEQ ID NO: 219. -5p gene (miRBase Accession No. MIMAT0027660 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6880-5p" can be obtained by the method described below. Its precursor, "hsa-mir-6880" (miRBase Accession No. MI0022727, SEQ ID NO: 479) is known.

[0297] As used herein, "hsa-miR-3960 gene" or "hsa-miR-3 The term "miR-3960" refers to the hsa-miR-3960 gene (miR-3960) set forth in SEQ ID NO: 220. RBase Accession No. MIMAT0019337) and other species Genes include homologs or orthologs. Biol Chem, vol. 286, pp. 12328-12339 In addition, "hsa-miR-3960" has a hairpin-like structure as its precursor. The structure of "hsa-mir-3960" (miRBase Accession No. .MI0016964, sequence number 480) is known.

[0298] As used herein, "hsa-miR-3648 gene" or "hsa-miR-3 The term "miR-3648" refers to the hsa-miR-3648 gene (miR-3648) set forth in SEQ ID NO: 221. RBase Accession No. MIMAT0018068) and other species These include homologs or orthologs. Genes are listed in Meiri E et al., 2010 , Nucleic Acids Res, Vol. 38, p. 6234-6246 hsa-miR-3648 can be obtained by the method described above. The hairpin-like structure of "hsa-mir-3648-1, hsa-mir-3648- 2” (miRBase Accession No. MI0016048, MI0031 512, SEQ ID NOs: 481, 482) are known.

[0299] As used herein, "hsa-miR-6721-5p gene" or "hsa-mi The term "miR-6721-5p" refers to hsa-miR-6721 set forth in SEQ ID NO: 222. -5p gene (miRBase Accession No. MIMAT0025852 ) and other species homologs or orthologs. , 2012, Gene, Vol. 497, pp. 330-335 In addition, "hsa-miR-6721-5p" has a hairpin "hsa-mir-6721" (miRBase Accession No. o.MI0022556, sequence number 483) is known.

[0300] As used herein, "hsa-miR-4492 gene" or "hsa-miR-4 The term "miR-4492" refers to the hsa-miR-4492 gene (miR-4492) set forth in SEQ ID NO: 223. RBase Accession No. MIMAT0019027) and other species These include homologs or orthologs. Genes are listed in Jima DD et al., 2010 It can be obtained by the method described in Blood, Vol. 116, p. e118-e127. In addition, "hsa-miR-4492" has a hairpin-like structure as its precursor. hsa-mir-4492” (miRBase Accession No. MI001 6854, sequence number 484) is known.

[0301] As used herein, "hsa-miR-744-5p gene" or "hsa-miR The term "miR-744-5p" refers to hsa-miR-744-5p set forth in SEQ ID NO: 224. Gene (miRBase Accession No. MIMAT0004945) and The gene includes homologs or orthologues of other species. v E et al., 2006, Genome Res, Vol. 16, p1289-1298 Furthermore, "hsa-miR-744-5p" can be obtained by the method described above. The precursor, "hsa-mir-744" (miRBase Ac Accession No. MI0005559, SEQ ID NO: 485) is known.

[0302] As used herein, "hsa-miR-7704 gene" or "hsa-miR-7 The term "miR-7704" refers to the hsa-miR-7704 gene (miR-7704) set forth in SEQ ID NO: 225. RBase Accession No. MIMAT0030019) and other species The genes include homologs or orthologs. , 2013, Biochem Biophys Res Commun, vol. 434, p. The "hsa-miR- 7704" has a hairpin-like structure as its precursor, "hsa-mir-7704" ( miRBase Accession No. MI0025240, SEQ ID NO: 486) It is known.

[0303] As used herein, "hsa-miR-4749-5p gene" or "hsa-mi The term "miR-4749-5p" refers to hsa-miR-4749 set forth in SEQ ID NO: 226. -5p gene (miRBase Accession No. MIMAT0019885 ) and other species homologs or orthologs. On H et al., 2011, Cancer Res, Vol. 71, p. 78-86 hsa-miR-4749-5p can be obtained by the method described above. The miRBase Accelerator has a hairpin-like structure called "hsa-mir-4749" ( Session No. MI0017388, SEQ ID NO: 487) is known.

[0304] As used herein, "hsa-miR-6794-5p gene" or "hsa-mi The term "miR-6794-5p" refers to hsa-miR-6794 set forth in SEQ ID NO: 227. -5p gene (miRBase Accession No. MIMAT0027488 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6794-5p" can be obtained by the method described below. Its precursor, "hsa-mir-6794" (miRBase Accession No. MI0022639, SEQ ID NO: 488) is known.

[0305] As used herein, "hsa-miR-6511a-5p gene" or "hsa-m The term "miR-6511a-5p" refers to hsa-miR-65 as set forth in SEQ ID NO: 228. 11a-5p gene (miRBase Accession No. MIMAT0025 478) and other species homologs or orthologs. yce CE et al., 2011, Hum Mol Genet, vol. 20, pp. 4025-40 40. Also, "hsa-miR-6511a" can be obtained by the method described in -5p has a hairpin-like structure as its precursor, hsa-mir-6511a-1 ,hsa-mir-6511a-2,hsa-mir-6511a-3,hsa-mir -6511a-4” (miRBase Accession No. MI0022223 , MI0023564, MI0023565, MI0023566, SEQ ID NO: 489,4 90,491,492) are known.

[0306] As used herein, "hsa-miR-6824-5p gene" or "hsa-mi The term "miR-6824-5p" refers to hsa-miR-6824 set forth in SEQ ID NO: 229. -5p gene (miRBase Accession No. MIMAT0027548 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6824-5p" can be obtained by the method described below. Its precursor, "hsa-mir-6824" (miRBase Accession No. MI0022669, SEQ ID NO: 493) is known.

[0307] As used herein, "hsa-miR-762 gene" or "hsa-miR-76 The term "miR-762" refers to the hsa-miR-762 gene (miRBa se Accession No. MIMAT0010313) and other species homologs orthologues, etc. The genes are described in Berezikov E et al., 2006 obtained by the method described in Genome Res, Vol. 16, pp. 1289-1298. In addition, "hsa-miR-762" has a hairpin-like structure as its precursor. The structure of "hsa-mir-762" (miRBase Accession No. I0003892, SEQ ID NO: 494) is known.

[0308] As used herein, the term "hsa-miR-6836-3p gene" or "hsa-mi The term "miR-6836-3p" refers to hsa-miR-6836 set forth in SEQ ID NO: 231. -3p gene (miRBase Accession No. MIMAT0027575 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6836-3p" can be obtained by the method described below. Its precursor, "hsa-mir-6836" (miRBase Accession No. MI0022682, SEQ ID NO: 495) is known.

[0309] As used herein, "hsa-miR-6727-5p gene" or "hsa-mi The term "miR-6727-5p" refers to hsa-miR-6727 set forth in SEQ ID NO: 232. -5p gene (miRBase Accession No. MIMAT0027355 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6727-5p" can be obtained by the method described above. Its precursor, "hsa-mir-6727" (miRBase Accession No. MI0022572, SEQ ID NO: 496) is known.

[0310] As used herein, "hsa-miR-4739 gene" or "hsa-miR-4 The term "miR-4739" refers to the hsa-miR-4739 gene (miR-4739) set forth in SEQ ID NO: 233. RBase Accession No. MIMAT0019868) and other species The gene includes homologs or orthologs. 1, Cancer Res, Vol. 71, p. 78-86 In addition, "hsa-miR-4739" has a hairpin-like structure as its precursor. Take "hsa-mir-4739" (miRBase Accession No. MI 0017377, SEQ ID NO: 497) is known.

[0311] As used herein, "hsa-miR-7977 gene" or "hsa-miR-7 The term "miR-7977" refers to the hsa-miR-7977 gene (miR-7977) set forth in SEQ ID NO: 234. RBase Accession No. MIMAT0031180) and other species Genes include homologs or orthologs. A et al., 2013, Mol Endocrinol, Vol. 27, pp. 1128-1141 hsa-miR-7977 can be obtained by the method described in The precursor of the hairpin-like structure "hsa-mir-7977" (miRBase Accession No. MI0025753, SEQ ID NO: 498) is known.

[0312] As used herein, "hsa-miR-4484 gene" or "hsa-miR-4 The term "miR-4484" refers to the hsa-miR-4484 gene (miR-4484) set forth in SEQ ID NO: 235. RBase Accession No. MIMAT0019018) and other species These include homologs or orthologs. Genes are listed in Jima DD et al., 2010 It can be obtained by the method described in Blood, Vol. 116, p. e118-e127. In addition, "hsa-miR-4484" has a hairpin-like structure as its precursor. hsa-mir-4484” (miRBase Accession No. MI001 6845, SEQ ID NO: 499) is known.

[0313] As used herein, "hsa-miR-6515-3p gene" or "hsa-mi The term "miR-6515-3p" refers to hsa-miR-6515 as set forth in SEQ ID NO: 236. -3p gene (miRBase Accession No. MIMAT0025487 ) and other species homologs or orthologues. CE et al., 2011, Hum Mol Genet, vol. 20, pp. 4025-4040 It can be obtained by the method described in the specification. The precursor of miRBa is “hsa-mir-6515” (miRBa (Accession No. MI0022227, SEQ ID NO: 500) do.

[0314] As used herein, "hsa-miR-373-5p gene" or "hsa-miR The term "miR-373-5p" refers to hsa-miR-373-5p as set forth in SEQ ID NO: 237. Gene (miRBase Accession No. MIMAT0000725) and The gene includes homologs or orthologs of other species. By the method described in Dev Biol, vol. 270, pp. 488-498, 2004. In addition, "hsa-miR-373-5p" is a precursor of hair follicles. The pin-like structure of "hsa-mir-373" (miRBase Accession No. No. MI0000781, SEQ ID NO: 501) is known.

[0315] As used herein, "hsa-miR-4258 gene" or "hsa-miR-4 The term "miR-4258" refers to the hsa-miR-4258 gene (miR-4258) set forth in SEQ ID NO: 238. RBase Accession No. MIMAT0016879) and other species These include homologs or orthologs. Genes are listed in Goff LA et al., 2009 It can be obtained by the method described in PLoS One, Vol. 4, e7192. In addition, "hsa-miR-4258" has a hairpin-like structure as its precursor, "hsa -mir-4258” (miRBase Accession No. MI001585 7, SEQ ID NO: 502) is known.

[0316] As used herein, "hsa-miR-4674 gene" or "hsa-miR-4 The term "miR-4674" refers to the hsa-miR-4674 gene (miR-4674) set forth in SEQ ID NO: 239. RBase Accession No. MIMAT0019756) and other species The gene includes homologs or orthologs. 1, Cancer Res, Vol. 71, p. 78-86 In addition, "hsa-miR-4674" has a hairpin-like structure as its precursor. Take "hsa-mir-4674" (miRBase Accession No. MI 0017305, SEQ ID NO: 503) is known.

[0317] As used herein, "hsa-miR-3180 gene" or "hsa-miR-3 The term "miR-3180" refers to the hsa-miR-3180 gene (miR-3180) set forth in SEQ ID NO: 240. RBase Accession No. MIMAT0018178) and other species Genes include homologs or orthologs. It can be obtained by the method described in PLoS One, Vol. 5, e9637, 2010. In addition, "hsa-miR-3180" has a hairpin-like structure as its precursor. “hsa-mir-3180-4,hsa-mir-3180-5” (miRBase Accession No. MI0016408, MI0016409, SEQ ID NO: 50 4,505) are known.

[0318] As used herein, "hsa-miR-6076 gene" or "hsa-miR-6 The term "miR-6076" refers to the hsa-miR-6076 gene (miR-6076) set forth in SEQ ID NO: 241. RBase Accession No. MIMAT0023701) and other species The gene includes homologs or orthologs. It can be obtained by the method described in 2012, RNA, Vol. 18, p. 472-484. In addition, "hsa-miR-6076" has a hairpin-like structure as its precursor. "hsa-mir-6076" (miRBase Accession No. MI00 20353, SEQ ID NO: 506) is known.

[0319] As used herein, "hsa-miR-1238-5p gene" or "hsa-mi The term "miR-1238-5p" refers to hsa-miR-1238 as set forth in SEQ ID NO: 242. -5p gene (miRBase Accession No. MIMAT0022947 ) and other species homologs or orthologs. Ikov E et al., 2007, Mol Cell, vol. 28, p328-336 Furthermore, "hsa-miR-1238-5p" can be obtained by the method The precursor of "hsa-mir-1238" (miRBase A Accession No. MI0006328, SEQ ID NO: 507) is known.

[0320] As used herein, "hsa-miR-4463 gene" or "hsa-miR-4 The term "miR-4463" refers to the hsa-miR-4463 gene (miR-4463) set forth in SEQ ID NO: 243. RBase Accession No. MIMAT0018987) and other species These include homologs or orthologs. Genes are listed in Jima DD et al., 2010 It can be obtained by the method described in Blood, Vol. 116, p. e118-e127. In addition, "hsa-miR-4463" has a hairpin-like structure as its precursor. hsa-mir-4463” (miRBase Accession No. MI001 6811, SEQ ID NO: 508) is known.

[0321] As used herein, "hsa-miR-4486 gene" or "hsa-miR-4 The term "miR-4486" refers to the hsa-miR-4486 gene (miR-4486) set forth in SEQ ID NO: 244. RBase Accession No. MIMAT0019020) and other species These include homologs or orthologs. Genes are listed in Jima DD et al., 2010 It can be obtained by the method described in Blood, Vol. 116, p. e118-e127. In addition, "hsa-miR-4486" has a hairpin-like structure as its precursor. hsa-mir-4486” (miRBase Accession No. MI001 6847, SEQ ID NO: 509) is known.

[0322] As used herein, "hsa-miR-4730 gene" or "hsa-miR-4 The term "miR-4730" refers to the hsa-miR-4730 gene (miR-4730) set forth in SEQ ID NO: 245. RBase Accession No. MIMAT0019852) and other species The gene includes homologs or orthologs. 1, Cancer Res, Vol. 71, p. 78-86 In addition, "hsa-miR-4730" has a hairpin-like structure as its precursor. Take "hsa-mir-4730" (miRBase Accession No. MI 0017367, SEQ ID NO: 510) is known.

[0323] As used herein, "hsa-miR-6766-3p gene" or "hsa-mi The term "miR-6766-3p" refers to hsa-miR-6766 set forth in SEQ ID NO: 246. -3p gene (miRBase Accession No. MIMAT0027433 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6766-3p" can be obtained by the method described below. Its precursor, "hsa-mir-6766" (miRBase Accession No. MI0022611, SEQ ID NO: 511) is known.

[0324] As used herein, "hsa-miR-4286 gene" or "hsa-miR-4 The term "miR-4286" refers to the hsa-miR-4286 gene (miR-4286) set forth in SEQ ID NO: 247. RBase Accession No. MIMAT0016916) and other species These include homologs or orthologs. Genes are listed in Goff LA et al., 2009 It can be obtained by the method described in PLoS One, Vol. 4, e7192. In addition, "hsa-miR-4286" has a hairpin-like structure as its precursor, "hsa -mir-4286” (miRBase Accession No. MI001589 4, SEQ ID NO: 512) is known.

[0325] As used herein, "hsa-miR-6511a-5p gene" or "hsa-m The term "miR-6511a-5p" refers to hsa-miR-65 as set forth in SEQ ID NO: 248. 11a-5p gene (miRBase Accession No. MIMAT0025 478) and other species homologs or orthologs. yce CE et al., 2011, Hum Mol Genet, vol. 20, pp. 4025-40 40. Also, "hsa-miR-6511a" can be obtained by the method described in -5p has a hairpin-like structure as its precursor, hsa-mir-6511a-1 ,hsa-mir-6511a-2,hsa-mir-6511a-3,hsa-mir -6511a-4” (miRBase Accession No. MI0022223 , MI0023564, MI0023565, MI0023566, SEQ ID NO: 513,5 14,515,516) are known.

[0326] As used herein, "hsa-miR-4739 gene" or "hsa-miR-4 The term "miR-4739" refers to the hsa-miR-4739 gene (miR-4739) set forth in SEQ ID NO: 249. RBase Accession No. MIMAT0019868) and other species The gene includes homologs or orthologs. 1, Cancer Res, Vol. 71, p. 78-86 In addition, "hsa-miR-4739" has a hairpin-like structure as its precursor. Take "hsa-mir-4739" (miRBase Accession No. MI 0017377, SEQ ID NO: 517) is known.

[0327] As used herein, "hsa-miR-6749-5p gene" or "hsa-mi The term "miR-6749-5p" refers to hsa-miR-6749 set forth in SEQ ID NO: 250. -5p gene (miRBase Accession No. MIMAT0027398 ) and other species homologs or orthologues. ig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645 Furthermore, "hsa-miR-6749-5p" can be obtained by the method described below. Its precursor, "hsa-mir-6749" (miRBase Accession No. MI0022594, SEQ ID NO: 518) is known.

[0328] Furthermore, mature miRNAs are derived from RNA precursors with hairpin-like structures. When excised as iRNA, one to several bases before and after the sequence may be excised shorter or longer. In some cases, base substitutions occur, resulting in mutants, which are called isomiRs (Mori n RD. et al., 2008, Genome Res., Vol. 18, pp. 610-621) In miRBase Release 20, the sequence is represented by any one of SEQ ID NOs: 1 to 250. In addition to the base sequence, there are numerous isomiRs, each of which has a sequence number from 519 to 812. Variants and fragments of the nucleotide sequence represented are also shown. These variants are also shown in SEQ ID NO: 1. The miRNA can be obtained as a miRNA having a base sequence represented by any one of the following nucleotide sequences: , SEQ ID NOs: 2, 3, 6, 7, 8, 11, 12, 13, 15, 19, 20, 25 of the present invention; 26, 27, 29, 31, 32, 37, 44, 45, 46, 47, 48, 49, 51, 5 2, 53, 54, 55, 56, 57, 59, 60, 61, 62, 63, 71, 72, 73 , 74, 76, 77, 78, 79, 83, 84, 86, 87, 88, 89, 90, 92, 94, 98, 102, 105, 106, 108, 111, 112, 113, 114, 11 6, 117, 118, 122, 123, 124, 128, 129, 133, 134, 13 5, 136, 137, 140, 141, 145, 146, 147, 148, 149, 15 0, 151, 153, 154, 155, 157, 158, 159, 160, 161, 16 2, 163, 166, 167, 168, 169, 176, 177, 178, 179, 18 0, 181, 182, 184, 186, 187, 190, 193, 196, 198, 20 1, 202, 203, 204, 205, 206, 207, 208, 209, 210, 21 1, 214, 215, 216, 217, 218, 220, 221, 222, 223, 22 4, 226, 228, 233, 235, 236, 237, 239, 240, 243, 24 4, 245, 247, 248, and 249 or the base sequence Among the variants of polynucleotides consisting of a base sequence in which u is t, for example, miRBas The longest variants registered in e Release 20 are SEQ ID NO: 5 19, 521, 523, 525, 527, 529, 531, 533, 535, 537, 5 39, 541, 543, 545, 547, 549, 551, 553, 555, 557, 5 59, 561, 563, 565, 567, 569, 571, 573, 575, 577, 5 79, 581, 583, 585, 587, 589, 591, 593, 595, 597, 5 99, 601, 603, 605, 607, 609, 611, 613, 615, 617, 6 19, 621, 623, 625, 627, 629, 631, 633, 635, 637, 6 39, 641, 643, 645, 647, 649, 651, 653, 655, 657, 6 59, 661, 663, 665, 667, 669, 671, 673, 675, 677, 6 79, 681, 683, 685, 687, 689, 691, 693, 695, 697, 6 99, 701, 703, 705, 707, 709, 711, 713, 715, 717, 7 19, 721, 723, 725, 727, 729, 731, 733, 735, 737, 7 39, 741, 743, 745, 747, 749, 751, 753, 755, 757, 7 59, 761, 763, 765, 767, 769, 771, 773, 775, 777, 7 79, 781, 783, 785, 787, 789, 791, 793, 795, 797, 7 Polynucleotides represented by 99, 801, 803, 805, 807, 809, and 811 In addition, the sequences of SEQ ID NOs: 2, 3, 6, 7, 8, 11, 12, 13, and 15 of the present invention are also included. , 19, 20, 25, 26, 27, 29, 31, 32, 37, 44, 45, 46, 47, 48, 49, 51, 52, 53, 54, 55, 56, 57, 59, 60, 61, 62, 6 3, 71, 72, 73, 74, 76, 77, 78, 79, 83, 84, 86, 87, 88 , 89, 90, 92, 94, 98, 102, 105, 106, 108, 111, 112, 113, 114, 116, 117, 118, 122, 123, 124, 128, 129, 133, 134, 135, 136, 137, 140, 141, 145, 146, 147, 148, 149, 150, 151, 153, 154, 155, 157, 158, 159, 160, 161, 162, 163, 166, 167, 168, 169, 176, 177, 178, 179, 180, 181, 182, 184, 186, 187, 190, 193, 196, 198, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 214, 215, 216, 217, 218, 220, 221, 222, 223, 224, 226, 228, 233, 235, 236, 237, 239, The nucleotide sequences represented by 240, 243, 244, 245, 247, 248, and 249 or a variant of the polynucleotide consisting of a base sequence in which u is t in the base sequence. For example, the shortest variant registered in miRBase Release 20 is and SEQ ID NOs: 520, 522, 524, 526, 528, 530, 532, and 533, respectively. 4, 536, 538, 540, 542, 544, 546, 548, 550, 552, 55 4, 556, 558, 560, 562, 564, 566, 568, 570, 572, 57 4, 576, 578, 580, 582, 584, 586, 588, 590, 592, 59 4, 596, 598, 600, 602, 604, 606, 608, 610, 612, 61 4, 616, 618, 620, 622, 624, 626, 628, 630, 632, 63 4, 636, 638, 640, 642, 644, 646, 648, 650, 652, 65 4, 656, 658, 660, 662, 664, 666, 668, 670, 672, 67 4, 676, 678, 680, 682, 684, 686, 688, 690, 692, 69 4, 696, 698, 700, 702, 704, 706, 708, 710, 712, 71 4, 716, 718, 720, 722, 724, 726, 728, 730, 732, 73 4, 736, 738, 740, 742, 744, 746, 748, 750, 752, 75 4, 756, 758, 760, 762, 764, 766, 768, 770, 772, 77 4, 776, 778, 780, 782, 784, 786, 788, 790, 792, 79 4, 796, 798, 800, 802, 804, 806, 808, 810, and 812 In addition to these variants and fragments, polynucleotides of the sequences shown in the figures are also included. ,SEQ ID NOs: 2, 3, 6, 7, 8, 11, 12, 13, 15, registered in miRBase , 19, 20, 25, 26, 27, 29, 31, 32, 37, 44, 45, 46, 47, 48, 49, 51, 52, 53, 54, 55, 56, 57, 59, 60, 61, 62, 6 3, 71, 72, 73, 74, 76, 77, 78, 79, 83, 84, 86, 87, 88 , 89, 90, 92, 94, 98, 102, 105, 106, 108, 111, 112, 113, 114, 116, 117, 118, 122, 123, 124, 128, 129, 133, 134, 135, 136, 137, 140, 141, 145, 146, 147, 148, 149, 150, 151, 153, 154, 155, 157, 158, 159, 160, 161, 162, 163, 166, 167, 168, 169, 176, 177, 178, 179, 180, 181, 182, 184, 186, 187, 190, 193, 196, 198, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 214, 215, 216, 217, 218, 220, 221, 222, 223, 224, 226, 228, 233, 235, 236, 237, 239, 240, 243, 244, 245, 247, 248, and 249 in numerous isomiRs. Further, a polynucleotide represented by any one of SEQ ID NOs: 1 to 250 can be used. Examples of polynucleotides containing the base sequences include precursors SEQ ID NOs: 251 to 256. 518.

[0329] Names of genes represented by SEQ ID NOs: 1 to 812 and miRBase Accession Numbers The registration numbers are listed in Table 1.

[0330] As used herein, the term "capable of specifically binding" refers to the nucleic acid probe or probe used in the present invention. This means that the primer binds to a specific target nucleic acid and is substantially incapable of binding to other nucleic acids. .

[0331] [Table 1]

[0332] JPEG2025124843000003.jpg220103

[0333] JPEG2025124843000004.jpg220104

[0334] JPEG2025124843000005.jpg222105

[0335] JPEG2025124843000006.jpg218102

[0336] JPEG2025124843000007.jpg221100

[0337] JPEG2025124843000008.jpg222105

[0338] JPEG2025124843000009.jpg221104

[0339] JPEG2025124843000010.jpg222104

[0340] JPEG2025124843000011.jpg220105

[0341] JPEG2025124843000012.jpg221104

[0342] JPEG2025124843000013.jpg224104

[0343] JPEG2025124843000014.jpg222107

[0344] JPEG2025124843000015.jpg222103

[0345] JPEG2025124843000016.jpg220105

[0346] JPEG2025124843000017.jpg219102

[0347] JPEG2025124843000018.jpg220103

[0348] JPEG2025124843000019.jpg106105

[0349] This specification is based on Japanese Patent Application No. 2016-073132 ( This document includes the disclosure of the application filed on March 31, 2016. [Effects of the Invention]

[0350] The present invention makes it possible to easily and accurately detect early stage pancreatic cancer or pancreatic cancer precursor lesions. It has become possible.

[0351] For example, several miRNAs can be expressed in the blood, serum, and / or plasma of patients, which can be collected minimally invasively. Using the measured amount of present data as an index, it is possible to easily determine whether a patient has early stage pancreatic cancer or a precursor lesion of pancreatic cancer. It can be put out. [Brief explanation of the drawings]

[0352] [Figure 1] This figure shows the relationship between the base sequences of hsa-miR-1343-3p, represented by sequence number 118, and hsa-miR-1343-5p, represented by sequence number 14, which are generated from the precursor hsa-mir-1343, represented by sequence number 264. [Figure 2]The left panel of Figure 2 shows a discriminant equation (3.10 × hsa-miR-miR-6784-5p-39.85) created using Fisher's discriminant analysis from the expression level measurements of hsa-miR-6784-5p (SEQ ID NO: 1) in the training cohort of 21 patients with precursor pancreatic cancer, 31 patients with early-stage pancreatic cancer, and 123 healthy individuals. The discriminant score obtained from the discriminant equation is plotted on the vertical axis, and the sample group is plotted on the horizontal axis. The dotted line in the figure indicates the discriminant boundary for discriminating between the two groups, where the discriminant score is 0. The right panel of Figure 2 shows the discriminant scores obtained from the discriminant formula for the training sample group for the measured expression levels of hsa-miR-6784-5p (SEQ ID NO: 1) in the validation cohort of patients with pancreatic cancer precursor lesions (12 patients), patients with early-stage pancreatic cancer (13 patients), and healthy subjects (61 patients). The dotted line in the figure indicates the discriminant boundary for discriminating between the two groups, where the discriminant score is 0. [Figure 3] The left panel of Figure 3 shows a discriminant equation (1.90 × hsa-miR-6784-5p + 1.72 × hsa-miR-1181 − 34.50) created using Fisher's discriminant analysis from the expression level measurements of hsa-miR-6784-5p (SEQ ID NO: 1) and hsa-miR-1181 (SEQ ID NO: 2) in patients with pancreatic cancer precursor lesions (21 patients), patients with early-stage pancreatic cancer (31 patients), and healthy subjects (123 patients) selected as the training sample group. The discriminant score obtained from the discriminant equation is plotted on the vertical axis and the sample group on the horizontal axis. The dotted line in the figure indicates the discriminant boundary for distinguishing between the two groups, where the discriminant score is 0. The right panel of Figure 3 shows the discriminant scores obtained from the discriminant formula for the training sample group for the measured expression levels of hsa-miR-6784-5p (SEQ ID NO: 1) and hsa-miR-1181 (SEQ ID NO: 2) in the 12 patients with precursor pancreatic cancer, 13 patients with early-stage pancreatic cancer, and 61 healthy individuals selected as the validation sample group. The dotted line in the figure indicates the discriminant boundary for discriminating between the two groups, where the discriminant score is 0. [Figure 4]The upper graph in Figure 4 shows the hsa-miR-4695-5p (SEQ ID NO: 106), hsa-miR-5090 (SEQ ID NO: 12), and hsa-miR-4673 (SEQ ID NO: 137) of 21 patients with precursor lesions of pancreatic cancer, 31 patients with early-stage pancreatic cancer, 128 healthy subjects, 61 patients with advanced pancreatic cancer, 66 patients with biliary tract cancer, 51 patients with breast cancer, 35 patients with prostate cancer, 31 patients with colon cancer, 32 patients with gastric cancer, 34 patients with esophageal cancer, 38 patients with liver cancer, 15 patients with benign pancreatic disease, and 26 patients with benign prostatic disease, selected as the learning sample group. A discriminant equation was created using Fisher's discriminant analysis from the expression level measurements of miR-6813-5p (SEQ ID NO: 119), miR-642a-3p (SEQ ID NO: 105) (0.48 × miR-4695-5p − 1.75 × miR-5090 + 1.31 × miR-4673 − 0.98 × miR-6813-5p − 1.16 × miR-642a-3p + 15.39), and the discriminant score obtained from the discriminant equation is plotted on the vertical axis and the sample group on the horizontal axis. The dotted line in the figure indicates the discriminant boundary for discriminating between the two groups, where the discriminant score is 0. The lower graph in Figure 4 shows the discrimination scores obtained from the discriminant equation created for the training sample group for the expression level measurements of hsa-miR-4695-5p (sequence number 106), hsa-miR-5090 (sequence number 12), hsa-miR-4673 (sequence number 137), hsa-miR-6813-5p (sequence number 119), and hsa-miR-642a-3p (sequence number 105) in the validation sample group, which consisted of 12 patients with pancreatic cancer precursor lesions, 13 patients with early-stage pancreatic cancer, 56 healthy subjects, 39 patients with advanced pancreatic cancer, 32 patients with biliary tract cancer, 23 patients with breast cancer, 17 patients with prostate cancer, 19 patients with colorectal cancer, 18 patients with gastric cancer, 16 patients with esophageal cancer, 14 patients with liver cancer, and 24 patients with benign pancreatic and prostate diseases, with the vertical axis representing the discrimination scores and the horizontal axis representing the sample group. The dotted line in the figure indicates the discrimination boundary for discriminating between the two groups, where the discrimination score is 0. DETAILED DESCRIPTION OF THE INVENTION

[0353] The present invention will be explained in more detail below. 1. Target nucleic acids for early stage pancreatic cancer or precursor lesions of pancreatic cancer The nucleic acid probe or primer for detecting early stage pancreatic cancer or pancreatic cancer precursor lesions as defined above according to the present invention - to detect early stage pancreatic cancer or pancreatic cancer precursor lesions or early stage pancreatic cancer or pancreatic cancer precursor lesion cells As a marker for early pancreatic cancer or precursor lesions to detect their presence and / or absence The main target nucleic acids of miR-6784-5p, miR-1181, hsa-miR-671-5p, hsa-miR-6857-5p, hsa-miR-4 276, hsa-miR-1914-3p, hsa-miR-149-3p, hsa-m iR-937-5p, hsa-miR-4675, hsa-miR-6795-5p, h sa-miR-4731-5p, hsa-miR-5090, hsa-miR-3620 -5p, hsa-miR-1343-5p, hsa-miR-6717-5p, hsa- miR-6825-5p, hsa-miR-6738-5p, hsa-miR-6769 a-5p, hsa-miR-4728-5p, hsa-miR-652-5p, hsa- miR-4257, hsa-miR-6785-5p, hsa-miR-7110-5p , hsa-miR-6887-5p, hsa-miR-887-3p, hsa-miR- 1228-5p, hsa-miR-5572, hsa-miR-6782-5p, hsa -miR-4298, hsa-miR-6786-5p, hsa-miR-5010-5 p, hsa-miR-6087, hsa-miR-6765-5p, hsa-miR-6 732-5p, hsa-miR-6787-5p, hsa-miR-6737-5p, h sa-miR-128-2-5p, hsa-miR-4270, hsa-miR-686 1-5p, hsa-miR-6756-5p, hsa-miR-1229-5p, hsa -miR-6891-5p, hsa-miR-6848-5p, hsa-miR-123 7-5p, hsa-miR-30c-1-3p, hsa-miR-1233-5p, hs a-miR-211-3p, hsa-miR-4758-5p, hsa-miR-614 , hsa-miR-6746-5p, hsa-miR-1915-5p, hsa-miR -4688, hsa-miR-3917, hsa-miR-5787, hsa-miR- 4632-5p, hsa-miR-6126, hsa-miR-135a-3p, hsa -miR-8063, hsa-miR-5698, hsa-miR-6089, hsa- miR-498, hsa-miR-296-3p, hsa-miR-4419b, hsa -miR-6802-5p, hsa-miR-6829-5p, hsa-miR-680 3-5p, hsa-miR-1199-5p, hsa-miR-6840-3p, hsa -miR-6752-5p, hsa-miR-6798-5p, hsa-miR-613 1, hsa-miR-4667-5p, hsa-miR-6510-5p, hsa-mi R-4690-5p, hsa-miR-920, hsa-miR-23b-3p, hsa -miR-4448, hsa-miR-2110, hsa-miR-4706, hsa- miR-7845-5p, hsa-miR-6808-5p, hsa-miR-4447 , hsa-miR-6869-5p, hsa-miR-6794-5p, hsa-miR -6511a-5p, hsa-miR-6824-5p, hsa-miR-6766-3 p, hsa-miR-6511a-5p, and at least one miRNA selected from the group consisting of hsa-miR-6749-5p is included.

[0354] Furthermore, these miRNAs can be combined with other early stage pancreatic cancers or pancreatic cancer precursors. Lesion markers, i.e., hsa-miR-1908-5p, hsa-miR-6729 -5p, hsa-miR-5195-3p, hsa-miR-638, hsa-miR- 6125, hsa-miR-3178, hsa-miR-3196, hsa-miR-8 069, hsa-miR-4723-5p, hsa-miR-4746-3p, hsa- miR-4689, hsa-miR-6816-5p, hsa-miR-6757-5p , hsa-miR-7109-5p, hsa-miR-6724-5p, hsa-miR -1225-3p, hsa-miR-6875-5p, hsa-miR-7108-5p , hsa-miR-4508, hsa-miR-6085, hsa-miR-6779- 5p, hsa-miR-642a-3p, hsa-miR-4695-5p, hsa-m iR-7847-3p, hsa-miR-3197, hsa-miR-6769b-5p , hsa-miR-7641, hsa-miR-187-5p, hsa-miR-318 5, hsa-miR-2861, hsa-miR-3940-5p, hsa-miR-1 203, hsa-miR-615-5p, hsa-miR-4787-5p, hsa-m iR-1343-3p, hsa-miR-6813-5p, hsa-miR-1225- 5p, hsa-miR-602, hsa-miR-4488, hsa-miR-125a -3p, hsa-miR-5100, hsa-miR-4294, hsa-miR-12 31, hsa-miR-6765-3p, hsa-miR-4442, hsa-miR- 718、hsa-miR-6780b-5p、hsa-miR-6090、hsa-mi R-6845-5p、hsa-miR-4741、hsa-miR-4467、hsa- miR-4707-5p, hsa-miR-4271, hsa-miR-4673, hs a-miR-3184-5p、hsa-miR-1469、hsa-miR-4640- 5p、hsa-miR-663a、hsa-miR-6791-5p、hsa-miR- 6826-5p、hsa-miR-4433b-3p、hsa-miR-1915-3p hsa-miR-4417, hsa-miR-4449, hsa-miR-4707 3p、hsa-miR-3180-3p、hsa-miR-5585-3p、hsa-m iR-1268a、hsa-miR-8072、hsa-miR-296-5p、hsa -miR-204-3p、hsa-miR-4454、hsa-miR-6722-3p hsa-miR-1290, hsa-miR-3622a-5p, hsa-miR-9 39-5p、hsa-miR-675-5p、hsa-miR-3131、hsa-mi R-4648、hsa-miR-1268b、hsa-miR-6741-5p、hsa -miR-6893-5p、hsa-miR-3162-5p、hsa-miR-642 b-3p、hsa-miR-4734、hsa-miR-150-3p、hsa-miR -8089、hsa-miR-6805-3p、hsa-miR-7113-3p、hs a-miR-6850-5p、hsa-miR-6799-5p、hsa-miR-67 68-5p、hsa-miR-92b-5p、hsa-miR-3679-5p、hsa -miR-4792、hsa-miR-3656、hsa-miR-92a-2-5p、 hsa-miR-4466, hsa-miR-4513, hsa-miR-6781-5 p、hsa-miR-4649-5p、hsa-miR-6775-5p、hsa-mi R-4651、hsa-miR-3195、hsa-miR-6726-5p、hsa- miR-6872-3p、hsa-miR-371a-5p、hsa-miR-6777 -5p、hsa-miR-6789-5p、hsa-miR-7975、hsa-miR -6821-5p、hsa-miR-4534、hsa-miR-619-5p、hsa -miR-7107-5p、hsa-miR-1228-3p、hsa-miR-677 4-5p、hsa-miR-6805-5p、hsa-miR-23a-3p、hsa- miR-4665-5p、hsa-miR-4505、hsa-miR-4638-5p hsa-miR-24-3p, hsa-miR-3135b, hsa-miR-474 5-5p、hsa-miR-128-1-5p、hsa-miR-4476、hsa-m iR-4687-3p、hsa-miR-3665、hsa-miR-6806-5p、 hsa-miR-3937, hsa-miR-711, hsa-miR-3141, hs a-miR-3188、hsa-miR-4281、hsa-miR-5196-5p、 hsa-miR-6880-5p、hsa-miR-3960、hsa-miR-364 8, hsa-miR-6721-5p, hsa-miR-4492, hsa-miR-7 44-5p、hsa-miR-7704、hsa-miR-4749-5p、hsa-m iR-762、hsa-miR-6836-3p、hsa-miR-6727-5p、h sa-miR-4739, hsa-miR-7977, hsa-miR-4484, hs a-miR-6515-3p, hsa-miR-373-5p, hsa-miR-425 8, hsa-miR-4674, hsa-miR-3180, hsa-miR-6076 , hsa-miR-1238-5p, hsa-miR-4463, hsa-miR-44 86, hsa-miR-4730, hsa-miR-4286, and hsa-miR- At least one miRNA selected from the group consisting of 4739 is also preferred as a target nucleic acid. It can be used easily.

[0355] The miRNA may have, for example, a base sequence represented by any one of SEQ ID NOs: 1 to 250. Human genes containing miR-6784-5p and miR-6784-5p, respectively R-1181, hsa-miR-671-5p, hsa-miR-6857-5p, hs a-miR-4276, hsa-miR-1914-3p, hsa-miR-149-3 p, hsa-miR-937-5p, hsa-miR-4675, hsa-miR-67 95-5p, hsa-miR-4731-5p, hsa-miR-5090, hsa-m iR-3620-5p, hsa-miR-1343-5p, hsa-miR-6717- 5p, hsa-miR-6825-5p, hsa-miR-6738-5p, hsa-m iR-6769a-5p, hsa-miR-4728-5p, hsa-miR-652- 5p, hsa-miR-4257, hsa-miR-6785-5p, hsa-miR- 7110-5p, hsa-miR-6887-5p, hsa-miR-887-3p, h sa-miR-1228-5p, hsa-miR-5572, hsa-miR-6782 -5p、hsa-miR-4298、hsa-miR-6786-5p、hsa-miR -5010-5p、hsa-miR-6087、hsa-miR-6765-5p、hs a-miR-6732-5p、hsa-miR-6787-5p、hsa-miR-67 37-5p、hsa-miR-128-2-5p、hsa-miR-4270、hsa- miR-6861-5p、hsa-miR-6756-5p、hsa-miR-1229 -5p、hsa-miR-6891-5p、hsa-miR-6848-5p、hsa- miR-1237-5p、hsa-miR-30c-1-3p、hsa-miR-123 3-5p、hsa-miR-211-3p、hsa-miR-4758-5p、hsa- miR-614、hsa-miR-6746-5p、hsa-miR-1915-5p、 hsa-miR-4688, hsa-miR-3917, hsa-miR-5787, h sa-miR-4632-5p、hsa-miR-6126、hsa-miR-135a -3p、hsa-miR-8063、hsa-miR-5698、hsa-miR-60 89, hsa-miR-498, hsa-miR-296-3p, hsa-miR-44 19b、hsa-miR-6802-5p、hsa-miR-6829-5p、hsa- miR-6803-5p、hsa-miR-1199-5p、hsa-miR-6840 -3p、hsa-miR-6752-5p、hsa-miR-6798-5p、hsa- miR-6131, hsa-miR-4667-5p, hsa-miR-6510-5p hsa-miR-4690-5p, hsa-miR-920, hsa-miR-23b -3p、hsa-miR-4448、hsa-miR-2110、hsa-miR-47 06、hsa-miR-7845-5p、hsa-miR-6808-5p、hsa-m iR-4447、hsa-miR-6869-5p、hsa-miR-1908-5p、 hsa-miR-6729-5p、hsa-miR-5195-3p、hsa-miR- 638, hsa-miR-6125, hsa-miR-3178, hsa-miR-31 96、hsa-miR-8069、hsa-miR-4723-5p、hsa-miR- 4746-3p、hsa-miR-4689、hsa-miR-6816-5p、hsa -miR-6757-5p、hsa-miR-7109-5p、hsa-miR-672 4-5p、hsa-miR-1225-3p、hsa-miR-6875-5p、hsa -miR-7108-5p、hsa-miR-4508、hsa-miR-6085、h sa-miR-6779-5p、hsa-miR-642a-3p、hsa-miR-4 695-5p、hsa-miR-7847-3p、hsa-miR-3197、hsa- miR-6769b-5p, hsa-miR-7641, hsa-miR-187-5p hsa-miR-3185, hsa-miR-2861, hsa-miR-3940 5p、hsa-miR-1203、hsa-miR-615-5p、hsa-miR-4 787-5p、hsa-miR-1343-3p、hsa-miR-6813-5p、h sa-miR-1225-5p、hsa-miR-602、hsa-miR-4488、 hsa-miR-125a-3p, hsa-miR-5100, hsa-miR-429 4, hsa-miR-1231, hsa-miR-6765-3p, hsa-miR-4 442、hsa-miR-718、hsa-miR-6780b-5p、hsa-miR -6090、hsa-miR-6845-5p、hsa-miR-4741、hsa-m iR-4467、hsa-miR-4707-5p、hsa-miR-4271、hsa -miR-4673、hsa-miR-3184-5p、hsa-miR-1469、h sa-miR-4640-5p、hsa-miR-663a、hsa-miR-6791 -5p、hsa-miR-6826-5p、hsa-miR-4433b-3p、hsa -miR-1915-3p、hsa-miR-4417、hsa-miR-4449、h sa-miR-4707-3p、hsa-miR-3180-3p、hsa-miR-5 585-3p、hsa-miR-1268a、hsa-miR-8072、hsa-mi R-296-5p、hsa-miR-204-3p、hsa-miR-4454、hsa -miR-6722-3p、hsa-miR-1290、hsa-miR-3622a- 5p、hsa-miR-939-5p、hsa-miR-675-5p、hsa-miR -3131、hsa-miR-4648、hsa-miR-1268b、hsa-miR -6741-5p、hsa-miR-6893-5p、hsa-miR-3162-5p hsa-miR-642b-3p, hsa-miR-4734, hsa-miR-15 0-3p、hsa-miR-8089、hsa-miR-6805-3p、hsa-mi R-7113-3p、hsa-miR-6850-5p、hsa-miR-6799-5 p、hsa-miR-6768-5p、hsa-miR-92b-5p、hsa-miR -3679-5p、hsa-miR-4792、hsa-miR-3656、hsa-m iR-92a-2-5p、hsa-miR-4466、hsa-miR-4513、hs a-miR-6781-5p、hsa-miR-4649-5p、hsa-miR-67 75-5p、hsa-miR-4651、hsa-miR-3195、hsa-miR- 6726-5p、hsa-miR-6872-3p、hsa-miR-371a-5p、 hsa-miR-6777-5p、hsa-miR-6789-5p、hsa-miR- 7975、hsa-miR-6821-5p、hsa-miR-4534、hsa-mi R-619-5p、hsa-miR-7107-5p、hsa-miR-1228-3p hsa-miR-6774-5p, hsa-miR-6805-5p, hsa-miR -23a-3p、hsa-miR-4665-5p、hsa-miR-4505、hsa -miR-4638-5p、hsa-miR-24-3p、hsa-miR-3135b 、hsa-miR-4745-5p、hsa-miR-128-1-5p、hsa-mi R-4476、hsa-miR-4687-3p、hsa-miR-3665、hsa- miR-6806-5p、hsa-miR-3937、hsa-miR-711、hsa -miR-3141、hsa-miR-3188、hsa-miR-4281、hsa- miR-5196-5p、hsa-miR-6880-5p、hsa-miR-3960 hsa-miR-3648, hsa-miR-6721-5p, hsa-miR-44 92, hsa-miR-744-5p, hsa-miR-7704, hsa-miR-4 749-5p、hsa-miR-6794-5p、hsa-miR-6511a-5p、 hsa-miR-6824-5p, hsa-miR-762, hsa-miR-6836 -3p, hsa-miR-6727-5p, hsa-miR-4739, hsa-miR -7977, hsa-miR-4484, hsa-miR-6515-3p, hsa-m iR-373-5p, hsa-miR-4258, hsa-miR-4674, hsa- miR-3180, hsa-miR-6076, hsa-miR-1238-5p, hs a-miR-4463, hsa-miR-4486, hsa-miR-4730, hsa -miR-6766-3p, hsa-miR-4286, hsa-miR-6511a- 5p, hsa-miR-4739, hsa-miR-6749-5p), their homologs, and variants or derivatives thereof. Transcription products, variants and derivatives are as defined above.

[0356] A preferred target nucleic acid is a human gene comprising a base sequence represented by any one of SEQ ID NOs: 1 to 812. A gene, its transcription product, more preferably the transcription product, i.e., miRNA, its precursor R It is a pri-miRNA or pre-miRNA that is a NA.

[0357] The first target gene is the hsa-miR-6784-5p gene, its homologs, and These are transcription products of the genes, or their variants or derivatives. There are reports that altered transcript expression can be a marker for early pancreatic cancer or precursor lesions of pancreatic cancer. It is not known.

[0358] The second target gene is the hsa-miR-1181 gene, its homologs, and their transcription factors. The gene or its transcript, or a variant or derivative thereof. There are no known reports that changes in the expression of α-glucan can be a marker for early pancreatic cancer or precursor lesions of pancreatic cancer. Not yet.

[0359] The third target gene is the hsa-miR-671-5p gene, its homologs, and their or their variants or derivatives. There are no reports that altered expression of these products can be markers for early pancreatic cancer or precursor lesions of pancreatic cancer. It has not been done.

[0360] The fourth target gene is the hsa-miR-6857-5p gene, its homologs, and These are transcription products of the genes, or their variants or derivatives. There are reports that altered transcript expression can be a marker for early pancreatic cancer or precursor lesions of pancreatic cancer. It is not known.

[0361] The fifth target gene is the hsa-miR-4276 gene, its homologs, and their transcription factors. The gene or its transcript, or a variant or derivative thereof. There are no known reports that changes in the expression of α-glucan can be a marker for early pancreatic cancer or precursor lesions of pancreatic cancer. Not yet.

[0362] The sixth target gene is the hsa-miR-1914-3p gene, its homologs, and These are transcription products of the genes, or their variants or derivatives. There are reports that altered transcript expression can be a marker for early pancreatic cancer or precursor lesions of pancreatic cancer. It is not known.

[0363] The seventh target gene is the hsa-miR-149-3p gene, its homologs, and their or their variants or derivatives. There are no reports that altered expression of these products can be markers for early pancreatic cancer or precursor lesions of pancreatic cancer. It has not been done.

[0364] The eighth target gene is the hsa-miR-937-5p gene, its homologs, and their or their variants or derivatives. There are no reports that altered expression of these products can be markers for early pancreatic cancer or precursor lesions of pancreatic cancer. It has not been done.

[0365] The ninth target gene is the hsa-miR-4675 gene, its homologs, and their transcription factors. The gene or its transcript, or a variant or derivative thereof. There are no known reports that changes in the expression of α-glucan can be a marker for early pancreatic cancer or precursor lesions of pancreatic cancer. Not yet.

[0366] The tenth target gene is the hsa-miR-6795-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0367] The eleventh target gene is the hsa-miR-4731-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0368] The 12th target gene is the hsa-miR-5090 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. There are no reports that altered expression of these proteins can be markers for early pancreatic cancer or precursor lesions of pancreatic cancer. It has not been done.

[0369] The 13th target gene is the hsa-miR-3620-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0370] The 14th target gene is the hsa-miR-1343-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0371] The 15th target gene is the hsa-miR-6717-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0372] The 16th target gene is the hsa-miR-6825-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0373] The 17th target gene is the hsa-miR-6738-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0374] The 18th target gene is the hsa-miR-6769a-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that altered expression of the transcripts of α-glucanase 1 (α-glucanase 1) can be a marker for early pancreatic cancer or precursor lesions of pancreatic cancer. The report is not known.

[0375] The 19th target gene is the hsa-miR-4728-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0376] The 20th target gene is the hsa-miR-652-5p gene, its homologs, and These are transcription products of the genes, or their variants or derivatives. There are reports that altered transcript expression can be a marker for early pancreatic cancer or precursor lesions of pancreatic cancer. It is not known.

[0377] The 21st target gene is the hsa-miR-4257 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. There are no reports that altered expression of these proteins can be markers for early pancreatic cancer or precursor lesions of pancreatic cancer. It has not been done.

[0378] The 22nd target gene is the hsa-miR-6785-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0379] The 23rd target gene is the hsa-miR-7110-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0380] The 24th target gene is the hsa-miR-6887-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0381] The 25th target gene is the hsa-miR-887-3p gene, its homologs, and These are transcription products of the genes, or their variants or derivatives. There are reports that altered transcript expression can be a marker for early pancreatic cancer or precursor lesions of pancreatic cancer. It is not known.

[0382] The 26th target gene is the hsa-miR-1228-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0383] The 27th target gene is the hsa-miR-5572 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. There are no reports that altered expression of these proteins can be markers for early pancreatic cancer or precursor lesions of pancreatic cancer. It has not been done.

[0384] The 28th target gene is the hsa-miR-6782-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0385] The 29th target gene is the hsa-miR-4298 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. There are no reports that altered expression of these proteins can be markers for early pancreatic cancer or precursor lesions of pancreatic cancer. It has not been done.

[0386] The 30th target gene is the hsa-miR-6786-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0387] The 31st target gene is the hsa-miR-5010-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0388] The 32nd target gene is the hsa-miR-6087 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. There are no reports that altered expression of these proteins can be markers for early pancreatic cancer or precursor lesions of pancreatic cancer. It has not been done.

[0389] The 33rd target gene is the hsa-miR-6765-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0390] The 34th target gene is the hsa-miR-6732-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0391] The 35th target gene is the hsa-miR-6787-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0392] The 36th target gene is the hsa-miR-6737-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0393] The 37th target gene is the hsa-miR-128-2-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that altered expression of the transcripts of α-glucanase 1 (α-glucanase 1) can be a marker for early pancreatic cancer or precursor lesions of pancreatic cancer. The report is not known.

[0394] The 38th target gene is the hsa-miR-4270 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. There are no reports that altered expression of these proteins can be markers for early pancreatic cancer or precursor lesions of pancreatic cancer. It has not been done.

[0395] The 39th target gene is the hsa-miR-6861-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0396] The 40th target gene is the hsa-miR-6756-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0397] The 41st target gene is the hsa-miR-1229-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0398] The 42nd target gene is the hsa-miR-6891-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0399] The 43rd target gene is the hsa-miR-6848-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0400] The 44th target gene is the hsa-miR-1237-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0401] The 45th target gene is the hsa-miR-30c-1-3p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that altered expression of the transcripts of α-glucanase 1 (α-glucanase 1) can be a marker for early pancreatic cancer or precursor lesions of pancreatic cancer. The report is not known.

[0402] The 46th target gene is the hsa-miR-1233-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0403] The 47th target gene is the hsa-miR-211-3p gene, its homologs, and These are transcription products of the genes, or their variants or derivatives. There are reports that altered transcript expression can be a marker for early pancreatic cancer or precursor lesions of pancreatic cancer. It is not known.

[0404] The 48th target gene is the hsa-miR-4758-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0405] The 49th target gene is the hsa-miR-614 gene, its homologs, and their transcription factors. The gene or its transcript, or a variant or derivative thereof. There are no known reports that changes in the expression of α-glucan can be a marker for early pancreatic cancer or precursor lesions of pancreatic cancer. Not yet.

[0406] The 50th target gene is the hsa-miR-6746-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0407] The 51st target gene is the hsa-miR-1915-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0408] The 52nd target gene is the hsa-miR-4688 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. There are no reports that altered expression of these proteins can be markers for early pancreatic cancer or precursor lesions of pancreatic cancer. It has not been done.

[0409] The 53rd target gene is the hsa-miR-3917 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. There are no reports that altered expression of these proteins can be markers for early pancreatic cancer or precursor lesions of pancreatic cancer. It has not been done.

[0410] The 54th target gene is the hsa-miR-5787 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. There are no reports that altered expression of these proteins can be markers for early pancreatic cancer or precursor lesions of pancreatic cancer. It has not been done.

[0411] The 55th target gene is the hsa-miR-4632-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0412] The 56th target gene is the hsa-miR-6126 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. There are no reports that altered expression of these proteins can be markers for early pancreatic cancer or precursor lesions of pancreatic cancer. It has not been done.

[0413] The 57th target gene is the hsa-miR-135a-3p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0414] The 58th target gene is the hsa-miR-8063 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. There are no reports that altered expression of these proteins can be markers for early pancreatic cancer or precursor lesions of pancreatic cancer. It has not been done.

[0415] The 59th target gene is the hsa-miR-5698 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. There are no reports that altered expression of these proteins can be markers for early pancreatic cancer or precursor lesions of pancreatic cancer. It has not been done.

[0416] The 60th target gene is the hsa-miR-6089 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. There are no reports that altered expression of these proteins can be markers for early pancreatic cancer or precursor lesions of pancreatic cancer. It has not been done.

[0417] The 61st target gene is the hsa-miR-498 gene, its homologs, and their transcription factors. The gene or its transcript, or a variant or derivative thereof. There are no known reports that changes in the expression of α-glucan can be a marker for early pancreatic cancer or precursor lesions of pancreatic cancer. Not yet.

[0418] The 62nd target gene is the hsa-miR-296-3p gene, its homologs, and These are transcription products of the genes, or their variants or derivatives. There are reports that altered transcript expression can be a marker for early pancreatic cancer or precursor lesions of pancreatic cancer. It is not known.

[0419] The 63rd target gene is the hsa-miR-4419b gene, its homologs, and their or their variants or derivatives. There are no reports that altered expression of these products can be markers for early pancreatic cancer or precursor lesions of pancreatic cancer. It has not been done.

[0420] The 64th target gene is the hsa-miR-6802-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0421] The 65th target gene is the hsa-miR-6829-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0422] The 66th target gene is the hsa-miR-6803-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0423] The 67th target gene is the hsa-miR-1199-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0424] The 68th target gene is the hsa-miR-6840-3p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0425] The 69th target gene is the hsa-miR-6752-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0426] The 70th target gene is the hsa-miR-6798-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0427] The 71st target gene is the hsa-miR-6131 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. There are no reports that altered expression of these proteins can be markers for early pancreatic cancer or precursor lesions of pancreatic cancer. It has not been done.

[0428] The 72nd target gene is the hsa-miR-4667-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0429] The 73rd target gene is the hsa-miR-6510-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0430] The 74th target gene is the hsa-miR-4690-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0431] The 75th target gene is the hsa-miR-920 gene, its homologs, and their transcription factors. The gene or its transcript, or a variant or derivative thereof. There are no known reports that changes in the expression of α-glucan can be a marker for early pancreatic cancer or precursor lesions of pancreatic cancer. Not yet.

[0432] The 76th target gene is the hsa-miR-23b-3p gene, its homologs, and These are transcription products of the genes, or their variants or derivatives. There are reports that altered transcript expression can be a marker for early pancreatic cancer or precursor lesions of pancreatic cancer. It is not known.

[0433] The 77th target gene is the hsa-miR-4448 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. There are no reports that altered expression of these proteins can be markers for early pancreatic cancer or precursor lesions of pancreatic cancer. It has not been done.

[0434] The 78th target gene is the hsa-miR-2110 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. There are no reports that altered expression of these proteins can be markers for early pancreatic cancer or precursor lesions of pancreatic cancer. It has not been done.

[0435] The 79th target gene is the hsa-miR-4706 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. There are no reports that altered expression of these proteins can be markers for early pancreatic cancer or precursor lesions of pancreatic cancer. It has not been done.

[0436] The 80th target gene is the hsa-miR-7845-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0437] The 81st target gene is the hsa-miR-6808-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0438] The 82nd target gene is the hsa-miR-4447 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. There are no reports that altered expression of these proteins can be markers for early pancreatic cancer or precursor lesions of pancreatic cancer. It has not been done.

[0439] The 83rd target gene is the hsa-miR-6869-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is not known.

[0440] The 84th target gene is the hsa-miR-1908-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. It has been reported that changes in the expression of transcripts can be markers for pancreatic cancer (see above). Patent document 2).

[0441] The 85th target gene is the hsa-miR-6729-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. It has been reported that changes in the expression of transcripts can be markers for pancreatic cancer (see above). Patent document 2).

[0442] The 86th target gene is the hsa-miR-5195-3p gene, its homologs, and These are transcription products, or variants or derivatives thereof. It has been reported that changes in the expression of transcripts can be markers for pancreatic cancer (see above). Patent document 2).

[0443] The 87th target gene is the hsa-miR-638 gene, its homologs, and their transcription factors. The gene or its transcript, or a variant or derivative thereof. It has been reported that changes in the expression of α-glucan can be a marker for pancreatic cancer (see the above-mentioned non-patent document). Reference 5).

[0444] The 88th target gene is the hsa-miR-6125 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. It has been reported that changes in the expression of these substances can be markers for pancreatic cancer (see the above patent document). 2).

[0445] The 89th target gene is the hsa-miR-3178 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. It has been reported that changes in the expression of these substances can be markers for pancreatic cancer (see the above patent document). 2).

[0446] The 90th target gene is the hsa-miR-3196 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. It has been reported that changes in the expression of these substances can be markers for pancreatic cancer (see the above-mentioned non-patent literature). Reference 5).

[0447] The 91st target gene is the hsa-miR-8069 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. It has been reported that changes in the expression of these substances can be markers for pancreatic cancer (see the above patent document). 2).

[0448] The 92nd target gene is the hsa-miR-4723-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. It has been reported that changes in the expression of transcripts can be markers for pancreatic cancer (see above). Patent document 2).

[0449] The 93rd target gene is the hsa-miR-4746-3p gene, its homologs, and These are transcription products, or variants or derivatives thereof. It has been reported that changes in the expression of transcripts can be markers for pancreatic cancer (see above). Patent document 2).

[0450] The 94th target gene is the hsa-miR-4689 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. It has been reported that changes in the expression of these substances can be markers for pancreatic cancer (see the above patent document). 2).

[0451] The 95th target gene is the hsa-miR-6816-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. It has been reported that changes in the expression of transcripts can be markers for pancreatic cancer (see above). Patent document 2).

[0452] The 96th target gene is the hsa-miR-6757-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. It has been reported that changes in the expression of transcripts can be markers for pancreatic cancer (see above). Patent document 2).

[0453] The 97th target gene is the hsa-miR-7109-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. It has been reported that changes in the expression of transcripts can be markers for pancreatic cancer (see above). Patent document 2).

[0454] The 98th target gene is the hsa-miR-6724-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. It has been reported that changes in the expression of transcripts can be markers for pancreatic cancer (see above). Patent document 2).

[0455] The 99th target gene is the hsa-miR-1225-3p gene, its homologs, and These are transcription products, or variants or derivatives thereof. It has been reported that changes in the expression of transcripts can be markers for pancreatic cancer (see above). Non-patent document 5).

[0456] The 100th target gene is the hsa-miR-6875-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0457] The 101st target gene is the hsa-miR-7108-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0458] The 102nd target gene is the hsa-miR-4508 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0459] The 103rd target gene is the hsa-miR-6085 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0460] The 104th target gene is the hsa-miR-6779-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0461] The 105th target gene is the hsa-miR-642a-3p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0462] The 106th target gene is the hsa-miR-4695-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Non-patent document 5).

[0463] The 107th target gene is the hsa-miR-7847-3p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0464] The 108th target gene is the hsa-miR-3197 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of these products can be markers for pancreatic cancer (see the above non-specific Permitted document 5).

[0465] The 109th target gene is the hsa-miR-6769b-5p gene and its homologs , their transcription products, or their variants or derivatives. It has been reported that changes in the expression of its transcripts can be a marker for pancreatic cancer (see above). The above patent document 2).

[0466] The 110th target gene is the hsa-miR-7641 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0467] The 111th target gene is the hsa-miR-187-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. It has been reported that changes in the expression of transcripts can be markers for pancreatic cancer (see above). Patent document 2).

[0468] The 112th target gene is the hsa-miR-3185 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0469] The 113th target gene is the hsa-miR-2861 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0470] The 114th target gene is the hsa-miR-3940-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0471] The 115th target gene is the hsa-miR-1203 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0472] The 116th target gene is the hsa-miR-615-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. It has been reported that changes in the expression of transcripts can be markers for pancreatic cancer (see above). Patent document 2).

[0473] The 117th target gene is the hsa-miR-4787-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Non-patent document 5).

[0474] The 118th target gene is the hsa-miR-1343-3p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0475] The 119th target gene is the hsa-miR-6813-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0476] The 120th target gene is the hsa-miR-1225-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Non-patent document 5).

[0477] The 121st target gene is the hsa-miR-602 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. It has been reported that changes in the expression of these substances can be markers for pancreatic cancer (see the above patent document). 2).

[0478] The 122nd target gene is the hsa-miR-4488 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of these products can be markers for pancreatic cancer (see the above non-specific Permitted document 5).

[0479] The 123rd target gene is the hsa-miR-125a-3p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0480] The 124th target gene is the hsa-miR-5100 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0481] The 125th target gene is the hsa-miR-4294 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0482] The 126th target gene is the hsa-miR-1231 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0483] The 127th target gene is the hsa-miR-6765-3p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0484] The 128th target gene is the hsa-miR-4442 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0485] The 129th target gene is the hsa-miR-718 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. It has been reported that changes in the expression of these substances can be markers for pancreatic cancer (see the above patent document). 2).

[0486] The 130th target gene is the hsa-miR-6780b-5p gene and its homologs , their transcription products, or their variants or derivatives. It has been reported that changes in the expression of its transcripts can be a marker for pancreatic cancer (see above). The above patent document 2).

[0487] The 131st target gene is the hsa-miR-6090 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0488] The 132nd target gene is the hsa-miR-6845-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0489] The 133rd target gene is the hsa-miR-4741 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0490] The 134th target gene is the hsa-miR-4467 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0491] The 135th target gene is the hsa-miR-4707-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0492] The 136th target gene is the hsa-miR-4271 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0493] The 137th target gene is the hsa-miR-4673 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0494] The 138th target gene is the hsa-miR-3184-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0495] The 139th target gene is the hsa-miR-1469 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0496] The 140th target gene is the hsa-miR-4640-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Non-patent document 5).

[0497] The 141st target gene is the hsa-miR-663a gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0498] The 142nd target gene is the hsa-miR-6791-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0499] The 143rd target gene is the hsa-miR-6826-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0500] The 144th target gene is the hsa-miR-4433b-3p gene and its homologs , their transcription products, or their variants or derivatives. It has been reported that changes in the expression of its transcripts can be a marker for pancreatic cancer (see above). The above patent document 2).

[0501] The 145th target gene is the hsa-miR-1915-3p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0502] The 146th target gene is the hsa-miR-4417 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0503] The 147th target gene is the hsa-miR-4449 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0504] The 148th target gene is the hsa-miR-4707-3p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Non-patent document 5).

[0505] The 149th target gene is the hsa-miR-3180-3p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Non-patent document 5).

[0506] The 150th target gene is the hsa-miR-5585-3p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0507] The 151st target gene is the hsa-miR-1268a gene, its homologs, and These are transcription products of the genes, or their variants or derivatives. It has been reported that altered expression of transcripts can be a marker for early pancreatic cancer or precursor lesions of pancreatic cancer. It is known (see Patent Document 4 mentioned above).

[0508] The 152nd target gene is the hsa-miR-8072 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0509] The 153rd target gene is the hsa-miR-296-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is known (see Patent Document 5 above).

[0510] The 154th target gene is the hsa-miR-204-3p gene, its homologs, and These are transcription products, or variants or derivatives thereof. It has been reported that changes in the expression of transcripts can be markers for pancreatic cancer (see above). Patent document 2).

[0511] The 155th target gene is the hsa-miR-4454 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0512] The 156th target gene is the hsa-miR-6722-3p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0513] The 157th target gene is the hsa-miR-1290 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0514] The 158th target gene is the hsa-miR-3622a-5p gene and its homologs , their transcription products, or their variants or derivatives. It has been reported that changes in the expression of its transcripts can be a marker for pancreatic cancer (see above). The above patent document 2).

[0515] The 159th target gene is the hsa-miR-939-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. Altered transcript expression may be a marker for early pancreatic cancer or precursor lesions is known (see Patent Document 4 above).

[0516] The 160th target gene is the hsa-miR-675-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. It has been reported that changes in the expression of transcripts can be markers for pancreatic cancer (see above). Non-patent document 5).

[0517] The 161st target gene is the hsa-miR-3131 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0518] The 162nd target gene is the hsa-miR-4648 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0519] The 163rd target gene is the hsa-miR-1268b gene, its homologs, and These are transcription products of the genes, or their variants or derivatives. It has been reported that changes in the expression of transcripts can be markers for pancreatic cancer (see the above non- Patent document 5).

[0520] The 164th target gene is the hsa-miR-6741-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0521] The 165th target gene is the hsa-miR-6893-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0522] The 166th target gene is the hsa-miR-3162-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0523] The 167th target gene is the hsa-miR-642b-3p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that altered expression of the transcripts of α-glucanase 1 (α-glucanase 1) can be a marker for early pancreatic cancer or precursor lesions of pancreatic cancer. The advertisement is known (see Patent Document 4 above).

[0524] The 168th target gene is the hsa-miR-4734 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0525] The 169th target gene is the hsa-miR-150-3p gene, its homologs, and These are transcription products, or variants or derivatives thereof. It has been reported that changes in the expression of transcripts can be markers for pancreatic cancer (see above). Patent document 2).

[0526] The 170th target gene is the hsa-miR-8089 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0527] The 171st target gene is the hsa-miR-6805-3p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0528] The 172nd target gene is the hsa-miR-7113-3p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0529] The 173rd target gene is the hsa-miR-6850-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0530] The 174th target gene is the hsa-miR-6799-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0531] The 175th target gene is the hsa-miR-6768-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0532] The 176th target gene is the hsa-miR-92b-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. It has been reported that changes in the expression of transcripts can be markers for pancreatic cancer (see above). Patent document 2).

[0533] The 177th target gene is the hsa-miR-3679-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Non-patent document 5).

[0534] The 178th target gene is the hsa-miR-4792 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0535] The 179th target gene is the hsa-miR-3656 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0536] The 180th target gene is the hsa-miR-92a-2-5p gene and its homologs , their transcription products, or their variants or derivatives. It has been reported that changes in the expression of its transcripts can be a marker for pancreatic cancer (see above). The above patent document 2).

[0537] The 181st target gene is the hsa-miR-4466 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of these products can be markers for pancreatic cancer (see the above non-specific Permitted document 5).

[0538] The 182nd target gene is the hsa-miR-4513 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0539] The 183rd target gene is the hsa-miR-6781-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0540] The 184th target gene is the hsa-miR-4649-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0541] The 185th target gene is the hsa-miR-6775-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0542] The 186th target gene is the hsa-miR-4651 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0543] The 187th target gene is the hsa-miR-3195 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of these products can be markers for pancreatic cancer (see the above non-specific Permitted document 5).

[0544] The 188th target gene is the hsa-miR-6726-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0545] The 189th target gene is the hsa-miR-6872-3p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0546] The 190th target gene is the hsa-miR-371a-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0547] The 191st target gene is the hsa-miR-6777-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0548] The 192nd target gene is the hsa-miR-6789-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0549] The 193rd target gene is the hsa-miR-7975 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0550] The 194th target gene is the hsa-miR-6821-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0551] The 195th target gene is the hsa-miR-4534 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0552] The 196th target gene is the hsa-miR-619-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. It has been reported that changes in the expression of transcripts can be markers for pancreatic cancer (see above). Patent document 2).

[0553] The 197th target gene is the hsa-miR-7107-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0554] The 198th target gene is the hsa-miR-1228-3p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0555] The 199th target gene is the hsa-miR-6774-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0556] The 200th target gene is the hsa-miR-6805-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0557] The 201st target gene is the hsa-miR-23a-3p gene, its homologs, and These are transcription products, or variants or derivatives thereof. It has been reported that changes in the expression of transcripts can be markers for pancreatic cancer (see above). Patent document 3).

[0558] The 202nd target gene is the hsa-miR-4665-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0559] The 203rd target gene is the hsa-miR-4505 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0560] The 204th target gene is the hsa-miR-4638-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0561] The 205th target gene is the hsa-miR-24-3p gene, its homologs, and These are transcription products of the genes, or their variants or derivatives. It has been reported that changes in the expression of transcripts can be markers for pancreatic cancer (see above). Permitted document 2).

[0562] The 206th target gene is the hsa-miR-3135b gene, its homologs, and These are transcription products of the genes, or their variants or derivatives. It has been reported that changes in the expression of transcripts can be markers for pancreatic cancer (see above). Permitted document 2).

[0563] The 207th target gene is the hsa-miR-4745-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Non-patent document 5).

[0564] The 208th target gene is the hsa-miR-128-1-5p gene and its homologs. , their transcription products, or their variants or derivatives. It has been reported that changes in the expression of its transcripts can be a marker for pancreatic cancer (see above). The above patent document 2).

[0565] The 209th target gene is the hsa-miR-4476 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0566] The 210th target gene is the hsa-miR-4687-3p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0567] The 211th target gene is the hsa-miR-3665 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of these products can be markers for pancreatic cancer (see the above non-specific Permitted document 5).

[0568] The 212th target gene is the hsa-miR-6806-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0569] The 213th target gene is the hsa-miR-3937 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of these products can be markers for pancreatic cancer (see the above non-specific Permitted document 5).

[0570] The 214th target gene is the hsa-miR-711 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. It has been reported that changes in the expression of these substances can be markers for pancreatic cancer (see the above-mentioned non-patent literature). Reference 5).

[0571] The 215th target gene is the hsa-miR-3141 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of these products can be markers for pancreatic cancer (see the above non-specific Permitted document 5).

[0572] The 216th target gene is the hsa-miR-3188 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0573] The 217th target gene is the hsa-miR-4281 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0574] The 218th target gene is the hsa-miR-5196-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0575] The 219th target gene is the hsa-miR-6880-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0576] The 220th target gene is the hsa-miR-3960 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of these products can be markers for pancreatic cancer (see the above non-specific Permitted document 5).

[0577] The 221st target gene is the hsa-miR-3648 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 1).

[0578] The 222nd target gene is the hsa-miR-6721-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0579] The 223rd target gene is the hsa-miR-4492 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of these products can be markers for pancreatic cancer (see the above non-specific Permitted document 5).

[0580] The 224th target gene is the hsa-miR-744-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. It has been reported that changes in the expression of transcripts can be markers for pancreatic cancer (see above). Non-patent document 5).

[0581] The 225th target gene is the hsa-miR-7704 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0582] The 226th target gene is the hsa-miR-4749-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Non-patent document 5).

[0583] The 227th target gene is the hsa-miR-6794-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. There are no known reports that altered expression of this transcript could be a marker for pancreatic cancer.

[0584] The 228th target gene is the hsa-miR-6511a-5p gene and its homologs. , their transcription products, or their variants or derivatives. There are no known reports suggesting that changes in the expression of these transcripts could be a marker for pancreatic cancer.

[0585] The 229th target gene is the hsa-miR-6824-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. There are no known reports that altered expression of this transcript could be a marker for pancreatic cancer.

[0586] The 230th target gene is the hsa-miR-762 gene, its homologs, and their The gene or its transcript, or a variant or derivative thereof. It has been reported that changes in the expression of these substances can be markers for pancreatic cancer (see the above-mentioned non-patent literature). Reference 5).

[0587] The 231st target gene is the hsa-miR-6836-3p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0588] The 232nd target gene is the hsa-miR-6727-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0589] The 233rd target gene is the hsa-miR-4739 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of these products can be markers for pancreatic cancer (see the above non-specific Permitted document 5).

[0590] The 234th target gene is the hsa-miR-7977 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0591] The 235th target gene is the hsa-miR-4484 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0592] The 236th target gene is the hsa-miR-6515-3p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0593] The 237th target gene is the hsa-miR-373-5p gene, its homologs, and These are transcription products, or variants or derivatives thereof. It has been reported that changes in the expression of transcripts can be markers for pancreatic cancer (see above). Non-patent document 5).

[0594] The 238th target gene is the hsa-miR-4258 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0595] The 239th target gene is the hsa-miR-4674 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0596] The 240th target gene is the hsa-miR-3180 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of these products can be markers for pancreatic cancer (see the above non-specific Permitted document 5).

[0597] The 241st target gene is the hsa-miR-6076 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0598] The 242nd target gene is the hsa-miR-1238-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. It has been reported that changes in the expression of transcripts of β-glucanase (β-glucanase) can be a marker for pancreatic cancer (see above). Patent document 2).

[0599] The 243rd target gene is the hsa-miR-4463 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of these products can be markers for pancreatic cancer (see the above non-specific Permitted document 5).

[0600] The 244th target gene is the hsa-miR-4486 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0601] The 245th target gene is the hsa-miR-4730 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of these products can be markers for pancreatic cancer (see the above non-specific Permitted document 5).

[0602] The 246th target gene is the hsa-miR-6766-3p gene, its homologs, The genes or their transcription products, or their variants or derivatives. There are no known reports that altered expression of this transcript could be a marker for pancreatic cancer.

[0603] The 247th target gene is the hsa-miR-4286 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of the product can be a marker for pancreatic cancer (see the above patent). Reference 2).

[0604] The 248th target gene is the hsa-miR-6511a-5p gene and its homologs , their transcription products, or their variants or derivatives. There are no known reports suggesting that changes in the expression of these transcripts could be a marker for pancreatic cancer.

[0605] The 249th target gene is the hsa-miR-4739 gene, its homologs, and their or their variants or derivatives. It has been reported that changes in the expression of these products can be markers for pancreatic cancer (see the above non-specific Permitted document 5).

[0606] The 250th target gene is the hsa-miR-6749-5p gene, its homologs, The genes or their transcription products, or their variants or derivatives. There are no known reports that altered expression of this transcript could be a marker for pancreatic cancer.

[0607] 2. Nucleic acid probes or primers for detecting early pancreatic cancer or pancreatic cancer precursor lesions In the present invention, the target nucleic acid as a marker for early stage pancreatic cancer or pancreatic cancer precursor lesion is The nucleic acid capable of specifically binding to the target protein is used as a nucleic acid for detecting or diagnosing early stage pancreatic cancer or a precursor lesion of pancreatic cancer. The acid can be used, for example, as a nucleic acid probe or primer.

[0608] In the present invention, a method for detecting early stage pancreatic cancer or a precursor lesion of pancreatic cancer, or for detecting early stage pancreatic cancer, Nucleic acid probes or primers that can be used to diagnose pancreatic cancer or precursor lesions of pancreatic cancer are available for early detection. Human-derived hsa-miR-6784 as a target nucleic acid for pancreatic cancer or pancreatic cancer precursor lesions -5p, hsa-miR-1181, hsa-miR-671-5p, hsa-miR- 6857-5p, hsa-miR-4276, hsa-miR-1914-3p, hsa -miR-149-3p, hsa-miR-937-5p, hsa-miR-4675, hsa-miR-6795-5p、hsa-miR-4731-5p、hsa-miR- 5090、hsa-miR-3620-5p、hsa-miR-1343-5p、hsa -miR-6717-5p、hsa-miR-6825-5p、hsa-miR-673 8-5p、hsa-miR-6769a-5p、hsa-miR-4728-5p、hs a-miR-652-5p、hsa-miR-4257、hsa-miR-6785-5 p、hsa-miR-7110-5p、hsa-miR-6887-5p、hsa-mi R-887-3p、hsa-miR-1228-5p、hsa-miR-5572、hs a-miR-6782-5p、hsa-miR-4298、hsa-miR-6786- 5p、hsa-miR-5010-5p、hsa-miR-6087、hsa-miR- 6765-5p、hsa-miR-6732-5p、hsa-miR-6787-5p、 hsa-miR-6737-5p、hsa-miR-128-2-5p、hsa-miR -4270、hsa-miR-6861-5p、hsa-miR-6756-5p、hs a-miR-1229-5p、hsa-miR-6891-5p、hsa-miR-68 48-5p、hsa-miR-1237-5p、hsa-miR-30c-1-3p、h sa-miR-1233-5p、hsa-miR-211-3p、hsa-miR-47 58-5p、hsa-miR-614、hsa-miR-6746-5p、hsa-mi R-1915-5p、hsa-miR-4688、hsa-miR-3917、hsa- miR-5787, hsa-miR-4632-5p, hsa-miR-6126, hs a-miR-135a-3p, hsa-miR-8063, hsa-miR-5698, hsa-miR-6089, hsa-miR-498, hsa-miR-296-3p, hsa-miR-4419b, hsa-miR-6802-5p, hsa-miR-68 29-5p, hsa-miR-6803-5p, hsa-miR-1199-5p, hs a-miR-6840-3p, hsa-miR-6752-5p, hsa-miR-67 98-5p, hsa-miR-6131, hsa-miR-4667-5p, hsa-m iR-6510-5p, hsa-miR-4690-5p, hsa-miR-920, h sa-miR-23b-3p, hsa-miR-4448, hsa-miR-2110, hsa-miR-4706, hsa-miR-7845-5p, hsa-miR-680 8-5p, hsa-miR-4447, hsa-miR-6869-5p, hsa-mi R-6794-5p, hsa-miR-6511a-5p, hsa-miR-6824- 5p, hsa-miR-6766-3p, hsa-miR-6511a-5p, and h sa-miR-6749-5p, or their combinations, and in combination with More combinations possible, hsa-miR-1908-5p, hsa-miR-6 729-5p, hsa-miR-5195-3p, hsa-miR-638, hsa-m iR-6125, hsa-miR-3178, hsa-miR-3196, hsa-mi R-8069, hsa-miR-4723-5p, hsa-miR-4746-3p, h sa-miR-4689, hsa-miR-6816-5p, hsa-miR-6757 -5p, hsa-miR-7109-5p, hsa-miR-6724-5p, hsa- miR-1225-3p、hsa-miR-6875-5p、hsa-miR-7108 -5p、hsa-miR-4508、hsa-miR-6085、hsa-miR-67 79-5p、hsa-miR-642a-3p、hsa-miR-4695-5p、hs a-miR-7847-3p、hsa-miR-3197、hsa-miR-6769b -5p、hsa-miR-7641、hsa-miR-187-5p、hsa-miR- 3185、hsa-miR-2861、hsa-miR-3940-5p、hsa-mi R-1203、hsa-miR-615-5p、hsa-miR-4787-5p、hs a-miR-1343-3p、hsa-miR-6813-5p、hsa-miR-12 25-5p、hsa-miR-602、hsa-miR-4488、hsa-miR-1 25a-3p、hsa-miR-5100、hsa-miR-4294、hsa-miR -1231、hsa-miR-6765-3p、hsa-miR-4442、hsa-m iR-718、hsa-miR-6780b-5p、hsa-miR-6090、hsa -miR-6845-5p、hsa-miR-4741、hsa-miR-4467、h sa-miR-4707-5p、hsa-miR-4271、hsa-miR-4673 hsa-miR-3184-5p, hsa-miR-1469, hsa-miR-46 40-5p、hsa-miR-663a、hsa-miR-6791-5p、hsa-m iR-6826-5p、hsa-miR-4433b-3p、hsa-miR-1915 -3p、hsa-miR-4417、hsa-miR-4449、hsa-miR-47 07-3p、hsa-miR-3180-3p、hsa-miR-5585-3p、hs a-miR-1268a、hsa-miR-8072、hsa-miR-296-5p、 hsa-miR-204-3p、hsa-miR-4454、hsa-miR-6722 -3p、hsa-miR-1290、hsa-miR-3622a-5p、hsa-mi R-939-5p、hsa-miR-675-5p、hsa-miR-3131、hsa -miR-4648、hsa-miR-1268b、hsa-miR-6741-5p、 hsa-miR-6893-5p、hsa-miR-3162-5p、hsa-miR- 642b-3p、hsa-miR-4734、hsa-miR-150-3p、hsa- miR-8089, hsa-miR-6805-3p, hsa-miR-7113-3p hsa-miR-6850-5p, hsa-miR-6799-5p, hsa-miR -6768-5p、hsa-miR-92b-5p、hsa-miR-3679-5p、 hsa-miR-4792、hsa-miR-3656、hsa-miR-92a-2- 5p、hsa-miR-4466、hsa-miR-4513、hsa-miR-678 1-5p、hsa-miR-4649-5p、hsa-miR-6775-5p、hsa -miR-4651、hsa-miR-3195、hsa-miR-6726-5p、h sa-miR-6872-3p、hsa-miR-371a-5p、hsa-miR-6 777-5p、hsa-miR-6789-5p、hsa-miR-7975、hsa- miR-6821-5p、hsa-miR-4534、hsa-miR-619-5p、 hsa-miR-7107-5p、hsa-miR-1228-3p、hsa-miR- 6774-5p, hsa-miR-6805-5p, hsa-miR-23a-3p, h sa-miR-4665-5p, hsa-miR-4505, hsa-miR-4638 -5p, hsa-miR-24-3p, hsa-miR-3135b, hsa-miR- 4745-5p, hsa-miR-128-1-5p, hsa-miR-4476, hs a-miR-4687-3p, hsa-miR-3665, hsa-miR-6806- 5p, hsa-miR-3937, hsa-miR-711, hsa-miR-3141 , hsa-miR-3188, hsa-miR-4281, hsa-miR-5196- 5p, hsa-miR-6880-5p, hsa-miR-3960, hsa-miR- 3648, hsa-miR-6721-5p, hsa-miR-4492, hsa-mi R-744-5p, hsa-miR-7704, hsa-miR-4749-5p, hs a-miR-762, hsa-miR-6836-3p, hsa-miR-6727-5 p, hsa-miR-4739, hsa-miR-7977, hsa-miR-4484 , hsa-miR-6515-3p, hsa-miR-373-5p, hsa-miR- 4258, hsa-miR-4674, hsa-miR-3180, hsa-miR-6 076, hsa-miR-1238-5p, hsa-miR-4463, hsa-miR -4486, hsa-miR-4730, hsa-miR-4286, and hsa-m iR-4739, or combinations thereof, their homologs, their transcripts, or or their mutants or derivatives, qualitatively and / or quantitatively to determine the presence, expression level or abundance of It allows you to measure.

[0609] The above target nucleic acid is more likely to be expressed in subjects with early stage pancreatic cancer or pancreatic cancer precursor lesions than in healthy subjects. In some cases, the expression level increases or decreases depending on the type of the target nucleic acid. For example, Table 2 shows the results of the following tests for healthy subjects: Target miRs corresponding to SEQ ID NOs: 1 to 226 in the blood (serum) of patients (humans) with precursor lesions of pancreatic cancer As shown in Table 2, the changes in the expression levels of target miRNAs were Therefore, there are miRNAs whose expression level increases and miRNAs whose expression level decreases. So, any of the target miRNAs selected and described herein can be used to treat a subject. The present invention can be used to detect and assess early stage pancreatic cancer or precursor lesions of pancreatic cancer.

[0610] Therefore, according to the present invention, a subject suspected of having early stage pancreatic cancer or a precursor lesion of pancreatic cancer measuring the expression level of the target nucleic acid in a body fluid derived from a subject (e.g., a human) and a body fluid derived from a healthy subject; These can be compared and used effectively to detect early stage pancreatic cancer or precursor lesions of pancreatic cancer with high accuracy. Furthermore, according to the present invention, it is possible to provide a method for treating a patient suspected of having early stage pancreatic cancer or a precursor lesion of pancreatic cancer. and body fluids derived from subjects (e.g., humans) and patients with advanced pancreatic cancer, biliary tract cancer, breast cancer, Prostate cancer patients, colon cancer patients, stomach cancer patients, esophageal cancer patients, liver cancer patients, benign pancreatic diseases and determining the target nucleic acid in a body fluid derived from a patient, a patient with benign prostatic disease, or a combination thereof. The expression levels of these genes are measured and compared to distinguish early-stage pancreatic cancer or pancreatic cancer from other cancers or benign diseases. It can be effectively used to specifically and accurately identify cancer precursor lesions.

[0611] Nucleic acid probes or primers that can be used in the present invention are those represented by SEQ ID NOs: 1 to 83, 227 to 22 At least one, at least two, or at least three of 9, 246, 248, and 250; A polynucleotide consisting of a base sequence represented by at least four or at least five is particularly A nucleic acid probe capable of binding heterologously, or a nucleic acid probe represented by SEQ ID NOs: 1 to 83, 227 to 229, or 246 , 248, and 250, at least one, at least two, at least three, at least To amplify a polynucleotide consisting of a base sequence represented by four or at least five It is a primer for.

[0612] Nucleic acid probes or primers that can be used in the present invention are further selected from SEQ ID NOs: 84 to 226, 2 At least one, at least two, or at least three of 30 to 245, 247, and 249 a polynucleotide consisting of a base sequence represented by at least four, or at least five A nucleic acid probe capable of specifically binding to a nucleic acid sequence represented by SEQ ID NOs: 84 to 226, 230 to 245, At least one, at least two, at least three, or at least four of 247 and 249 for amplifying a polynucleotide consisting of one or at least five base sequences A primer may be included.

[0613] Specifically, the nucleic acid probe or primer is any one of SEQ ID NOs: 1 to 250. or a polynucleotide containing a base sequence in which u is t in the base sequence. A group of nucleotides and their complementary polynucleotides, a base sequence complementary to the base sequence Polynucleotides that hybridize with the DNA of interest under stringent conditions (see below) Otides and their complementary polynucleotides, and the bases of those polynucleotides A group of polynucleotides containing 15 or more, preferably 17 or more consecutive bases in the sequence In this regard, the present invention includes a combination of one or more polynucleotides selected from the following: The target miRNAs used in the present invention are, for example, those shown in SEQ ID NOs: 251 to 518 in Table 1. precursor miRNAs, as well as isoform miRNAs such as those set forth in SEQ ID NOS: 519-812. Isotype miRNAs are short, with only about 15 bases, The present invention includes those having a length of about 29, and those having mutations such as substitutions. The nucleic acid probe or primer may be a precursor miRNA or a target isoform miRNA. Nucleic acid probes or primers for making expression measurable are also included. The leutide is used to detect the above-mentioned early stage pancreatic cancer or pancreatic cancer precursor lesion markers, which are target nucleic acids. The nucleic acid probes and primers can be used for the following purposes:

[0614] More specifically, examples of nucleic acid probes or primers that can be used in the present invention include the following: At least one (all) selected from the group consisting of nucleotides (a) to (e). i.e., one or more polynucleotides. (a) SEQ ID NO: 1 to 83, 227 to 229, 246, 248, and 250 or a polynucleotide consisting of a base sequence in which u is t a nucleotide, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases; (b) SEQ ID NO: 1 to 83, 227 to 229, 246, 248, and 250 a polynucleotide comprising a base sequence to be (c) SEQ ID NO: 1 to 83, 227 to 229, 246, 248, and 250 or a base sequence in which u is t in the base sequence, A polynucleotide consisting of a sequence, its variant, its derivative, or 15 or more consecutive bases The fragment containing (d) SEQ ID NO: 1 to 83, 227 to 229, 246, 248, and 250 or a base sequence in which u is t in the base sequence, a polynucleotide comprising the sequence, and (e) A polynucleotide that binds to any one of the polynucleotides (a) to (d) under stringent conditions. Hybridizing polynucleotide.

[0615] The nucleic acid probe or primer that can be used in the present invention further includes the above-mentioned polynucleotide ( At least one (i.e., one or more) poly(ethylene glycol) copolymer selected from any of a) to (e) In addition to nucleotides, at least one of the following (f) to (j) (i.e. , one or more) polynucleotides. (f) a sequence represented by any one of SEQ ID NOs: 84 to 226, 230 to 245, 247, and 249; or a polynucleotide consisting of a base sequence in which u is t a fragment thereof containing 15 or more consecutive bases, (g) a sequence represented by any one of SEQ ID NOs: 84 to 226, 230 to 245, 247, and 249 a polynucleotide comprising a base sequence (h) a sequence number represented by any one of SEQ ID NOs: 84 to 226, 230 to 245, 247, and 249; or a base sequence complementary to the base sequence in which u is t a polynucleotide consisting of, or a variant or derivative thereof, or a polynucleotide containing 15 or more consecutive bases Fragments of Muso, (i) Represented by any of SEQ ID NOs: 84 to 226, 230 to 245, 247, and 249 or a base sequence complementary to the base sequence in which u is t and a polynucleotide comprising (j) A method for detecting a polynucleotide that is hybridized with any one of the polynucleotides (f) to (i) under stringent conditions. Hybridizing polynucleotide.

[0616] In the above polynucleotide, "a fragment containing 15 or more consecutive bases" means each polynucleotide. In a base sequence of a polynucleotide, for example, 15 consecutive bases or less than the total number of bases in the sequence, It may contain a range of base numbers, such as 7 to less than the total number of bases in the sequence, or 19 to less than the total number of bases in the sequence. The present invention can be implemented in the following ways, but is not limited to these.

[0617] The polynucleotides or fragments thereof used in the present invention may be DNA. RNA may also be used.

[0618] The above polynucleotides that can be used in the present invention can be synthesized by DNA recombination techniques, PCR methods, DNA / It can be prepared using common techniques such as methods using an automatic RNA synthesizer.

[0619] The DNA recombination technique and the PCR method are described, for example, in Ausubel et al., Current Proc. otocols in Molecular Biology, John Wille y & Sons, US (1993); Sambrook et al., Molecula r Cloning A Laboratory Manual, Cold Spr. Harbor Laboratory Press, US (1989), etc. The techniques described in can be used.

[0620] Human-derived hsa-miR-6784-5p, hsa -miR-1181, hsa-miR-671-5p, hsa-miR-6857-5p , hsa-miR-4276, hsa-miR-1914-3p, hsa-miR-14 9-3p, hsa-miR-937-5p, hsa-miR-4675, hsa-miR -6795-5p, hsa-miR-4731-5p, hsa-miR-5090, hs a-miR-3620-5p, hsa-miR-1343-5p, hsa-miR-67 17-5p, hsa-miR-6825-5p, hsa-miR-6738-5p, hs a-miR-6769a-5p, hsa-miR-4728-5p, hsa-miR-6 52-5p, hsa-miR-4257, hsa-miR-6785-5p, hsa-m iR-7110-5p, hsa-miR-6887-5p, hsa-miR-887-3 p, hsa-miR-1228-5p, hsa-miR-5572, hsa-miR-6 782-5p, hsa-miR-4298, hsa-miR-6786-�p, hsa- miR-5010-5p, hsa-miR-6087, hsa-miR-6765-5p , hsa-miR-6732-5p, hsa-miR-6787-5p, hsa-miR -6737-5p, hsa-miR-128-2-5p, hsa-miR-4270, h sa-miR-6861-5p, hsa-miR-6756-5p, hsa-mi...

Claims

1. A kit for detecting early stage pancreatic cancer or a precursor lesion of pancreatic cancer, comprising a nucleic acid probe capable of specifically binding to a polynucleotide of miR-6803-5p, which is a marker for early stage pancreatic cancer or a precursor lesion of pancreatic cancer, and / or a primer that specifically recognizes and amplifies the polynucleotide.

2. The nucleic acid probe and / or primer is a polynucleotide selected from any one of the following (a) to (e): (a) a polynucleotide consisting of the base sequence represented by SEQ ID NO: 66 or the base sequence in which u is t, or a fragment thereof containing 19 or more consecutive bases; (b) a polynucleotide comprising the base sequence represented by SEQ ID NO: 66; (c) a polynucleotide consisting of a base sequence complementary to the base sequence represented by SEQ ID NO: 66 or the base sequence in which u is t, or a fragment thereof containing 19 or more consecutive bases; (d) a polynucleotide comprising a base sequence complementary to the base sequence represented by SEQ ID NO: 66 or the base sequence in which u is t; and (e) a polynucleotide that hybridizes under stringent conditions with any one of the polynucleotides (a) to (d); The kit of claim 1, wherein the polynucleotide is selected from the group consisting of:

3. Read miR-6784-5p、miR-1181、miR-671-5p 、miR-6857-5p、miR-4276、miR-1914- 3p、miR-149-3p、miR-937-5p、miR-467 5、miR-6795-5p、miR-4731-5p、miR-5 090、miR-3620-5p、miR-6717-5p、miR -6825-5p、miR-6738-5p、miR-6769a- 5p、miR-4728-5p、miR-652-5p、miR-42 57、miR-7110-5p、miR-6887-5p、miR- 887-3p、miR-1228-5p、miR-5572、miR -6782-5p、miR-4298、miR-6786-5p、m iR-5010-5p、miR-6087、miR-6765-5p、 miR-6732-5p、miR-6787-5p、miR-673 7-5p、miR-128-2-5p、miR-4270、miR- 6861-5p、miR-6756-5p、miR-1229-5p 、miR-6891-5p、miR-6848-5p、miR-123 7-5p、miR-30c-1-3p、miR-1233-5p、m iR-211-3p、miR-4758-5p、miR-614、m iR-6746-5p、miR-1915-5p、miR-4688 、miR-3917、miR-5787、miR-6126、miR- 135a-3p、miR-8063、miR-5698、miR-6 089、miR-498、miR-296-3p、miR-4419 b、miR-6802-5p、miR-6829-5p、miR-1 199-5p、miR-6840-3p、miR-6752-5p、m iR-6798-5p、miR-6131、miR-4667-5p 、miR-6510-5p、miR-4690-5p、miR-92 0、miR-23b-3p、miR-4448、miR-2110、 miR-4706、miR-7845-5p、miR-6808-5p 、miR-4447、miR-6869-5p、miR-1908- 5p、miR-6729-5p、miR-5195-3p、miR-6 38、miR-6125、miR-3178、miR-3196、m iR-8069、miR-4723-5p、miR-4746-3p、miR-4689、miR-6816-5p、miR-6757-5p、miR-7109-5p、miR-6724-5p、miR-1 225-3p、miR-6875-5p、miR-7108-5p、miR-4508、miR-6085、miR-6779-5p、m iR-642a-3p、miR-4695-5p、miR-7847-3p、miR-3197、miR-6769b-5p、miR-7 641、miR-187-5p、miR-3185、miR-2861、miR-3940-5p、miR-1203、miR-615-5 p、miR-4787-5p、miR-1343-3p、miR-6813-5p、miR-1225-5p、miR-602、miR- 4488、miR-125a-3p、miR-5100、miR-4294、miR-1231、miR-6765-3p、miR-444 2、miR-718、miR-6780b-5p、miR-6090、miR-6845-5p、miR-4741、miR-4467、 miR-4707-5p、miR-4271、miR-4673、miR-3184-5p、miR-1469、miR-4640-5p、 miR-663a、miR-6791-5p、miR-6826-5p、miR-4433b-3p、miR-1915-3p、miR- 4417、miR-449、miR-4707-3p、miR-3180-3p、miR-5585-3p、miR-1268a、miR -8072、miR-296-5p、miR-204-3p、miR-4454、miR-6722-3p、miR-1290、miR- 3622a-5p、miR-939-5p、miR-675-5p、miR-3131、miR-4648、miR-1268b、miR- 6741-5p、miR-6893-5p、miR-3162-5p、miR-642b-3p、miR-4734、miR-150-3 p、miR-8089、miR-6805-3p、miR-7113-3p、miR-6850-5p、miR-6799-5p、miR- 6768-5p、miR-92b-5p、miR-3679-5p、miR-4792、miR-3656、miR-92a-2-5p、 miR-4466、miR-4513、miR-6781-5p、miR-4649-5p、miR-6775-5p、miR-4651、miR-3195, miR-6726-5p, miR-6872-3p, miR-371a-5p, miR-6777-5p, miR-6789-5p, miR-7975, miR-6821- 5p, miR-4534, miR-619-5p, miR-7107-5p, miR-1228-3p, miR-6774-5p, miR-6805-5p, miR-23a-3p, miR-4 665-5p, miR-4505, miR-4638-5p, miR-24-3p, miR-3135b, miR-4745-5p, miR-128-1-5p, miR-4476, miR-4 687-3p, miR-3665, miR-6806-5p, miR-3937, miR-711, miR-3141, miR-3188, miR-4281, miR-5196-5p, miR- 6880-5p, miR-3960, miR-3648, miR-6721-5p, miR-4492, miR-744-5p, miR-7704, miR-4749-5p, miR-6794 -5p, miR-6824-5p, miR-762, miR-6836-3p, miR-6727-5p, miR-7977, miR-4484, miR-6515-3p, miR-373-5p 3. The kit according to claim 1 or 2, further comprising a nucleic acid probe capable of specifically binding to at least one polynucleotide selected from the group consisting of miR-4258, miR-4674, miR-3180, miR-6076, miR-1238-5p, miR-4463, miR-4486, and miR-4730, and / or a primer that specifically recognizes and amplifies the polynucleotide.

4. The nucleic acid probe and / or primer is a polynucleotide represented by any one of (f) to (j) below: (f) a polynucleotide consisting of a base sequence represented by any one of SEQ ID NOs: 1 to 13, 15 to 21, 23 to 54, 56 to 65, 67 to 83, 84 to 226, 227 to 229, and 230 to 245, or a base sequence in which u is t in the base sequence, or a fragment thereof containing 19 or more consecutive bases; (g) a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs: 1 to 13, 15 to 21, 23 to 54, 56 to 65, 67 to 83, 84 to 226, 227 to 229, and 230 to 245; (h) a polynucleotide consisting of a base sequence complementary to any of SEQ ID NOs: 1 to 13, 15 to 21, 23 to 54, 56 to 65, 67 to 83, 84 to 226, 227 to 229, and 230 to 245, or the base sequence in which u is t, or a fragment thereof containing 19 or more consecutive bases; (i) a polynucleotide comprising a base sequence complementary to any of SEQ ID NOs: 1 to 13, 15 to 21, 23 to 54, 56 to 65, 67 to 83, 84 to 226, 227 to 229, and 230 to 245, or the base sequence in which u is t; and (j) a polynucleotide that hybridizes under stringent conditions with any one of the polynucleotides (f) to (i); The kit of claim 3, wherein the polynucleotide is selected from the group consisting of:

5. A device for detecting early stage pancreatic cancer or a precursor lesion of pancreatic cancer, comprising a nucleic acid probe capable of specifically binding to a polynucleotide of miR-6803-5p, which is a marker for early stage pancreatic cancer or a precursor lesion of pancreatic cancer, and / or a primer that specifically recognizes and amplifies the polynucleotide.

6. The nucleic acid probe and / or primer is a polynucleotide selected from any one of the following (a) to (e): (a) a polynucleotide consisting of the base sequence represented by SEQ ID NO: 66 or the base sequence in which u is t, or a fragment thereof containing 19 or more consecutive bases; (b) a polynucleotide comprising the base sequence represented by SEQ ID NO: 66; (c) a polynucleotide consisting of a base sequence complementary to the base sequence represented by SEQ ID NO: 66 or the base sequence in which u is t, or a fragment thereof containing 19 or more consecutive bases; (d) a polynucleotide comprising a base sequence complementary to the base sequence represented by SEQ ID NO: 66 or the base sequence in which u is t; and (e) a polynucleotide that hybridizes under stringent conditions with any one of the polynucleotides (a) to (d); The device of claim 5, wherein the polynucleotide is selected from the group consisting of:

7. The device is another early pancreatic cancer or pancreatic cancer precursor lesion marker, miR-6784-5p, miR-1181, miR-671-5p, miR-6857-5p, miR-4276, miR-1914-3p, miR-149-3p, miR-937-5p, miR-4675, miR-6795-5p, miR-4731-5p, miR-5090, miR-3620-5p, miR-6717-5p, miR-6825-5p, miR-6738-5p, miR-6769a-5p, miR-4728-5p, miR-652-5p, miR-4257, miR-7110-5p, miR-6887-5p, miR-887-3p, miR-1228-5p, miR-5572, miR-6782-5p, miR-4298, miR-6786-5p, miR-5010-5p, miR-6087, miR-6765-5p, miR-6732-5p, miR-6787-5p, miR-6737-5p, miR-128-2-5p, miR-4270, miR-6861-5p, miR-6756-5p, miR-1229-5p, miR-6891-5p, miR-6848-5p, miR-1237-5p, miR-30c-1-3p, miR-1233-5p, miR-211-3p, miR-4758-5p, miR-614, miR-6746-5p, miR-1915-5p, miR-4688, miR-3917, miR-5787, miR-6126, miR-135a-3p, miR-8063, miR-5698, miR-6089, miR-498, miR-296-3p, miR-4419b, miR-6802-5p, miR-6829-5p, miR-1199-5p, miR-6840-3p, miR-6752-5p, miR-6798-5p, miR-6131, miR-4667-5p, miR-6510-5p, miR-4690-5p, miR-920, miR-23b-3p, miR-4448, miR-2110, miR-4706, miR-7845-5p, miR-6808-5p, miR-4447, miR-6869-5p, miR-1908-5p, miR-6729-5p, miR-5195-3p, miR-638, miR-6125, miR-3178, miR-3196, miR-8069, miR-4723-5p,miR-4746-3p、miR-4689、miR-6816-5p、miR-6757-5p、miR-7109-5p、miR- 6724-5p、miR-1225-3p、miR-6875-5p、miR-4508、miR-6085、 miR-6779-5p、miR-642a-3p、miR-4695-5p、miR-7847-3p、miR-3197、miR-6 769b-5p、miR-187-5p、miR-3185、miR-2861、miR-3940-5p、miR- 1203、miR-615-5p、miR-4787-5p、miR-1343-3p、miR-1225-5 p、miR-602、miR-4488、miR-125a-3p、miR-5100、miR-4294、miR-1231、miR- 6765-3p、miR-442、miR-718、miR-6780b-5p、miR-6090、miR-6845-5p、miR -4741、miR-467、miR-4707-5p、miR-4271、miR-4673、miR-3184-5p、miR-1 469、miR-4640-5p、miR-663a、miR-6791-5p、miR-6826-5p、miR-4433b-3p 、miR-1915-3p、miR-4417、miR-449、miR-4707-3p、miR-3180-3p、miR-558 5-3p、miR-1268a、miR-8072、miR-296-5p、miR-204-3p、miR-4454、miR-672 2-3p、miR-1290、miR-3622a-5p、miR-939-5p、miR-675-5p、miR-3131、miR- 4648、miR-1268b、miR-6741-5p、miR-6893-5p、miR-642b-3p 、miR-4734、miR-150-3p、miR-8089、miR-6805-3p、miR-7113-3p、miR-6850 -5p、miR-6799-5p、miR-6768-5p、miR-92b-5p、miR-3679-5p、miR-4792、mi R-3656、miR-92a-2-5p、miR-4466、miR-4513、miR-6781-5p、miR-4649-5p、miR-6775-5p, miR-4651, miR-3195, miR-6726-5p, miR-6872-3p, miR-371a-5p, miR-6777-5p, miR-6789-5p, miR-7975, miR-6821-5p, miR-4534, miR-619-5p, miR-7107-5p, miR-1228-3p, miR-6774-5p, miR-6805-5p, m iR-23a-3p, miR-4665-5p, miR-4505, miR-4638-5p, miR-24-3p, miR-3135b, miR-4745-5p, miR-128-1-5p, mi R-4476, miR-4687-3p, miR-3665, miR-6806-5p, miR-3937, miR-711, miR-3141, miR-3188, miR-4281, miR-51 96-5p, miR-6880-5p, miR-3960, miR-3648, miR-6721-5p, miR-4492, miR-744-5p, miR-7704, miR-4749-5p, m iR-6794-5p, miR-6824-5p, miR-762, miR-6836-3p, miR-6727-5p, miR-7977, miR-4484, miR-6515-3p, miR-3 The device according to claim 5 or 6, further comprising a nucleic acid probe capable of specifically binding to at least one polynucleotide selected from the group consisting of miR-73-5p, miR-4258, miR-4674, miR-3180, miR-6076, miR-1238-5p, miR-4463, miR-4486, and miR-4730, and / or a primer that specifically recognizes and amplifies the polynucleotide.

8. The nucleic acid probe and / or primer is a polynucleotide represented by any one of (f) to (j) below: (f) a polynucleotide consisting of a base sequence represented by any one of SEQ ID NOs: 1 to 13, 15 to 21, 23 to 54, 56 to 65, 67 to 83, 84 to 226, 227 to 229, and 230 to 245, or a base sequence in which u is t in the base sequence, or a fragment thereof containing 19 or more consecutive bases; (g) a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs: 1 to 13, 15 to 21, 23 to 54, 56 to 65, 67 to 83, 84 to 226, 227 to 229, and 230 to 245; (h) a polynucleotide consisting of a base sequence complementary to any of SEQ ID NOs: 1 to 13, 15 to 21, 23 to 54, 56 to 65, 67 to 83, 84 to 226, 227 to 229, and 230 to 245, or the base sequence in which u is t, or a fragment thereof containing 19 or more consecutive bases; (i) a polynucleotide comprising a base sequence complementary to any of SEQ ID NOs: 1 to 13, 15 to 21, 23 to 54, 56 to 65, 67 to 83, 84 to 226, 227 to 229, and 230 to 245, or the base sequence in which u is t; and (j) a polynucleotide that hybridizes under stringent conditions with any one of the polynucleotides (f) to (i); The device of claim 7, wherein the polynucleotide is selected from the group consisting of:

9. The device according to any one of claims 5 to 8, which is a device for measurement by hybridization technology.

10. The device of claim 9 , wherein the hybridization technology is a nucleic acid array technology.

11. A method for assisting in the detection of early stage pancreatic cancer or a precursor lesion of pancreatic cancer in a subject, comprising measuring the expression level of miR-6803-5p in a specimen from the subject using the kit according to any one of claims 1 to 4 or the device according to any one of claims 5 to 10, comparing the measured expression level in the subject with a control expression level in a similarly measured healthy subject, and assessing in vitro whether the subject is suffering from early stage pancreatic cancer or a precursor lesion of pancreatic cancer when the expression level in the subject is higher than the control expression level in the healthy subject.

12. A method for assisting in the detection of early pancreatic cancer or a pancreatic cancer precursor lesion in a subject, comprising measuring the expression level of miR-6803-5p in a specimen from the subject using the kit according to any one of claims 1 to 4 or the device according to any one of claims 5 to 10, and substituting the expression level of miR-6803-5p in the specimen from the subject into a discriminant that is prepared using the gene expression levels of a specimen from a subject known to have early pancreatic cancer or a pancreatic cancer precursor lesion and a specimen from a healthy subject as teacher samples, and that is capable of distinctively distinguishing between early pancreatic cancer or a pancreatic cancer precursor lesion and a healthy subject, thereby evaluating the presence or absence of early pancreatic cancer or a pancreatic cancer precursor lesion.

13. 13. The method of claim 11 or 12, wherein the subject is a human.

14. The method according to any one of claims 11 to 13, wherein the sample is blood, serum, or plasma.

15. Use of the polynucleotide of miR-6803-5p as a marker for early stage pancreatic cancer or precursor lesion of pancreatic cancer for detecting early stage pancreatic cancer or precursor lesion of pancreatic cancer.

16. miR-6784-5p、miR-1181、miR-671-5p、miR-4276、miR-1914 -3p、miR-149-3p、miR-937-5p、miR-4731-5p、miR -5090、miR-3620-5p、miR-6717-5p、miR-6825-5p、miR-6738-5p、miR-6769 a-5p、miR-4728-5p、miR-652-5p、miR-4257、miR-7110-5p、miR-6887-5p、m iR-887-3p、miR-1228-5p、miR-5572、miR-6782-5p、miR-4298、miR-6786-5 p、miR-5010-5p、miR-6087、miR-6765-5p、miR-6732-5p、miR-6787-5p、miR -6737-5p、miR-128-2-5p、miR-4270、miR-6861-5p、miR-122 9-5p、miR-6891-5p、miR-1237-5p、miR-30c-1-3p、miR-1233 -5p、miR-211-3p、miR-4758-5p、miR-614、miR-6746-5p、miR-1915-5p、miR -4688、miR-3917、miR-5787、miR-6126、miR-135a-3p、miR-8063、miR-5698 、miR-6089、miR-498、miR-296-3p、miR-4419b、miR-6802-5p、miR-6829-5p 、miR-1199-5p、miR-6840-3p、miR-6752-5p、miR-6798-5p、miR-6131、miR- 4667-5p、miR-6510-5p、miR-4690-5p、miR-920、miR-23b-3p、miR-4448、mi R-2110、miR-4706、miR-7845-5p、miR-6808-5p、miR-4447、miR-6869-5p、m iR-1908-5p、miR-6729-5p、miR-5195-3p、miR-638、miR-6125、miR-3178、m iR-3196、miR-8069、miR-4723-5p、miR-4746-3p、miR-4689、miR-6816-5p、miR-6757-5p、miR-7109-5p、miR-6724-5p、miR-1225-3p、miR-6875-5p、mi R-7108-5p、miR-4508、miR-6085、miR-6779-5p、miR-642a-3p、miR-4695-5 p、miR-7847-3p、miR-3197、miR-6769b-5p、miR-7641、miR-187-5p、miR-31 85、miR-2861、miR-3940-5p、miR-1203、miR-615-5p、miR-4787-5p、miR-134 3-3p、miR-6813-5p、miR-1225-5p、miR-602、miR-4488、miR-125a-3p、miR- 5100、miR-4294、miR-1231、miR-6765-3p、miR-4442、miR-718、miR-6780b-5 p、miR-6090、miR-6845-5p、miR-4741、miR-4467、miR-4707-5p、miR-4271、 miR-4673、miR-3184-5p、miR-1469、miR-4640-5p、miR-663a、miR-6791-5p、 miR-6826-5p、miR-4433b-3p、miR-1915-3p、miR-4417、miR-449、miR-470 7-3p、miR-3180-3p、miR-5585-3p、miR-1268a、miR-8072、miR-296-5p、miR- 204-3p、miR-4454、miR-6722-3p、miR-1290、miR-3622a-5p、miR-939-5p、m iR-675-5p、miR-3131、miR-4648、miR-1268b、miR-6741-5p、miR-6893-5p、m iR-3162-5p、miR-642b-3p、miR-4734、miR-150-3p、miR-8089、miR-6805-3 p、miR-7113-3p、miR-6850-5p、miR-6799-5p、miR-92b-5p、mi R-3679-5p、miR-4792、miR-3656、miR-92a-2-5p、miR-4466、miR-4513、miR -6781-5p、miR-4649-5p、miR-6775-5p、miR-4651、miR-3195、miR-6726-5p、miR-6872-3p, miR-371a-5p, miR-6777-5p, miR-6789-5p, miR-7975, miR-6821-5p, miR-4534, miR -619-5p, miR-7107-5p, miR-1228-3p, miR-6774-5p, miR-6805-5p, miR-23a-3p, miR-4665-5p, mi R-4505, miR-4638-5p, miR-24-3p, miR-3135b, miR-4745-5p, miR-128-1-5p, miR-4476, miR-4687 -3p, miR-3665, miR-6806-5p, miR-3937, miR-711, miR-3141, miR-3188, miR-4281, miR-5196-5p, miR-6880-5p, miR-3960, miR-3648, miR-6721-5p, miR-4492, miR-744-5p, miR-7704, miR-4749-5 p, miR-6794-5p, miR-6824-5p, miR-762, miR-6836-3p, miR-6727-5p, miR-7977, miR-4484, miR-6 The use according to claim 15, further comprising at least one polynucleotide selected from the group consisting of miR-515-3p, miR-373-5p, miR-4258, miR-4674, miR-3180, miR-6076, miR-1238-5p, miR-4463, miR-4486, and miR-4730, or a fragment thereof comprising 19 or more consecutive bases.

Images